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Abstract
Mus musculus is a human commensal species and an important model of human development
and disease with a need for approaches to determine the contribution of copy number variants
(CNVs) to genetic variation in laboratory and wild mice, and arising with normal mouse
development and disease. Here, the Mouse Diversity Genotyping array (MDGA)-approach to
CNV detection is developed to characterize CNV differences between laboratory and wild
mice, between multiple normal tissues of the same mouse, and between primary mammary
gland tumours and metastatic lung tissue.
A CNV detection pipeline was used in conjunction with evaluated probe sets, targeting
925,378 loci at an inter-probe-set median distance of 319 bp, to identify CNVs in a publiclyavailable dataset that includes representatives of 114 classical laboratory (CL) strain mice, 52
wild-derived (WD) mice, and 19 wild-caught (WC) mice. On average, WC and WD mice (~50
CNVs/mouse) have twice as many CNVs as CL mice. DdPCR confirmed 96% of MDGApredicted copy number states. CL CNVs impact gene pathways related to immunity and
nucleosome-associated functions, whereas olfaction and pheromone detection are impacted in
WC mice. WD mice share impacted genic pathways with both cohorts.
In a five-member C57BL/6J inbred mouse family, losses of developmentally-important
HOXA genes were detected and confirmed in multiple normal tissues. Further confirmation of
postzygotic Hoxa13 losses in unrelated C57BL/6J, CBA/CaJ, and DBA/2J mice points to a
widespread phenomenon occurring in mice, involving mutation hotspots and/or programmed
losses.
In comparison to normal tissues (25 CNVs/mouse), cancer samples from an MMTVPyMT mouse breast cancer model with lung metastasis have 1.6- to 3.2-fold more CNVs. CNV
size is reduced and CNV recurrence is increased among primary tumours in the absence of the
hyaluronan-mediated motility receptor, suggestive of altered mechanisms of CNV formation
and selection for specific phenotypes in the tumour microenvironment, respectively.
CNVs were found to arise during normal development, producing different CNV
profiles than with tumorigenesis and metastasis. CNV profiles also differ between laboratory
ii

and wild mice. This thesis presents improvements to an array-based CNV detection and
analysis pipeline which was used to determine the contribution of CNVs to genetic variation
in M. musculus.

Keywords
Mus musculus, Mouse Diversity Genotyping Array, copy number variants, single nucleotide
polymorphism, somatic mosaicism, de novo genetic variation, cancer, classical laboratory
strains, wild-derived strains, wild-caught mice.
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Chapter 1

1

Introduction to CNVs and Thesis Aims

1.1 Copy Number Variants (CNVs)
Copy number variants (CNVs) are a source of genomic variation that contributes to normal
and pathogenic phenotypes1–4 through the structural alteration of a genome. As a result,
CNVs can play an important role in fitness for an individual organism and at a population
level5,6. Improvements to the resolution and sensitivity of CNV detection technology have
led to the discovery that CNVs are a common genomic phenomenon, with CNV differences
being found even between individual cells form the same tissue7. Here, high-resolution
SNP microarray technology is employed to explore and gain a better understanding of the
CNV landscape across the genome of Mus musculus, a human commensal species8 and
important animal model of human diseases, from the perspective of adaptation and
evolution, somatic mosaicism, and disease.

1.1.1

Defining CNVs

Copy number variants (CNVs) are defined as large segments of DNA ranging from ~50 bp
to several megabases in size, that are present in different numbers of copies between
genomes9. While the lower size limit of CNVs is not clearly defined since it can overlap
with other structural variant types like indels (small insertions or deletions), the limit has
decreased from the commonly used 1 kb minimum as the resolution of CNV detection
technology and computational methods improved9–11. CNV differences between genomes
can exist at all levels, ranging from the genomes of two cells of an individual to the
genomes of two different organisms. In a diploid genome, the expected copy number of
most DNA regions is two. A DNA segment that occurs as a copy state of one in a diploid
genome, as opposed to the default two copies, is called a loss or deletion while a DNA
segment that is present in more than two copies is referred to as a CNV gain, duplication,
or amplification. Since CNVs can span thousands to millions of base pairs in length, many
CNVs overlap the full spectrum of functional elements in a genome and can impact
phenotypes if these elements are dosage sensitive. As such, CNVs play important roles in
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both normal and pathogenic diversity in many organisms including plants, animals and
unicellular organisms.

1.1.2

CNVs and natural and artificial selection

If CNVs alter the expression of genomic elements that determine phenotypes, then positive
or negative selection of traits can occur if fitness is affected. Trait selection can occur
quickly through artificial means when humans intentionally breed and select plants,
animals and other organisms for specific qualities, sometimes following intentional
mutation induction. Examples of artificial selection by humans are numerous and include
generation of different dog breeds12, creating ornamental plant cultivars13, and
improvement of lactic acid bacteria strains used for producing fermented dairy products14.
Sometimes there are unintended consequences of artificial selection. For example, some
mutations in livestock and pets produce desirable traits when present in a heterozygous
state but are deleterious when present in a homozygous state15. Under natural selection,
traits that confer a fitness advantage to individuals within a population will be positively
selected while deleterious traits will negatively affect fitness and be under negative
selection. CNVs are known to impact phenotypes and cause diseases through numerous
mechanisms including gene dosage changes, gene interruption, gene fusion, position
effects, unmasking recessive alleles or functional polymorphisms, and potential
transvection effects16.
More than 145 CNV genes show evidence of positive selection in humans17. During
recent human evolution, different human populations gained variation in the copy number
of the dosage-sensitive salivary amylse gene, AMY1. Gains in AMY1 range from two to
twenty copies within human populations, have not been observed in Denisovan or
Neanderthal genomes, and are thought to be associated with the introduction of starch-rich
foods into the human diet18–20. Individual differences in AMY1 copy number can lead to
different oral perceptions of starch viscosity, and this in turn may influence individual food
choices and consumption levels of starch-containing foods21. Because AMY1 is expressed
in multiple tissues and salivary a-amylase has a limited role in starch digestion, it was
proposed that additional adaptive advantages may be responsible for retaining AMY1 copy
number gains in humans18. The spread of prehistoric agriculture not only impacted humans,
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it also correlates with the copy number expansion of the pancreatic amylase gene, AMY2B,
in dogs22. Dog breeds which were more likely to have had high starch diets historically,
have more AMY2B copies on average than do dog breeds who had low starch diets23.
Positive selection can occur for copy number losses as well as gains. Three genomic
elements that were deleted or pseudogenized in humans are an enhancer located near the
growth arrest and DNA damage inducible gamma (GADD45G) gene, the caspase 12
(CASP12) gene, and an androgen receptor (AR) enhancer. In modern humans, CASP12 has
nearly reached complete fixation for a null allele that reduces susceptibility to severe
sepsis24. Deletion of the GADD45G enhancer correlates increased growth of specific brain
regions while the deletion of the AR enhancer is associated with the loss of sensory
vibrissae and penile spines25. The loss of penile spines in the human lineage may have been
in response to a changing reproductive strategy that included pair bonding and
monogamy26.
In the modern human genome, 91% of genes that are greater than 10 kb, occur in a
fixed diploid state27. Almost half of the duplicated genes are not variable in copy number
between individuals, and of the genes that are variable, 80% do not exceed a copy number
state of five27. This implies that the majority of the human genome is fairly stable with
regard to copy number and a limited number of gene families have extreme variation. This
is consistent with studies of bacteria that have shown gene amplifications to be unstable
and associated with increased fitness costs28; excess gene copies are quickly being reduced
to lower copy numbers. After comparing the human data to the gorilla, chimpanzee and
orangutan genomes, Sudmant et al (2010) were able to identify 53 gene families with
increased copy number in humans, including eight gene families that appeared to be fixed
in humans27. The human specific duplications included genes related to brain development
and function.
Similarly, many human CNVs are enriched for genes with chemosensation and
immune response functions29. Chemosensation genes include olfactory receptor (OR)
genes, which belong to the largest gene family in humans and are known to undergo gene
duplication and pseudogenization events30. The rate of OR gene pseudogenization has
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occurred almost 4-fold faster in humans than in other primates, possibly resulting from a
lowered dependence on chemosensory perception in humans, relative to apes31. Additional
support for environmental pressures shaping the OR gene family in humans is provided by
observations that the number of intact and functional OR genes differs greatly between
modern human populations32. Although humans have more OR pseudogenes than many
mammals, research suggests that contrary to popular belief, humans do not have a poor
sense of smell in comparison to other mammals, like dogs, which are known for their sense
of smell33.
CNVs are frequently found to overlap genes with functions important to the human
immune system. Human antibody heavy chains are produced by immunoglobulin heavy
chain (IHC) gene families that arose through duplication and diversification, and are
currently hotspots for CNV formation34,35. The effects of CNVs on innate immunity have
been difficult to characterize and their impact on disease susceptibility and progress has
been controversial36. An example of this is the defensin genes, which are commonly studied
for their antimicrobial functions37. In humans, copy number polymorphisms of defensin
genes are limited to a subset of defensin genes and do not appear to be a general feature of
innate immunity genes38. CNVs of defensin genes have been associated with HIV
progression to AIDS, and susceptibility to numerous disorders including cervical cancer,
autoimmune disorders like ankylosing spondylitis and lupus, sarcoidosis in females,
ulcerative colitis susceptibility, and more39–44. Although there are many findings of
associations between copy number of immunological genes and disease susceptibility,
confirmation of the biological roles of candidate CNVs in disease susceptibility is
required36.
Also relevant to human health, is the role of CNVs in antibiotic resistance. Bacterial
acquisition of antibiotic resistance is a two-step process involving the initial amplification
event of dosage-sensitive genes that confers antibiotic resistance and the subsequent
mutational events that reduce the fitness costs of the amplification45. These bacterial gene
amplifications are generated and lost at high rates, making them difficult to study. There
are at least 22 known instances of multiple bacterial species acquiring antibiotic resistance
through gene amplifications occurring either on plasmid DNA or chromosome DNA45. One
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such example is the acquisition of tobramycin resistance in multidrug-resistant
Acinetobacter baumannii, isolated from a patient46. Treatment of A. baumannii isolates
with increasing tobramycin concentrations results in either moderate tobramycin resistance
(≤8 μg/ml) with no fitness costs via low amplification of the aminoglycoside resistance
gene aphA1, or high tobramycin resistance (16 μg/ml) with impaired fitness resulting from
greater amplification of aphA1. This experiment mimics the selective pressures acting on
bacteria outside of the laboratory that are created by humans mainly through excessive and
improper use of antibiotics, as well as other actions related to infection control and
prevention47. It is important to understand the mechanisms by which resistance to
antibiotics is conferred since antibiotic resistance has become a serious health concern for
both humans, and for conventional livestock farming where antibiotics are routinely used
in a prophylactic manner48.
In agriculturally relevant animals, CNV studies are often conducted between
different breeds to identify contributors to different desirable traits. For chickens, CNVs
have been studied in different breeds to identify breed- or line-specific CNVs and to
determine if they have an effect on egg production, body size, growth rate, abdominal fat
content, feather growth and pea-comb phenotype49–52. CNV studies on pigs have been used
to determine if there is an association between CNVs and coat colour, backfat thickness,
meat quality, fatty acid composition and growth traits53–56. In cattle, genomes were
examined for CNV impacts on growth, milk protein and fat traits, meat quality, and health
traits57–61. CNV research that is primarily aimed at discovering associations with
phenotypic traits has also been conducted on agriculturally important animals like sheep,
goats, ducks, turkeys, and horses62–66 and plants, including in maize, rice, barley, wheat,
grapes, tomatoes, sorghum, foxtail millet and soybeans67–75. For both plants and animals
important to agriculture, there is a need to understand structural variation that occurs in the
genome. This knowledge would assist with maintenance and monitoring of genetic
diversity in crops or livestock, selecting desirable phenotypic traits, improving the
understanding of and monitoring for health issues, and improving knowledge regarding the
domestication history of different species.
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1.1.3

CNVs and human disease

CNVs have been extensively studied from a human disease perspective. Over 90% of
pathogenic CNVs contain ohnologs, which are genes that have been retained following
ancestral whole-genome duplication events76. This is far lower than observations for
nonpathogenic CNVs (~30% contain an ohnolog), which suggests that the dosage sensitive
nature of many ohnologs contained in CNVs appears to be an important part of the
pathogenicity. Following whole-genome duplication, dosage balancing was required, and
now, this careful regulation of gene expression is disrupted if the ohnologs are duplicated
or deleted77. Down syndrome (trisomy 21) is an example of a genetic disorder caused by
gene dosage alteration, in this case an increase in dosage. The majority of genes associated
with this genetic disorder can be classified as ohnologs76. These findings regarding the
relationships between CNVs, dosage-sensitive ohnologs, and aberrant phenotypes with
increased risk to multiple diseases, are valuable since they may help narrow the list of
candidates involved in certain diseases. However, it is important to recognize that not all
dosage-sensitive genes are ohnologs.
Pathogenic CNVs are involved in both simple, single-gene diseases, and complex
diseases. With simple diseases, a mutation affecting only one gene or other important
genomic element (e.g. expression regulators) is enough to result in a disease phenotype.
For example, CNV duplications of peripheral myelin protein 22 (PMP22), lamin B1
(LMNB1), and nuclear receptor binding SET domain protein 1 (NSD1) cause CharcotMarie-Tooth 1A disease, autosomal dominant leukodystrophy, and a growth retardation
syndrome, respectively78–80. When deleted, PMP22 causes hereditary neuropathy with
liability to pressure palsies while a NSD1 deletion causes Sotos syndrome78,81,82. When a
gene is impacted in such a way that it leads to decreased expression and a pathogenic
phenotype, whether via a CNV deletion or other means, this is called haploinsufficiency.
CNVs implicated in complex diseases, including neurological disorders like autism, vary
in nature in regard to size, copy number state, whether they are recurrent or not, or inherited
or de novo83–86. Complex diseases and traits with CNV associations include Parkinson
disease, Alzheimer disease, schizophrenia, epilepsy, and HIV-1 infection susceptibility87–
92

.
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1.1.3.1

Disease thresholds, heteroplasmy and pathogenic
mosaicism

CNV deletions and duplications of dosage-sensitive genes may not result in an abnormal
phenotype if a certain threshold of cellular or tissue malfunction is not reached. Disease
“thresholds” are commonly used when discussing mitochondrial heteroplasmy – the
presence of more than one mitochondrial genome in the mitochondrial population within a
cell or individual. The threshold level for when a phenotypic effect is present is dependent
on the particular mutation and tissue93. Phenotypic threshold levels for mtDNA mutations
are generally above 60% and deletions generally have lower thresholds than other
mutations types94.
Mitochondrial mutations are common in normal cells and likely inherited
frequently. In 1995, Chen et al. found that approximately 50% of tested oocytes contained
a frequently occurring 4,977 bp deletion95. This particular deletion is found in a
subpopulation of people with chronic progressive external ophthalmoplegia, and Kearns
Sayre syndrome95–97. A likely explanation for why some people with mitochondrial
deletions develop diseases while others do not is that people who developed a disease
inherited a higher mutation load or acquired spontaneous de novo mutations earlier than
people who did not develop a disease. If a mitochondrion acquired a de novo mutation in a
zygote, that will have a minimal effect on the developing individual compared to a zygote
where 90% of mitochondria are inherited mutants and the phenotype threshold has been
surpassed. Although generally thought to occur randomly, some evidence suggests that
mitochondrial segregation is not always random and heteroplasmy levels can be maintained
in daughter cells for numerous mitoses98.
Genotype differences can also occur between the nuclear DNA of somatic cells, in
a phenomenon called somatic mosaicism. Cancer is a well-known example of somatic
mosaicism where tumour cell populations are known to have genetic instability and high
heterogeneity in comparison to adjacent healthy tissues99,100. Cancer-predisposing
mutations can be inherited or occur de novo in an individual. One group of individuals who
are predisposed to developing cancer and have high levels of de novo CNVs are people
with Li-Fraumeni syndrome (LFS)101. They are more likely to have high CNV levels than
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healthy individuals or individuals who develop the same TP53 mutation spontaneously,
rather than inherit it. The reason for this is that germline TP53 tumor suppressor mutations
in individuals with LFS are thought to increase genomic instability, leading to the
formation of more CNVs and carcinogenic mutations101. The CNV levels were found to be
even higher once LFS-affected individuals developed cancer when compared to mutant
carriers not yet affected by cancer. Similar to the idea of a phenotypic threshold, there
appears to be a dose-response relationship between CNV frequency and cancer phenotype
severity for LFS101.
CNVs are commonly implicated in cancer, particularly recurrent copy number
gains of oncogenes and recurrent losses of tumour suppressor genes102. There are known
associations between cancer and the copy number duplication and overexpression of over
70 genes103. With respect to copy number losses, tumour suppressor gene losses can lead
to decreased gene expression which may subsequently play a role in cancer initiation or
progression104. Tumour suppressor genes, including phosphatase and tensin homolog
(PTEN), microcephalin 1 (MCPH1), F-box protein 25 (FBXO25), SMAD family member
4 (SMAD4), tripartite motif-containing 35 (TRIM35), RB transcriptional corepressor 1
(RB1), and methylthioadenosine phosphorylase (MTAP), have shown concordance
between copy number loss and decreased gene expression in multiple tumour samples104.
MTAP, which is involved in purine biosynthesis, showed this relationship in 14 cancer
types104. In non-small cell lung cancer, decreased MTAP expression is associated with poor
overall survival and higher risk of tumour reoccurrence105. The mutation and gene
expression profile for a given type of cancer can help direct cancer treatments, like using
trastuzumab for cancers with estrogen-related receptor beta type 2 (ERRB2) amplifications
or AKT serine/threonine kinase 1 and 2 (AKT1/2) inhibitors if there is no response to
trastuzumab or lapatinib106. However, the genetic heterogeneous makeup of tumours can
make cancer difficult to treat because often when a dominant cell subpopulation is targeted
and eliminated, other tumour cell subpopulations become dominant107,108.
In spite of tumour heterogeneity, many cancer types were found to have unique
underlying mutation profiles or “signatures” that can be used to diagnose tumour types109.
The collective mutations present across a genome, and their characteristics (e.g. type, size,
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location, genic content), constitute the mutation “profile” of a sample. Cancer mutation
signatures commonly involve multiple genes and mutation types109. Soh et al (2017)109
applied machine learning to tumour DNA sequence data, representative of 28 different
cancer types, and found that the cancer type of a tumour sample can be correctly identified
in almost 84% of cases when using SNP and CNV data for 100 genes. The same study
showed that the accuracy of cancer type identification decreases when fewer genes are used
and if only SNPs or only CNVs are used as a predictor. CNVs are a better predictor of
cancer type than SNPs since use of CNV data alone can result in an overall prediction
accuracy of ~75% while SNP data alone have a much lower prediction accuracy of
~49%109.

1.1.3.2

CNV impact on drug metabolism

CNVs can play important roles in disease treatment since they can influence drug
metabolism. Cytochrome P450 2D6 (CYP2D6) is an extensively studied human gene that
encodes an enzyme capable of metabolizing numerous drugs including selective serotonin
reuptake inhibitors, atypical antipsychotic medications, tricyclic antidepressants, beta
blockers, opioid pain medications, antimalarial medication, poly (ADP-ribose) polymerase
inhibitors (anticancer agents), and more110. CYP2D6 is a dosage-sensitive gene which
causes decreased drug metabolism if copies are deleted, and increased metabolism if the
gene is duplicated. A study of over 30,000 Americans found that a large minority (12.6%)
of people have either fewer or more than two copies of CYP2D6111. This minority group
may be given incorrect medication doses and be more likely to suffer side effects when
taking drugs metabolized by CYP2D6, if the dosage is not adjusted for CYP2D6 enzyme
levels. One such example is codeine, which can be lethal to those with CYP2D6
duplications and the associated ultra-rapid metabolizer phenotype112,113.

1.1.4

Mouse models of human disease

While many studies have been performed to study the effects of CNVs in humans, mice
are also of great importance and help to fill in gaps in human research with respect to
disease etiology, progression, and treatment. Mice are one of the most commonly used
animals in human disease research and their value is evident from the fact that in 2002,
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Mus musculus was the first mammal to have its genome fully sequenced114. By 2011,
genome sequences were available for 17 inbred laboratory mouse strains115. The popularity
of the mouse as an animal model comes from the many advantages of working with mice.
For example, mouse breeding can be controlled to minimize or maximize genetic
heterogeneity between individuals, family studies can be conducted, studies can be
conducted at any age, there is no shortage of available tissues, the scale of the experiment
can be much larger than with humans, diet and environment can be controlled, and the
genomes can be manipulated to generate specific phenotypes and diseases. Some disease
mouse models that involve DNA gains and losses are used to study mitochondrial deletion
disorders116, the contribution of dosage imbalance to complex diseases like Alzheimer’s
disease117, haploinsufficiency118 and overexpression disorders119, and cancer120.
Due to the importance of mice in research, it is necessary to gain an understanding
of the mouse genetics and to develop tools for studying the mouse genome. Determining
what normal mutation levels are for different mouse strains and tissues will help with
identification of abnormal genomic alterations, discovery of mouse-, strain-, and tissuespecific mutation hotspots, and development of appropriate study designs. Although mouse
studies are invaluable for human research, animal models do not always accurately mimic
human diseases and study results for the two species are not always concordant, for reasons
concerning both biological (i.e. species-specific differences) and non-biological aspects
(e.g. study design quality, availability/suitability of technology, sample availability, cost,
etc.) 121,122. Mouse genetic studies can be useful beyond human-relevant medical research,
and have also contributed in the areas of evolution and ecology123,124, and uncovering the
history of human colonization125.

1.1.5

Mechanisms of CNV formation

There are several mutational mechanisms that give rise to CNVs, which can be grouped
into homology-based and non-homology-based mechanisms126. The breakpoint junctions
surrounding a CNV, as well as the CNV size, can indicate what mechanism was responsible
for creating a CNV. Long homologous regions in the breakpoint junctions, like low copy
repeats, tend to be associated with non-allelic homologous recombination (NAHR). Allelic
homologous recombination is normally used to repair broken chromosomes with two ended
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double-strand breaks (DSBs) but mismatches between homologues can occur in repetitive
regions, leading to recombination between non-allelic homologous regions. When
occurring between chromatids and chromosomes, NAHR can produce reciprocal
duplications and deletions, but when occurring within a chromatid, NAHR will produce
only deletions127.
In the human male germline, the rate of NAHR-mediated CNV deletions was found
to be two-fold higher than the duplication rate128. However, the proportion of duplications
and deletions appears to be similar in healthy humans, suggesting that other mechanisms
might be biased towards duplications or there is stronger selection against cells carrying
deletions128,129. NAHR is the most common mechanism for generating recurrent CNVs130.
Recurrent CNVs are the same length and share fixed (common) breakpoints. Short
homologous regions enriched for mobile elements like long or short interspersed nuclear
elements (LINEs and SINEs), are associated with CNV insertion and deletion events that
can occur via NAHR, nonhomologous end joining (NHEJ) or replication-based
mechanisms131–133. NAHR breakpoints are also associated with hypomethylation and open
chromatin134. Exposed DNA is more susceptible to damage like DSBs than condensed
DNA is, and DNA is particularly vulnerable when it is in a single-stranded state during
transcription134.
In the absence of large homologous regions, NHEJ may be used to repair DNA.
NHEJ is an important mechanism for repairing DSBs involving blunt ends or short
microhomologies (1-4 bp), with the repair outcome typically resulting in small insertions
and deletions ranging from one base pair to a couple hundred base pairs in length135,136.
When longer terminal microhomologies (>5 bp) are involved in DSB resolution, the
mechanism is called microhomology-mediated end joining (MMEJ) and it may be used in
place of NHEJ when some components required for NHEJ are not available136.
In addition to producing small structural alterations, NHEJ is capable of altering
large regions of the genome, and producing CNV deletions involving thousands of base
pairs or more137–140. NHEJ is also associated with large CNV duplications, which
sometimes occur via a two-step process involving homologous recombination (HR) in
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addition to NHEJ139,141,142. Unlike NAHR, the NHEJ process requires little to no homology
and is known to create non-recurrent CNVs, which have unique sizes and breakpoints130.
DSBs can occur throughout all cell cycle stages, as can NHEJ-mediated repair.
However, NHEJ is affected by the cell phases with regard to its frequency and repair
outcomes (e.g. deletions of varying sizes are common in G1)143. HR is an alternative
mechanism to repairing DSBs and can occur during the S/G2 phase if homologues are
present near the DSBs144. In comparison to HR, NHEJ repairs DSBs more quickly and
efficiently in human cells, but also with less accuracy145. Being a DSB repair mechanism,
NHEJ-mediated CNVs are likely to be found in regions of the genome that are susceptible
to breakage. For example, LINE-1 causes DSBs via endonuclease activity during
retrotransposition events, so DSBs are expected to occur in regions containing such mobile
elements146. Spontaneous DSBs can also occur during DNA replication when replication
forks collapse and by extension could occur if mutagens interfere with replication
progress147. However, mechanisms other than NHEJ are involved in DNA repair following
replication fork collapse since the breaks involve a single double-stranded end with no
other end to join it to.
Like NAHR and NHEJ, replication-based mechanisms are important contributors
to CNV formation and formation of de novo CNVs can be observed when canonical NHEJ
is blocked in mouse embryonic stem cells148. In the absence of canonical NHEJ, CNVs
arising during replication were 1.9-fold larger when occurring at mutation hotspots than
non-hotspots, and more CNV deletions than duplications were observed at both hotspots
(100% deletions) and non-hotspots (79.5% deletions). Excluding possible alternative endjoining mechanisms, one replicative mechanism which could have contributed to the
formation of these CNVs is microhomology-mediated break-induced replication
(MMBIR), which is involved in repairing one-ended DSBs following replication fork
collapse149.
Following replication fork collapse, MMBIR finds microhomologies between the
broken DNA strand and a DNA template to repair the break. Breakpoint junctions
following MMBIR repair can often be found near LCRs150,151. Additionally, it was
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predicted that MMBIR could create LCRs which can later be utilized for NAHR149.
MMBIR can create large, complex structural alterations where the outcome is dependent
on the which DNA template is used for repair and how many template switches occur.
When a sister chromosome or homologue behind the fork breakage is used, a duplication
will result, whereas the use of a template positioned ahead of the fork breakage will result
in a deletion. Other outcomes include inversions, translocations, triplication and a rolling
circle.
Junctions at the endpoints of MMBIR show microhomology (2-5 bp), sometimes
leading to confusion as to whether MMBIR or NHEJ was responsible for the repair event,
although the presence of complexity is more indicative of MMBIR than NHEJ126. Like
NHEJ, MMBIR creates nonrecurrent CNVs, but in contrast to end-joining mechanisms,
MMBIR is a favoured mechanism for the production of CNVs arising during replication,
particularly for CNV amplifications.
NAHR, NHEJ and MMBIR are important DNA damage repair mechanisms that
can produce CNVs, although other repair mechanisms exist as well. The outcome of DNA
repair is dependent on numerous factors including, but not limited to, the type of damage
(e.g. one or two-ended DSBs), the cell cycle stage, the surrounding genomic context (e.g.
presence or absence of homologues and repeats), and the availability of key components
for specific repair pathways.

1.1.6

CNV mutation rates

For CNVs greater than 500 bp in length, array-based HapMap data representing 450
individuals provided a genome-wide CNV mutation rate of 3 × 10−2 per genome per
generation152. The authors predict that this mutation rate is an underestimate since purifying
selection against deleterious CNVs was not taken into consideration. A second study
showed that the general CNV mutation rate based on 4,187 genomic regions from HapMap
Phase II human populations is estimated to be at an order of 10−5 CNVs per locus per
generation, but was as high as 10−3 CNVs per generation for 2.5% of 4,187 loci, with 47%
of these mutation hotspots overlapping genes153. A similar average mutation rate at an order
of 10−5 was estimated based on 856 CNV loci from HapMap Phase III human
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populations154. This average CNV mutation rate is consistent with NAHR-mediated CNV
mutation rates in human sperm155.
In the human male germline, NAHR deletion rates at a mutation hotspot were found
to differ greatly between individuals, ranging from 9.82 × 10−6 to 6.96 × 10−5 per
individual, with an average deletion rate of 3.52 × 10−5 (± 3.04 × 10−6 SEM)155. An earlier
study examining the same locus observed very similar NAHR deletion rates in male sperm
(4.20 × 10−5 ± 2.99 × 10−6 SEM)128. For three other mutation hotspots, the average NAHR
deletion rates were different, ranging from 2.16 × 10−5 to 1.87 × 10−6. The average NAHR
duplication rates were lower than the duplication rates for all four hotspots and ranged from
1.73 × 10−5 to 1.73 × 10−7. This finding is consistent with observations from other studies
where NAHR-mediated deletions were found to be more frequent than duplications128,153.
In a third study focusing on a region of Chromosome 17, NAHR CNV rates associated
with male meiosis were also found to be on an order of 10−5 to 10−7 156.
Contrary to the mutation rates determined above which were determined based on
a few disease-relevant loci, the frequency of NAHR-mediated CNVs detected across whole
genomes would suggest that the mutation rates are higher than expected. For a mutation
rate at an order of 10-5, 0.00324 de novo deletions and duplications per generation, or 0.324
NAHR-mediated CNVs per individual when separated from the reference genome by 100
generations would be expected yet 24 NAHR-mediated CNVs per individual were
observed157.
Although additional genome-wide studies would be helpful in resolving the NAHR
mutation rates for CNV formation, NAHR rates have been more extensively studied than
the difficult to determine NHEJ or MMBIR mutation rates. Identifying NAHR-associated
breakpoints is simpler because it involves searching for large homologies, while
mechanisms that generate nonrecurrent CNVs have little to no homology at breakpoints
and it can be difficult to assign an exact mechanism to a CNV. Little is known about NHEJ
rates, although the CNV generation rate via NHEJ is predicted to be less than 10-7 per locus
per generation152. However, based on deletion breakpoints examined from the 1000
Genomes project data, nonhomologous mechanisms generate more CNVs (61% of
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detected CNV deletions) than NAHR (13%), with 42% of these deletions predicted to have
occurred via NHEJ and 58% through template-switching mechanism like MMBIR134.
Like NHEJ, there is little information regarding MMBIR-mediated CNV rates.
While MMBIR is associated with replication fork collapse, the rate of replication fork
collapse in humans is unknown. If recombination frequency during replication is used as a
measure of replication fork collapse, then replication fork collapse is expected to occur
multiple times per cell division cycle158. Although not all replication fork collapses are
resolved with a CNV outcome, the sheer number of replication events required to create an
adult human from a zygote and to renew cells in tissues provides many opportunities for
CNV formation. To reach the predicted 3.72 × 1013 cells present in an adult human when
starting from a zygote, the cell population will have needed to double approximately 45
times through numerous independent replication events159. These frequent but nonrecurrent
mutation events would result in high levels of somatic mosaicism in healthy individuals
that could be difficult to detect if there is insufficient clonal expansion to meet a required
detection threshold. Mutations that arise early in embryogenesis would have high clonal
expansions in an adult, assuming there are no fitness costs to the affected cells.
Aneuploidy mosaicism in blastocysts is known to occur frequently, increasing from
~50% to ~90% of tested blastocysts, as a woman’s age and meiotic error risk increases160.
In preimplantation embryos, aneuploidy mosaicism is associated with clinical implications
like reduced implantation success and increased risk of miscarriage with embryos that have
aneuploidy in 20%-80% of their cells (in a 5-cell biopsy)160. CNVs are known to arise
during gametogenesis and embryogenesis and with estimates of the rate of de novo CNV
occurrence in offspring being placed at 1.2 × 10−2 CNVs per genome per transmission, for
CNVs over 100 kb in length161. In rare cases, individuals with genomic disorders present a
CNV mutator phenotype and have an unusually high number of de novo CNVs (5-10 CNVs
per individual)162. This mutational process appears to be transient, only occurring
perizygotically, possibly as a consequence of replicative repair. It is hypothesized that
mutant maternal proteins or transcripts are responsible for driving a CNV mutator
phenotype in early embryogenesis and the mutation process ceases once zygotic genome
transcription is activated and wild-type proteins and transcripts are generated162. The
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mutations that arise early in embryogenesis are likely to have large clonal populations in
the developed individual and therefore have high phenotypic impact potential.

1.2 CNV detection
There are several approaches that can be used for the identification of CNVs. Fluorescent
in-situ hybridization (FISH) is a commonly used CNV detection technique, and is often
used for diagnostic purposes in the clinic163–165. With FISH-based approaches, locusspecific fluorescent probes are hybridized to metaphase or interphase spreads to visualize
CNVs at a single cell level166. This method provides an absolute CNV count, typically at a
resolution ranging from tens of thousands to hundreds of thousands of base pairs167,
although the resolution has been improved with newer methods like Fiber FISH which is
performed on extended chromatin fibers168. The drawbacks to FISH approaches are that
they are low throughput in comparison to other CNV-detection technologies like
microarrays, and CNV discovery is limited to the loci that have sequences complementary
to the designed probes, meaning a priori knowledge of the target CNVs is required166.
Higher throughput technologies for CNV detection include array-based
comparative genomic hybridization (aCGH) and non-CGH microarrays like SNP-based
oligonucleotide arrays169. In an aCGH approach, sample and reference DNA are
cohybridized to DNA probes on an array. A sample of interest, for example, may be DNA
from a disease-affected individual while the reference DNA would come from a healthy
individual170. The goal would be to identify chromosomal abnormalities in the sample of
interest compared to the healthy reference and see if there is an association to the disease
phenotype. The sample and reference DNA are labelled with different fluorescent dyes so
that for each locus, the ratio between the two fluorescence signals can be used to infer a
copy number state171. Since aCGH-based CNV detection is dependent on the use of a
reference genome, absolute counts of DNA copies are not detected like with FISH. An
advantage over FISH, is that aCGH uses thousands of probes in parallel which allows for
genome-wide CNV detection. Array CGH has been used in the identification of CNVs
associated with diseases including but not limited to pancreatic cancer172, metastatic breast
cancer173, neurodevelopmental disorders or multiple congenital anomalies174, and autism
spectrum disorder175. Array CGH has also been used in a human evolutionary study, and
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found copy number expansions in humans when compared to four other hominoid species
(bonobo, chimpanzee, gorilla, and orangutan) that could account for some of the speciesspecific phenotypic characteristics such as brain structure and function176.
Non-CGH microarrays are an alternative approach to aCGH for CNV detection and
do not require cohybridization with a reference DNA sample. With SNP-based
oligonucleotide microarrays, for example, the DNA of interest is hybridized to singlestranded DNA probes on an array and the overall fluorescence intensity signal of each locus
is compared to a reference diploid signal to detect CNV gains and losses177. Thus, SNP
microarray CNV detection is reference based and does not provide absolute copy number
counts. High resolution SNP microarrays have been used for a variety of different CNV
studies including but not limited to studies of human anthropomorphic traits178, crossspecies comparisons between humans and rhesus macaques179, fetal alcohol spectrum
disorder180, autism spectrum disorder181, and thoracic aortic aneurysms and dissections182.
Overall, both aCGH and non-CGH microarrays that are used for CNV detection come in a
variety of designs and vary greatly in several aspects including but not limited to their
resolution and sensitivity, in the type of mutations that they can detect, and the amount of
DNA required for hybridization183–185.
A more advanced approach to CNV detection than microarrays, particularly with
respect to resolution and sensitivity, is the use of sequencing technologies, which provide
single base-pair resolution. Sequencing technologies, which are rapidly improving and
developing, are used in high-throughput approaches for genome-wide CNV discovery,
even for single cells, and they allow for the identification of translocations, rare variants,
and CNV breakpoint junctions186,187. However, assembling raw sequencing data into a
useful output is a complex process for numerous reasons that include but are not limited to
the large quantities of output data, various limitations between the different sequencing
technology platforms and algorithms, dependence on reference genomes for read
alignment, and a lack of standardization and simplified workflows188,189. In regard to
clinical application, many tests that look for structural alterations of the genome are not
conducted using sequencing since often times more affordable methods like FISH, or PCRbased techniques are sufficient, especially when testing for known variants and
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diseases190,191. Microarrays are currently being used in clinics for genetic testing of
individuals, particularly children, with developmental delays and intellectual disabilities,
autism spectrum disorders and dysmorphic features with unknown causes192. Microarrays
are also used in the detection of clinically relevant CNVs in fetuses for prenatal diagnosis
of cytogenic abnormalities193. Sequencing is of great value for studying complex or
monogenic diseases where rare structural or sequence alterations that are associated with
the disease have yet to be discovered194.
Due to the high demand for products and services for human research, CNV
detection technology and methodology for the human genome have seen rapid advances.
However, mouse models are still necessary for many aspects of human-relevant research
but the costs of some CNV detection methods like whole genome sequencing are
prohibitively expensive to use on a large scale for mice. Therefore, more affordable
technologies like high-density microarrays are of value to animal model research,
particularly when the study requires looking at the whole genome and at many samples.
One such microarray is the Mouse Diversity Genotyping Array (MDGA; Thermo Fisher
Scientific Inc, Waltham, MA), a high-resolution, mouse SNP genotyping array that was
reported in 2009195.

1.3 Thesis goal and specific aims
The overall goal of this thesis is to explore and characterize the CNV landscape of Mus
musculus (house mouse), as detected by the MDGA in order to advance our knowledge of
an important model organism from the perspectives of adaptation and evolution, normal
development, and disease. M. musculus was selected as it is the most common mouse
species used in research, the reference genome has been sequenced and annotated, and it is
compatible with the MDGA since the array design is based off of the M. musculus reference
genome195. The MDGA was selected as the detection technology of choice due to its
affordability and because it was the highest resolution mouse microarray available at the
time. The chapters in this thesis describe experiments that were conducted with the goals
of improving the reliability of the MDGA CNV detection pipeline and determining its
utility for CNV detection in mice. This thesis will also explore how CNVs contribute to
the genomic landscape in different mouse groups affected by natural or artificial selection,
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in multiple tissues within an inbred mouse family, and in a mouse model of cancer. The
specific aims and the rationale for these aims are described below.
Aim 1: To assist in the development of a reliable, validated, and user-friendly CNV
detection pipeline for use with the MDGA by 1) identifying probes that are predicted to
perform poorly and excluding them from computations associated with CNV calling, and
2) updating probe annotations where necessary, and 3) developing a CNV output
visualization method to assist with identifying patterns in the number, state, and spatial
distribution of CNVs within and across the genomic landscapes of multiple samples.
This aim was necessary due to inconsistencies found in the original probe annotation files
and a lack of CNV detection software that can generate calls using both the single
nucleotide polymorphism-based probes and the invariant genomic probes. Results relating
to MDGA improvements and recommendations for use are presented mostly in Chapter 2,
and the CNV detection pipeline was used in the experiments described in Chapters 3-5,
with some stated modifications between different experiments. A method for visualizing
the CNV distribution across a genome is described in Chapter 3B.
Aim 2: To use the developed CNV detection pipeline to explore the CNV landscape of
multiple mouse subspecies and characterize differences between laboratory-bred and wildcaught mice.
This aim is used to test the pipeline developed in Aim 1 on a large M. musculus dataset and
the results of this broad survey have been published. Chapter 3 also includes a mouse cohort
comparison study that is an extension of the broad survey and has a stronger focus on the
genetic variation between classical laboratory-bred, wild-caught and wild-derived mouse
cohorts.
Aim 3: To study the contribution of CNVs to somatic mosaicism in an inbred mouse family
and assess the MDGA tool for this objective.
The goal of this aim is to provide a mutational baseline for what a CNV profile looks like
across multiple healthy tissues of one of the most commonly used laboratory mouse strains,
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C57BL/6J, as this would allow for identification of abnormal mutation profiles in future
mutation studies. The results of this work are presented in Chapter 4.
Aim 4: To assess the utility of the MDGA in the context of tumorigenesis and metastasis.
The MDGA was originally used to genotype normal mouse samples. The purpose of this
aim is to determine if the MDGA can be applied to disease samples like cancerous tissue,
where there is a high degree of genetic heterogeneity that also includes small size clones
of de novo mutations. The work from this aim is presented in Chapter 5.
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Chapter 2

2

The Mouse Diversity Genotyping Array: Overview

Parts of this chapter were published in Locke et al, BMC Genomics (2015)1. Probe filtering
based on BLAST analysis was performed by Nisha Patel. Chloe Rose isolated DNA from
naked mole-rat samples.

2.1 Introduction
2.1.1

Study motivation

To assist with the fulfillment of Aim 1 in this thesis - the development of a reliable,
validated and user-friendly CNV detection pipeline for use with the Mouse Diversity
Genotyping Array (MDGA) - probe lists were filtered according to defined criteria to
include only probes predicted to perform well in CNV detection. The impact of probe list
filtering was assessed by comparing SNP genotyping results pre- and post-filtering. The
MDGA probe design was evaluated in comparison to the Genome-Wide Human SNP
Array 6.0, which was selected as a standard for high quality. Additionally, the utility of the
MDGA for rodent samples within and outside of the genus Mus was tested to identify crossspecies hybridization limitations. This chapter provides background on the design of the
MDGA, and discusses sample selection, the CNV calling process, and data quality
assessment.

2.1.2

The Mouse Diversity Genotyping Array design

The Mouse Diversity Genotyping Array (Thermo Fisher Scientific Inc, Waltham, MA) was
designed by Yang et al (2009) with the intent to assess genetic diversity in Mus2. It is a
high-density genotyping array with probe sequences designed based on the sequenced
C57BL/6J mouse strain reference genome (Mus musculus domesticus)2. The MDGA can
be used to determine single nucleotide polymorphism (SNP) genotypes and identify CNVs.
Single nucleotide variants are considered polymorphic if they are present in at least 1% of
the individuals of a population3. The MDGA has 2,093,288 different probes that interrogate
two SNP alleles (alleles “A” and “B”) at 623,124 uniformly-spaced loci (~1 SNP per 4.3
kb)2,4. These probes were designed to target SNPs selected to capture the genetic diversity
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present in classical laboratory and wild-derived mouse strains. A detailed description of
how the loci were selected is available in the supplementary information of the Yang et al
paper2. A second group of probes, called invariant genomic probes (IGPs), target 597,758
non-polymorphic regions in exons and are used in CNV calling. IGPs were designed to
target ~93% of known exons in the mouse genome (Ensembl version 49)2. Exon 1 and
Exon 2 probe types make up the largest group of IGPs on the MDGA at a total of 1,195,516
probes and are divided into the two exon groups based on Affymetrix-specified criteria for
meeting probe design standards. CNV calling in this thesis is performed using both SNP
probes and Exon 1 and 2 probes.

2.1.3

SNP probes and invariant genomic probes

For each SNP locus, there are four different probe sequences that make up a probe set – a
sense and antisense sequence for each of the two alleles. The probes that make up a SNP
probe are found in a total of eight separate locations or “features” on the array – there are
two features for each of the four SNP probe sequences. SNP genotyping will result in one
of four genotype calls being generated per SNP locus: homozygous for allele A (AA),
homozygous for allele B (BB), heterozygous (AB), or an inability to determine a genotype
(No Call). The invariant genomic probes (IGPs), Exon 1 and Exon 2 probes, were designed
so that there are six probe sequences per exon. The IGPs target approximately 93% of the
annotated exons in the mouse genome2. There are three sense strand probes spaced out
along each exon in conserved (invariant) regions, and for each sense probe there is a
complementary antisense probe. These six probes make up an IGP set and unlike the SNP
probes, there is only one feature on the array per probe sequence. On the MDGA, each 5
µm x 5 µm feature has approximately 1.66-6 picomoles of copies of a particular probe
sequence5.

2.1.4

Fluorescence-based SNP and CNV genotyping

Prior to hybridization to the MDGA, sample DNA undergoes several preparatory steps,
including biotin labelling. Biotin-labelled sample DNA that has hybridized to MDGA
probes can be stained with streptavidin-bound phycoerythrin, a fluorescent protein. The
fluorescence intensity from sample DNA that is bound to IGPs and SNP probes can be
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used to determine how many relative copies of that particular DNA sequence are present
in the sample genome.
If a feature on the array does not emit light, then no hybridization occurred. This
could occur due the absence of DNA template or the presence of single nucleotide
mutations within the DNA template. Depending on the type of variant calling performed,
a lack of a fluorescence signal would translate into either an inability to detect a SNP
genotype or a copy number loss. To call a copy number loss, a predetermined number of
probes targeting consecutive loci would have to emit a similar fluorescence signal. If the
fluorescence intensity for probes targeting a given genomic region is higher or lower than
what is expected for a copy number of two, then this would suggest the presence of a copy
number gain or loss, respectively.

2.1.5

Generating SNP genotype and CNV calls

2.1.5.1

SNP genotyping with Affymetrix Power Tools

Prior to CNV calling, SNP genotyping is performed. SNP genotype calls for the MDGA
can be generated using the BRLMM-P algorithm with Affymetrix Power Tools’ aptprobeset-genotype program (APT; Thermo Fisher Scientific)6,7. Data from multiple
microarrays are genotyped together and any inter-sample variability in the signal intensity
needs to be corrected. This can be done with an APT normalization step. Quantile
normalization is typically used for SNP genotyping, with the exception of cancer samples
where median normalization is recommended8. A median polish summarization step
follows normalization and is applied to summarize the information from all the probes for
one allele of a SNP by using the median value. Median polish takes into account both intersample variation and variation in signal intensity arising from sequence-dependent
hybridization specificity9.
After genotyping, other APT programs are used to generate log R Ratio (LRR) and
B Allele Frequency (BAF) values for the SNP probes. The LRR represents the total
fluorescence intensity signals from each SNP probe set. The BAF values represent the
fluorescence signal ratio between the B and A allele probes at each SNP locus. The
clustering of genotype calls into AA, AB, and BB genotypes, and the generation of LRR
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and BAF values, is assisted by a model clustering file that specifies where each genotype
cluster for a given SNP is likely to be located. This file can be created by the user or
downloaded from the product page for the MDGA on the Thermo Fisher Scientific
website10. Specific information about APT installation and required files for MDGA-based
SNP genotyping are available online, along with a sample genotyping script11.
SNP genotyping is not only needed for generating CNV calls, it can be used to
identify false positive calls for putative CNV losses. A requirement for CNV identification
in this thesis is that the CNV calls include SNP probes and not only IGPs. SNP probes
within a CNV with a predicted state of zero should only have “No Call” genotypes since a
state of zero would mean that no target DNA is present in that region of the genome.
Heterozygous SNP genotypes (“AB” calls) would not be expected for SNP probes
underlying a CNV with a state of one since only one copy of the allele would be present.

2.1.5.2

CNV calling with PennCNV

Following SNP genotyping, PennCNV software11 can be used to generate CNV calls.
PennCNV is open source software capable of using both SNP probes and IGPs for CNV
calling and detect copy number states ranging from zero to four. The SNP genotyping step
is a necessary step prior to CNV calling because PennCNV requires LRR and BAF
information to identify CNVs. Before the LRR and BAF files are used for CNV calling,
the SNP genotyping call rates for each sample are assessed and any unusual outliers are
removed. The call rate for a sample is the percentage of loci that have a genotype call12.
After outliers are removed, the genotyping step is performed again and new LRR and BAF
files are created. SNP genotyping does not have to be repeated if there are no failing
samples to remove. Another file necessary for CNV calling is a PFB-formatted file that
contains the genomic location for all SNP probes and IGPs. For a given copy number state
to be assigned to a genomic region, consecutively located target DNA sequences must emit
the same fluorescence intensity after hybridizing to the probes. The MDGA probe locations
are based on the sequenced Mus musculus genome and need to be updated as the reference
genome is updated. Probes excluded from the PFB file will not be used by PennCNV when
it generates CNV calls.
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PennCNV uses a hidden Markov model (HMM) algorithm to make CNV calls. The
HMM algorithm determines how likely a probe signal is to represent a particular copy
number state while taking the inter-probe distance and the fluorescence signal of the
previous probe into consideration11. CNV calling in PennCNV for a dataset of interest is
assisted by a trained HMM model file that provides information about probabilities and
possible copy number outcomes, based on a training dataset.
Several consecutive probes of the same assigned copy number state are required to
call a putative CNV. The specific number of consecutive probes required to make a CNV
call is selected by the user although a minimum of three or more probes is generally used13.
From a biological perspective, most regions of the genome are expected to be in a copy
state of two and it is uncommon to have two opposite copy number states next to each
other, like a loss immediately followed by a gain or vice versa.
The CNVs called by PennCNV require experimental confirmation to determine if
the CNVs are biological events, and to locate the exact position of the CNV junctions.
PennCNV provides start and end positions for each CNV call but the array does not have
single nucleotide-level resolution, so these positions are rough estimations of the junction
locations. The true CNV junctions are assumed to lie somewhere between the probes at the
ends of the predicted CNV and the probes just outside of the CNV ends. Further
information about the use of PennCNV with microarrays designed by Affymetrix is
available on the PennCNV website14.

2.1.6

Discrepancies in annotations for the probe files of the Mouse
Diversity Genotyping Array

Following the release of the MDGA, discrepancies were found in the chromosomal
positions listed in the annotation files for the SNP probes15. Later, the probe annotation
files were filtered by S.T. Eitutis (2013)16 based on several inclusion criteria including, but
not limited to, probe length consistency, perfect match genome alignment scores, the
absence of restriction enzyme recognition sites in the target DNA, presence of only one
known SNP locus within a probe set, and sufficient genomic distance between target SNPs.
In this chapter, the probe annotation files for both SNP probes and IGPs are filtered to
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remove unreliable probes from use in CNV identification. The CNV-specific filtering
criteria for the MDGA are described in the methods section.
Although probe filtering can be used to improve CNV calling reliability, the CNVs
identified by microarrays are putative and require additional experimental confirmation.
Several computational based methods, discussed later in Section 2.5, can be used to assess
the quality of the MDGA data prior to experimental confirmation.

2.1.7

Assessment of probe design for the Genome-Wide Human
SNP Array 6.0

Following assessment of the MDGA probe design, probe annotation files from the
Genome-Wide Human SNP Array 6.0 (SNP Array 6.0; Affymetrix®, Thermo Fisher
Scientific Inc, Waltham, MA) were assessed for issues in SNP probe design, for
comparison purposes (see Results section 2.3.1). The SNP Array 6.0, designed by
McCarroll et al (2008)17, is a human SNP-based genotyping array comparable to the
MDGA, which was available for use one year after the SNP Array 6.018. The SNP Array
6.0 contains 1,863,892 different probe sequences that provide SNP genotype calls at
931,946 loci (full CDF file)19. Each SNP genotype is determined by a set of two probe
sequences representing two alleles.
Like the MDGA, the SNP Array 6.0 can provide both SNP and CNV genotype
calls17. The impact of probe filtering on the two arrays can be assessed and compared by
looking at the SNP genotyping call rates pre- and post-filtering. An increase in SNP
genotype call rates is expected if the probe filtering is effective at removing probes that do
not return a genotype call. In this chapter, SNP Array 6.0 probe filtering is limited to
inclusion criteria that are relevant to SNP genotype calling. The probe inclusion criteria
include: probe length of 25 nt, probe sequence uniqueness, and absence of NspI or StyI
recognition sites in the target DNA. If the target DNA is unable to bind the probes due to
being digested at the probe target site, then a genotype call cannot be made, and removal
of these poorly-performing probes should result in an increased call rate.
SNP genotyping can also be affected by the genotyping algorithm used. The
Birdseed algorithm is commonly used for the SNP Array 6.0 and there are two versions
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available (v1 and v2). The two Birdseed versions differ in their use of SNP-specific models.
For Birdseed v1, a Gaussian mixture model is fitted into two-dimensional A- and B-signal
space and the SNP-specific models are used as starting points for ExpectationMaximization algorithm iterations for genotype clustering6. Birdseed v2 is more robust
than Birdseed v1 in the sense that the clustering is more reliant on SNP-specific priors.
Here, both Birdseed versions are tested on a HapMap320 dataset of 874 samples, to
observe the effect on SNP call rates, in comparison to probe filtering effects. The Birdseed
algorithm is used as opposed to other existing algorithms because Birdseed is used by
Affymetrix® for array testing and validation21. Two versions of Birdseed are included in
this study rather than one because they are known to produce slightly different genotyping
outcomes for the same dataset22.

2.1.8

Cross-species hybridization and considerations for SNP
genotyping

SNP microarrays are generally made for a limited number of organisms that are of
scientific interest, including humans, model organisms like mice, agriculturally-important
animals like cows, and companion species like dogs1,21,23,24. These microarrays can
sometimes be used for organisms for which they were not designed. The hybridization of
Antarctic fur seal (Arctocephalus gazelle) DNA to a dog (Canis familiaris) array is one
such example and the study obtained SNP genotype calls for 19.2% of loci targeted by the
array25. This low percentage of usable SNP loci is expected since, according to this study,
there are 44 million years of divergence between the seal and dog.
Cross-species array hybridization has also been used for gene expression studies.
Some examples include Weddell seal (Leptonychotes weddellii) samples being applied to
a human gene expression array26, Sordaria macrospora fungus samples being applied to
an array based on the closely related Neurospora crassa fungus27, and bell pepper and
eggplant samples being applied to a tomato gene expression array28.
For cross-species microarray assays, it is expected that if there is low sequence
divergence between the species being tested and the species upon which an array was
designed, as is expected with closely related species, then there will be high levels of probe-
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target hybridization. Sequence divergence as small as 1% will have a detectable decrease
in hybridization levels29. Fish gene expression array experiments have shown that gene
expression results are most consistent for species that diverged from each other less than
10 million years ago30. The same study showed that some results, although more limited,
can be generated by expression arrays for species that diverged from the array reference
species more than 200 million years ago. A similar observation was found for the MDGA,
where increased genetic distance of Mus musculus samples from the C57BL/6J reference
strain was associated with an increase in heterozygous SNP calls and No Calls31.
CNVs are identified by collective calls of an altered copy number state using
consecutive uninterrupted markers. Therefore, unlike SNP genotyping, the ability to
identify CNV events is heavily dependent on knowing the genomic position of probe
targets, relative to each other. In order to use the MDGA for CNV calling in a different
species, the MDGA probe sequences would have to be reannotated based on the sequenced
reference genome for the species of interest, given the likelihood of genomic
rearrangements over evolutionary time. To ensure that only consecutively located probes
are used to identify CNVs, probes with sequences that occur more than once in the genome
should be excluded from CNV calling and the probes need to be annotated so that they are
assigned a genomic position.

2.1.9

General goal, specific objectives, and predicted outcomes

Overall, the filtered probe lists and recommendations for MDGA use and data quality
assessment described in this chapter are expected to assist in the improvement of the
MDGA as a tool for SNP genotyping and CNV detection in mice.
The specific objectives of this chapter are:
1. To identify MDGA probes that are predicted to perform poorly in CNV detection
based on defined criteria for probe design, and to generate a list of probes
recommended for use CNV detection.
2. To assess the impact of filtering probe lists to contain valid probes only, with
filtering success being evaluated in terms of increased SNP genotype call rates.
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3. To compare the impact of MDGA probe list filtering on SNP genotype calling to
the impact of Genome-Wide Human SNP Array 6.0 probe list filtering.
•

The Genome-Wide Human SNP Array 6.0 is predicted to have a better
probe design and is used here as a standard for comparison.

4. To evaluate the applicability and hence the utility of the MDGA for rodent species
other than Mus musculus.
5. To make recommendations for study design considerations to ensure that reliable
and useful MDGA data is generated.
6. To discuss approaches for assessing quality of MDGA data.
The filtering of probe annotation files for the MDGA is expected to result in improved SNP
genotype calling and help create a more reliable list of probes for use in CNV calling. SNP
Array 6.0 probe filtering is also predicted to result in improvements to SNP genotype
calling. However, the greater use and earlier development of human versus mouse
microarray technologies may have resulted in a better designed microarray for humans,
requiring fewer probes to be excluded from genotyping. It is expected that the MDGA can
be used for cross-species hybridization studies of SNP-based genetic diversity and that the
array will be most informative for samples closely related to Mus musculus.

2.2 Materials and methods
2.2.1

Probe filtering and SNP genotyping for the Mouse Diversity
Genotyping Array

MDGA annotation files for IGPs and SNP probes were filtered using criteria relevant for
CNV calling, and these filtered probe lists were used to identify CNVs described in
multiple projects in subsequent chapters of this thesis. IGP annotation files were
downloaded from the Center for Genome Dynamics website32. IGPs that were classified as
Exon 1 and Exon 2 were locally run through BLAST to ensure that the probe sequences
were found only once in the mouse haploid genome (UCSC:mm9) and to verify the
annotated position (Fig. 2-1). Inclusion criteria for probe sequences required a length of 25
nt, one probe ID per probe sequence and the presence of complementary sense and
antisense sequences.
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In-house scripts removed probe sets likely to contribute to background noise and
false positives, including those containing palindromic NspI or StyI recognition sites within
a given probe sequence and its 12 nt flanking region (as the genomic target sequence is
digested by these restriction enzymes prior to hybridization to the array) as well as probe
sets overlapping other probe sets based on genomic position, as these would compete for
genomic DNA template (Fig. 2-1). This filtered list was used to identify CNVs in the broad
survey discussed in Chapter 3. Following the completion of CNV calling and analyses, the
SNP and IGP annotation files were further filtered to create a more stringent probe list (Fig.
2-1), which was used in the mouse cohort comparison study of Chapter 3. The additional
filtering included removing overlapping probes because they would compete for the same
DNA template, which could affect the fluorescence intensity of that genomic region. The
check for overlapping probes included all probe types on the MDGA. It is important to
note that overlap was determined based on the reference genome locations
(UCSC:mm9/NCBI Build 37) and that which probes are overlapping each other may
change with updates to the reference genome. The probe identifiers for the stringently
filtered probe list are provided in Locke et al. (2015)33.
For 351 mouse .CEL files downloaded from the Center for Genome Dynamics at
The Jackson Laboratory website34, SNP genotype calls were generated using the APT
BRLMM-P algorithm and default parameters. The three probe lists used for SNP
genotyping were the unfiltered MDGA probe list, the filtered list provided by S. T. Eitutis
(2013) and the stringent list recommended for CNV calling in Locke et al16,33.

2.2.2

Probe filtering and SNP genotyping for the Genome-Wide
Human SNP Array 6.0

SNP Array 6.0 probe sequence, flanking sequence, probe annotation, and library files were
downloaded from the Thermo Fisher Scientific website35. SNP probe sequences with
“SNP_A” identifiers were filtered, using in-house scripts, based on probe length, sequence
uniqueness among other SNP probes, and restriction enzyme recognition sites (Fig. 2-2;
Appendix 2A). If one probe sequence in the set of two failed to meet inclusion criteria, the
whole probe set was removed from analysis. SNP probes were not filtered based on probe
overlap criteria which would remove probes competing for the same target DNA. Unlike
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CNV calling, SNP genotyping is not dependent on the fluorescence intensity levels relative
to an expected diploid intensity, which can be affected by probe competition for shared
DNA targets. After filtering was applied to the 25 nt probe sequences, restriction enzyme
recognition site filtering was applied to the annotation files containing flanking sequence
information for each probe (Appendix 2B). Flanking sequences contain the 25 nt probe
sequence and eight additional nucleotides.
SNP genotype calls were generated using Affymetrix® Power Tools with the
Birdseed (version 1 and version 2) algorithm and default parameters6, and 874 HapMap3
CEL files (Appendix 2C) that were downloaded from NCBI’s HapMap ftp site36. This
dataset represents individuals from various ethnic backgrounds including African ancestry,
Gujarati Indian, Han Chinese, Japanese, Luhya, Maasai, Mexican ancestry, Toscani,
Utah/Mormon and Yoruba. Sample APT scripts are provided in the supplementary
materials (Appendix 2D).
Graphical images were generated using R37. Sample numbers in Figure 2-3
correspond with the “Sample_Number” column in Appendix 2C and sample numbers in
Figure 2-4 correspond with the “Sample_Number” column in Appendix 2E.

2.2.3

Cross-species hybridization with SNP genotyping

The Mus subgenera sample set includes a total of 27 Mus, Pyromys, Coelomys, and
Nannomys samples (Table 2-1). MDGA CEL files for Mus samples were downloaded from
the Center for Genome Dynamics website38. H. glaber tail tissue samples were provided
by Dr. Melissa Holmes (University of Toronto Mississauga). DNA was extracted according
to the Wizard® Genomic DNA Purificaiton Kit protocol (Promega, Madison, Wisconsin,
USA), with two modifications: 1) tissues were digested by proteinase K for 24 to 48 hours,
and 2) RNAse disgestion was used for all tissues. DNA quantity and purity were assessed
using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham,
Massachusetts, USA). MDGA hybridization was performed at the London Regional
Genomics Centre (Robarts Research Institute, Western University, London, ON). SNP
genotyping was performed for combined Mus and H. glaber samples as well as separately
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for each of these two groups. Genotype calls were generated using the stringent filtered
MDGA probe list (Section 2.2.1), APT BRLMM-P algorithm, and default parameters.
Table 2-1. Mus species and Heterocephalus glaber samples.
CEL ID
Mus Subgenus
SNP_mDIV_D7-473_012209.CEL
Coelomys
SNP_mDIV_D6-472_012209.CEL
Mus
SNP_mDIV_D7-644_101509-redo.CEL
Mus
SNP_mDIV_D7-644_91809.CEL
Mus
SNP_mDIV_D3-639_101509-redo.CEL
Mus
SNP_mDIV_D3-639_91809.CEL
Mus
SNP_mDIV_D8-646_101509-redo.CEL
Mus
SNP_mDIV_D8-646_91809.CEL
Mus
SNP_mDIV_A2-645_102109.CEL
Mus
SNP_mDIV_D9-647_101509-redo.CEL
Mus
SNP_mDIV_D9-647_91809.CEL
Mus
SNP_mDIV_D4-640_101509-redo.CEL
Mus
SNP_mDIV_D4-640_91809.CEL
Mus
SNP_mDIV_D8-474_012209.CEL
Mus
SNP_mDIV_D5-642_101509-redo.CEL
Mus
SNP_mDIV_D5-642_91809.CEL
Mus
SNP_mDIV_D6-643_101509-redo.CEL
Mus
SNP_mDIV_D6-643_91809.CEL
Mus
SNP_mDIV_A7-654_102109.CEL
Nannomys
SNP_mDIV_D11-653_101509-redo.CEL
Nannomys
SNP_mDIV_D11-653_91809.CEL
Nannomys
SNP_mDIV_D10-652_101509-redo.CEL
Nannomys
SNP_mDIV_D10-652_91809.CEL
Nannomys
SNP_mDIV_A3-648_102109.CEL
Pyromys
SNP_mDIV_A4-649_102109.CEL
Pyromys
SNP_mDIV_A5-650_102109.CEL
Pyromys
SNP_mDIV_A6-651_102109.CEL
Pyromys
DNA3337.CEL
N/A
DNA3338.CEL
N/A
DNA3339.CEL
N/A
DNA3340.CEL
N/A

Species
Mus pahari
Mus caroli
Mus caroli
Mus caroli
Mus castaneus
Mus castaneus
Mus cervicolor
Mus cervicolor
Mus cookii
Mus dunni
Mus dunni
Mus famulus
Mus famulus
Mus famulus
Mus fragilicauda
Mus fragilicauda
Mus fragilicauda
Mus fragilicauda
Mus mattheyi
Mus minutoides
Mus minutoides
Mus orangiae
Mus orangiae
Mus platythrix
Mus platythrix
Mus saxicola
Mus saxicola
Heterocephalus glaber
Heterocephalus glaber
Heterocephalus glaber
Heterocephalus glaber

Sex
Male
Male
Male
Male
Female
Female
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Male
Female
Female
Male
Male
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2.3 Results
2.3.1

Mouse Diversity Genotyping Array and Genome-Wide
Human SNP Array 6.0 probe filtering

Following filtering of MDGA probe sequences, 94% of SNP probe sequences and 71% of
exon probe sequences remained (Fig. 2-1). In total, approximately 4.79 million unique
probes targeting 915,195 loci are available for use in CNV calling. In comparison to the
original, unfiltered SNP probe list, SNP genotype calling improved for 100% of tested
samples when using both the filtered list by S.T. Eitutis (2013)16, and the filtered list in this
study (Table 2-2). The average percent by which the call rates increased is similar for the
two filtered probe lists.
The SNP Array 6.0 probe files were filtered for the purpose of determining if SNP
genotyping call rates would improve or not following filtering. SNP probe filtering left
95% of SNP probes available for genotyping (Fig. 2-2). For this array, the SNP call rate is
most improved when using a different calling algorithm with the original probe list and not
by filtering the probe list (Table 2-2). When using the unfiltered human array probe list,
174 probes fail to call a genotype in any of the 874 samples (Appendix 2F). Filtering the
probe list does not result in the removal of any of the 174 probes and they continue to
provide No Call genotypes. The call rate improvement following probe filtering proved to
be minimal for the human array, with an average call rate increase of 0.009% (Birdseed
v1) or 0.0093% (Birdseed v2), and a maximum individual sample increase of
approximately 0.06% (Table 2-2).
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Figure 2-1. Impact of application of probe list filtering criteria for SNP, Exon 1 and Exon 2 Mouse Diversity Genotyping Array
probes. Non-bolded criteria were used to construct the probe list used in the broad survey in Chapter 3. Bolded criteria were used to
construct the stringent probe list used in the mouse cohort comparison study in Chapter 3. SNP probe filtering was performed on a probe
list previously filtered by S. T. Eitutis (2013)16. The Exon probe list had not been filtered previously.
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Table 2-2. Changes in SNP genotyping call rate when changing algorithm version and SNP probe lists.
Array

Mouse Diversity
Genotyping Array

Genome-Wide Human
SNP Array 6.0

a

Percentage of samplese with
improved call rates (%)

Average call rate
increase (%; range)

Average call rate
decrease (%; range)

100

0.538 (0.16-1.08)

N/A

100

0.536 (0.16-1.08)

N/A

Birdseed (v1),
filteredc

72.65

0.009 (0-0.061)

0.0044 (2x10-5-0.018)

Birdseed (v1),
flankingc

31.24

0.011 (8x10-5-0.051)

0.013 (5x10-5-0.061)

Birdseed (v1),
original listd

95.88

0.083 (6.7x10-4-0.17)

0.018 (3.3x10-4-0.065)

Birdseed (v2),
filteredd

74.37

0.0093 (3x10-5-0.057)

0.0044 (3x10-5-0.018)

Birdseed (v2),
flankingd

29.98

0.011 (5x10-5-0.045)

0.013 (5x10-5-0.064)

Algorithm and
probe lista
BRLMM-P, S. T.
Eitutisb
BRLMM-P, Locke
et al b

‘Filtered’ refers to the probe list filtering applied to only the 25 nt probe sequence. ‘Flanking’ excludes “Filtered” probes whose flanking

regions contain NspI or StyI recognition sites.
b

Compared to original MDGA list with BRLMM-P

c

Compared to original SNP Array 6.0 list with Birdseed (v1)

d

Compared to original SNP Array 6.0 list with Birdseed (v2)

e

Genotyping was performed for 351 MDGA CEL files and 874 HapMap3 CEL files for the MDGA and SNP Array 6.0, respectively.
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Remaining loci
25 nt probe length
931,946
931,932
903,296

Figure 2-2. Impact of application of probe list filtering criteria for Genome-Wide Human SNP Array 6.0 SNP probes. Probe
sequences representing both SNP alleles of a locus were excluded if at least one probe sequence did not meet the inclusion criteria.
When Birdseed (v1) is used instead of Birdseed (v2) as the genotyping algorithm, the call rate improves for 96% of samples
(Table 2-2). However, the change in call rate is small. The average call rate across samples increases by 0.083%, and the highest increase
in an individual sample’s call rate is 0.17%. For samples where the call rate decreases, the average decrease in call rate is 0.018%. When
looking solely at call rates, the differences in call rates between different algorithms is very small. At an individual sample level, some
call rates are not greatly affected by changes in algorithm version or probe list used, while other samples are more affected (Fig. 2-3).
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Figure 2-3. Call rates for 351 Jackson Laboratory samples, generated with different
probe lists. Black lines connect the call rates for individual samples and represent the call
rate difference.
The difference in effect of probe filtering on SNP genotype call rates for the mouse
and human arrays can be best observed in Figures 2-3 and 2-4. The average call rate
increase following filtering for the MDGA is approximately 0.54%, which is nine times
higher than the maximum call rate increase for an individual human sample following
filtering (~0.06%). The highest call rate increase for an individual mouse sample postfiltering is 1.08%.
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Figure 2-4. Call rates for HapMap3 samples, generated with Birdseed (v1), Birdseed
(v2), and filtered probe lists. Black lines connect the call rates for individual samples and
represent the call rate difference.
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2.3.2

Cross-species hybridization

The average SNP genotyping call rate is highest for members of the subgenus Mus while H. glaber has the lowest average call rate at
approximately half the call rate of the Mus subgenus group (Table 2-3). The H. glaber call rate almost doubles when it is genotyped
together with Mus samples.
Table 2-3. SNP genotype call rates for Heterocephalus glaber samples genotyped together with and without a set of 27 samples
representing four Mus subgenera: Mus, Pyromys, Coelomys, and Nannomys.
Samples
Heterocephalus glaber
(Naked mole-rat)

Divergence time from
Mus musculus domesticus

Sample size

73.1 million years ago39

4

Genotyped with or
without other samples
Without
With Mus set

Average call rate
44%
86%
Mus (90%)

Mus (17)
Mus set

≤ 7.6 million years ago40

Without

Pyromys (85%)
Coelomys (83%)

Pyromys (4)

Nannomys (86%)

Coelomys (1)

Mus (91%)

Nannomys (5)

With four H. glaber samples

Pyromys (88%)
Coelomys (86%)
Nannomys (88%)
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2.4 Discussion
2.4.1

Impact of probe filtering for the Mouse Diversity Genotyping
Array and the Genome-Wide Human SNP Array 6.0

MDGA probe filtering improved overall SNP genotype call rates, as predicted, and it did
so for all tested mouse samples. Therefore, filtered probe lists are recommend for use in
variant detection with the MDGA, particularly for SNP genotyping. Testing the effect of
probe filtering on CNV calling is more challenging as it would require algorithms to be
tested on samples where the CNVs have been previously identified so that the copy number
state and genomic location are known. Although not tested here, probe filtering is expected
to improve CNV detection so filtered probe lists will be used for CNV detection in the
studies described later in this thesis. CNV calls are directly affected by SNP probe
performance. If a probe does not bind its target efficiently, then the fluorescence intensity
of that region will be lower than the fluorescence intensity of the neighbouring probes and
may break up a larger CNV gain, making it falsely appear to be two separate CNV events.
False negatives can occur when minimum marker requirements are used for CNV calling
and poorly performing probes in a CNV region prevent the cut-offs from being met. For
example, a CNV spanning a required minimum of three probe loci may not be identified
as a CNV because one of the probes is providing false signal information due to poor target
DNA binding.
SNP Array 6.0 data indicate that probe filtering based on NspI and StyI recognition
sites does not greatly improve the average call rate, particularly when compared to the
effect of using algorithm versions on call rate. Furthermore, a group of 174 probes that
produced No Call genotypes in all tested samples, were not removed by probe filtering.
This implies that there are factors other than restriction enzyme digestion involved in
preventing hybridization. No combination of probe list and algorithm resulted in an
increased call rate for all samples. The highest call rates overall were observed when using
the unfiltered probe list and the Birdseed (v1) algorithm. This suggests that the SNP Array
6.0 is well-designed with respect to the location of restriction enzyme recognition sites and
does not appear to benefit from the use of a filtered probe list. The difference in the average
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call rate was very minor (<0.1%) between algorithm versions and this finding is consistent
with previous algorithm comparisons when genotyping using the Genome-Wide Human
SNP Array 6.022. However small the differences may appear to be, the algorithm choice
does still impact the genotyping results and selection of the wrong algorithm can result in
variants going undetected or being incorrectly associated with a biological event or
phenotype. The importance of algorithm selection is supported by Bucasas et al41, who
found that the CRLMM algorithm yielded higher call rates than the Birdseed (v2) algorithm
but also showed decreased tolerance to low quality samples. Users selecting algorithms for
variant detection should be aware that some outcomes may be algorithm-specific. The
reasons for why Birdseed (v1) yields higher call rates than Birdseed (v2) would need to be
investigated in a future study.

2.4.2

Cross-species hybridization and considerations for SNP
genotyping

Like other microarrays, the MDGA can also be used for cross-species hybridization but the
call rates are heavily influenced by how the genotyping is performed. For instance, naked
mole-rat samples applied to the MDGA yield very different genotyping call rates
depending on whether or not the samples are genotyped along with Mus samples or
independently. By genotyping the naked mole-rat samples along with Mus samples, the
call rates are artificially increased so that they are more similar to the mouse samples.
Genotyping Mus samples with naked mole-rat samples results in a slight increase, up to
3%, in the average Mus call rate. These results suggest that when conducting cross-species
hybridization analysis, it is important to perform the genotyping for the different species
separately.
Aside from technical issues, low call rates can occur if a sample’s genome is
distantly related to the reference genome that the probe design was based on. In this case,
sequence divergence between species means that there are hybridization incompatibilities
between the target DNA and the array probes. The MDGA probes can hybridize with SNP
probes to a degree that is associated with the time of species divergence from Mus musculus
domesticus. Mus subgenus samples have the highest call rates among the Mus genus
samples tested, likely due to having a closer genetic relationship to M. m. domesticus42 and
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therefore more sequence complementarity between the MDGA probe sequences and the
target DNA. The subgenra Pyromys, Coelomys, and Nannomys have call rates in the 80s
and are more distantly related to the M. musculus species42. Heterocephalus glaber (naked
mole rat) samples, which have the lowest call rates, are also the samples that are the most
distantly related to M. m. domesticus39.
Unlike SNP genotyping, it is more difficult to apply cross-species hybridization for
CNV detection. This is because accurate CNV detection requires high genomic coverage
by probes that are contiguously located in the genome. If an organism is distantly related
to the organism whose genome was used to design the array, then it is likely that many
probes will not have a target to bind to due to sequence divergence or if they do bind a
target, the locations may not be contiguous due to low synteny. When choosing to perform
cross-species hybridization, it is advisable to check the array probe sequences against a
reference genome (if available) to determine if the sequence is present in the genome and
where it is located. This will provide the user with an idea of how many probes should
return a genotype call and which part of the genome is being targeted. The naked mole rat,
for example, has 41,225 syntenic regions with the mouse genome, covering ~83% of the
naked mole rat genome43. In comparison, there are 24,999 syntenic regions between the
naked mole rat and human genomes, covering ~92% of the naked mole rat genome43. This
means that both mouse and human microarrays could be used for CNV detection in the
naked mole rat, provided that there is sufficient sequence similarity between the microarray
probes and the sample DNA.

2.5 Computation-based assessment of MDGA data quality
CNV results generated by microarrays require experimental confirmation to ensure that the
calling methods are reporting biological events. Even if the microarray probes are designed
well, false positive and negative calls can occur. Some CNV calling errors can result from
hybridization problems while other errors result from the CNV calling methods or
algorithms employed44,45. A study comparing multiple algorithms on SNP microarray data
found less than ~50% concordance in detected CNVs, between any two algorithms tested46.
The study’s authors advised, based on findings in multiple studies, that the use of multiple
algorithms for a dataset can reduce false negative calls but will also increase false positive
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calls. Typically, PCR-based methods are used to experimentally confirm putative CNVs.
In studies where a large number of CNVs are detected, it is not practical or cost-effective
to confirm every putative CNV. Therefore, a targeted approach to confirmation can be
used. With a targeted approach, computational assessment of the data quality can be used
first to evaluate if the CNV call quality is sufficient to move forward with wet lab
confirmation. The following chapter sections discuss computational methods of data
quality assessment.

2.5.1

Assessing MDGA data quality through visualization of
fluorescence intensity data

One of the simplest ways of checking the quality of microarray hybridization for newly
generated data or unfiltered, publicly available data, is to generate coloured images
showing the hybridization signal for each array feature. Some arrays can have regions of
abnormally low or high hybridization signal, which can result from an unequal application
of the DNA solution, precipitate formation, and poor sample preparation47. Once array
hybridization has been assessed visually for the presence of artifacts, and problematic
arrays have been removed from the dataset, SNP genotyping and CNV calling can be
performed. Depending on the software used for interpreting the fluorescence intensity data
and the size of the artifacts, artifact reduction may be possible. For small artifacts, the
probes in those regions can be identified and excluded from analysis. Normalization may
help in cases were the overall array fluorescence intensity is lower or higher than expected
unless the signal is too low for detection or the array is oversaturated.

2.5.2

Assessing quality of SNP genotype output

SNP genotype call rates are an indicator of the array quality and sample suitability. For a
call to be generated, the probes have to bind sufficient DNA template so that a hybridization
fluorescence signal can be detectable. Errors affecting DNA preparation and inappropriate
hybridization conditions can reduce probe-target binding48, leading to low SNP genotype
call rates.
For samples closely related to the reference genome, hybridization success may be
reduced if off-target mutations (when nucleotide mismatches occur at sites other than the
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SNP locus) are present. The expected MDGA SNP call rate for a Mus musculus domesticus
laboratory strain is 97% or higher7. Lower call rates are expected for other subspecies of
mouse like M. m. musculus, M. m. castaneous and M. m. molossinus, and different species
of mouse like M. spretus and M. spicilegus are expected to have call rates in the low
nineties1. To ensure the highest call rates possible for MDGA samples, probes that are
predicted to perform poorly with regards to hybridization, or cannot be annotated, should
be excluded from genotyping.
The SNP genotyping output is important for CNV calling when using PennCNV
software because PennCNV requires information about the frequency of the B allele (BAF)
and the Log R ratio (LRR)11,49. The LRR represents the normalized, total fluorescent
intensity signals from each SNP probe set and is related to the amount of sample DNA
bound to the probes. BAF values represent the normalized fluorescent signal ratio between
the B and A allele probes at each SNP locus. The amount of deviation of BAF values from
the expected BAF values for AA (0.0), AB (0.5) and BB (1.0) clusters, is called the BAF
drift. Commonly, a filtering step is applied to the LRR standard deviation (LRR_SD) and
BAF drift values to determine if a sample is suitable to use for CNV calling. Low LRR_SD
and BAF drift values are desirable and PennCNV uses cutoffs of 0.30 for LRR_SD and
0.01 for BAF drift50. Exclusion criteria based on the waviness factor (WF <0.05) are used
as well50,51. The waviness factor describes the dispersion in the signal intensity; low
amounts of dispersion are desirable and are an indicator of DNA quality. Lower or higher
LRR_SD, BAF drift, and WF cutoffs can be used depending on the type of array used and
user preference for cutoffs. Affymetrix arrays, for example, tend to produce more noise
than Illumina arrays so less stringent cutoffs should be used for Affymetrix array data52.

2.5.3

Assessing MDGA data quality by examining the nature of
CNV calls

There are several indicators that are helpful in predicting the reliability of CNV calls. In
the case of CNV losses, state-zero losses should not overlap SNP probes with genotype
calls other than No Call genotypes and state-one losses should not overlap SNP probes
with heterozygous genotype calls. The reason for this is that if there is only one copy of a
DNA segment that contains SNP loci, only one allele should be present which would result
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in the generation of a homozygous genotype call. If there are no copies of the DNA
segment, SNP probes would not bind target DNA, so it would not be possible to generate
a genotype call.
CNV losses are less likely to occur and be maintained in genomic regions
containing functional elements, in particular for genes vital for cell survival53,54. Although
it is possible for such losses to be present in subpopulations of cells in cases of mosaicism,
these losses are unlikely to have been inherited or to have arisen early in development.
There are over 700 genes and noncoding elements, overlapping MDGA probes, that are
known to cause deleterious phenotypes when copies are lost, or are highly conserved and
unlikely to vary in copy number (Appendix 2G). Most of the genes listed in Appendix 2G
come from the International Mouse Phenotyping Consortium (IMPC)55. The IMPC’s
purpose is to generate and characterize 20,000 knockout mouse strains, and it a useful
source for determining the phenotypic impact of gene deletions in mice. The remaining
genes in the Appendix 2G come from independent studies and were compiled as resource
in Locke et al33. These genes are expected to overlap very few putative CNVs detected in
normal healthy tissues, with the exception of some mosaicism events, and can therefore be
used to assess the MDGA data quality.
When generating CNV calls for a dataset with mice of different backgrounds, it is
expected that the number of CNVs will differ between mice and there will be a mix of copy
number losses and gains called13,33,56. Excessive CNV calls in one sample may indicate
poor array quality or an unusually high mutation load in that individual. Similarly,
detecting only gains or only losses in a dataset may be an indicator of either technical issues
or true mutational events (e.g. from exposure to a mutagen or disease models). Based on
Locke et al.’s33 study which uses the MDGA, Mus musculus subspecies have an average
of 29 CNVs per mouse, although the number of CNVs can differ greatly depending on the
mouse genetic background and health. To determine what is a normal CNV profile for a
single healthy mouse of a specific background, comparisons should be made to CNVs from
samples from multiple individuals of this background. For these comparisons, the CNV
detection approach used should be the same.
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The size of the CNVs detected is dependent on the probe density and spacing across
the genome. CNVs that are most likely to be biological events are expected to be those that
are detected by many, closely-spaced probes since the resolution would be higher. A
consequence of low resolution is that a large detected CNV may actually be multiple CNVs
that have been called as one event due to low probe density or uneven probe spacing that
includes large gaps13. CNV calls can be excluded based on the number of probes used to
make that call as well as the probe density. The probe density is calculated by dividing the
CNV length by the number of probes underlying a call, so it does not take into account
probe spacing within the CNV region. Therefore, large CNVs should be assessed for probe
spacing to ensure that the call does not include probe “deserts”, which can affect the
accuracy of the call.
Confidence in the putative CNVs calls is greater if the CNVs have been detected
before in multiple, independent studies. Recurrent CNVs can be found in mutation hotspots
or they may be mouse strain- or species-specific as a result of an inherited mutational event
in a common ancestor. One such example, is the presence of duplications of the insulindegrading enzyme (Ide) gene in some C57BL/6J mice from The Jackson Laboratories
colony, which is thought to have arisen sometime after 1994 and spread throughout the
colony via breeding57. The Ide duplication may have an impact on disease models but does
not appear to be under negative selection in the general C57BL/6J population57. The
support for recurrent, strain- or species-specific CNVs being true events is increased when
the same CNVs have been observed the same mouse strain or species in previous studies.

2.5.4

Probe annotation: Providing genomic context

Updating the genomic positions of SNP probe and IGP sequences to the latest mouse
genome build is required when using updated annotation information from databases like
Ensembl and UCSC genome browser58–60. Probe annotation updates are also important for
CNV calling accuracy, which is heavily dependent on knowing which probes target
consecutively located DNA regions. Updated genomic positions for the MDGA can be
downloaded from the Thermo Fisher Scientific website9. It is not uncommon, however, for
there to be compatibility issues between the genome version used to specify probe locations
and the genome version for genomic information downloaded from various databases.
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2.5.5

Assessing MDGA data quality with pairwise genetic distance
comparisons

The genetic distance between samples can be used as an indicator of microarray data
quality. Closely related individuals are expected to have a smaller genetic distance between
them than unrelated or distantly related individuals. Likewise, samples taken from the same
individual would have a smaller genetic distance value than samples coming from different
individuals. If pairwise genetic distances calculated for a sample set does not reproduce the
known relative relationships between those samples, then there may be a problem with the
array data or there was not sufficient genetic variation at the loci that were used for the
calculations.
Genetic distance can be calculated using SNP or CNV genotypes. The pairwise
genetic distance values generated for a sample set can then be used to create distance
matrices. The following calculation is used to produce a pairwise SNP genetic distance
value for two samples:
!"#"$%& (%)$*#&" =
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There are multiple definitions for what constitutes a SNP difference. One definition
includes counting any genotype (AA, AB, BB, No Call) difference between the two
samples, at a given locus, as a difference. Alternatively, No Calls can be excluded from
this calculation since a genotype could not be determined. Using this formula, the pairwise
genetic distance value will range from 0 to 1. If two samples have no SNP genotype
differences, the value will be 0. The more similar two samples are genetically, the closer
the value will be to 0.
A matrix containing the pairwise SNP genetic distance values for a sample set can be used
to construct a phenogram. A phenogram depicts the degree of similarity between
individuals, based on selected characteristics, without including measures of evolutionary
time or defining common ancestors.
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CNVs can also be used to calculate genetic distance. For CNV calls, the probes
underlying a CNV are assigned the copy number state of that CNV as a genotype. Then a
formula similar to the one for SNP genetic distance can be used to calculate CNV genetic
distance between two samples:
!"#"$%& (%)$*#&" =

,-$*. <0= 2"#-$34" 5%66"7"#&") 8"$9""# $9- )*:4.")
,-$*. #;:8"7 -6 .-&% &-:4*7"5

SNP- and CNV-based genetic distances will not necessarily show the same
relationship between the same samples and SNP-based distance is more likely to reiterate
known genealogy13. Cutler et al.13 attribute these differences to the nature of CNV
inheritance from parents as well as the smaller numbers of CNVs, compared to SNPs,
which leads to greater intergenerational fluctuations in CNV content. However, CNVbased genetic distance can be informative about relatedness and ancestry when populationspecific copy number variable regions61 or fixed deletions and duplications in different
species’ lineages62 are used.

2.5.6

Considerations for Mus musculus sample set size and sex of
mice

When designing an experiment, it is important to select the mouse species, number of
samples and tissue type, with considerations of MDGA detection limits in mind. The
MDGA is best suited for detecting genetic variation in Mus musculus subspecies. When
using a BRLMM-P algorithm for SNP genotyping of MDGA data, it is recommended that
at least 60 samples are genotyped together for the data to cluster properly63. However, other
sources using a different microarray found that high performance BRLMM-P clustering
can be achieved with 44 samples or fewer64. In genome-wide association studies (GWAS)
using SNP microarrays, thousands of disease and control samples may be required if rare
variants are involved65. Increasing sample size generally has a greater effect than increasing
microarray genome coverage with regards to identifying disease-associated SNP variants66.
In addition to sample size, the sex of the mice for the samples in the dataset should
be given consideration. Ideally, the user will know the sex of the samples and input this
information into PennCNV. Where the sex of the sample is unknown, PennCNV will use
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B allele frequency (BAF) values from the X chromosome SNPs to generate CNV calls for
the X chromosome – information regarding the sex of the samples is not required when
using PennCNV for the autosomes, which are run separately from the X chromosome67.
From a SNP genotyping perspective, greatly skewed sex ratios in a dataset might
negatively affect clustering and the BAF values for the X chromosome. Datasets using only
females can have three genotype clusters (AA, AB, and BB genotypes) while male samples
are expected to lack a heterozygous genotype cluster.

2.5.7

Considerations for tissue type

The MDGA, like other microarrays, is more likely to detect CNVs that are in the majority
of cells of the tissue sample. When using a microarray, a consensus result will be generated
for all the genomes present within a sample. Rare losses or gains may not influence the
florescence signal sufficiently to be detected. Genome mosaicism has been detected at
levels as low as <5% using a SNP-based microarray, although detection limits are generally
higher68. Another study found that mosaicism is readily detectable at 20%, although the
threshold can be lowered to 10% following additional statistical calulations69. It would be
expected that a detection threshold will differ based on the specific microarray and
computational detection method employed.
The implications of microarray sensitivity limitations are that the MDGA may not
be suitable for identifying rare mosaicism events in diseased or normal tissue. Tumour
samples for example, tend to have high amounts of genetic heterogeneity due to genomic
instability70. While low level tumour mosaicism may be not be detected by microarrays,
SNP microarrays have been of use in cancer research71–73 since many mutations are
detectable. In normal tissues, genetic variation can arise spontaneously during development
or later in life and is a commonly occurring phenomenon74. The clonal size of a genetic
variant in an individual will vary based on factors including but not limited to the when the
variant arose and the phenotypic impact of the variant75–78. To identify cell lineage-specific
variants, variant detection should be conducted on isolated cell types or subpopulations
within a tissue if it is comprised of heterogeneous cell populations78–81.
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2.6

Conclusion

When compared to the Genome-Wide Human SNP Array 6.0, the MDGA has more probes
that are predicted to perform poorly. However, these probes can be identified and excluded
from analyses to improve the overall performance of the MDGA, which was assessed using
SNP genotype call rate in this study. The generation of good quality array data is also
dependent on having study designs that incorporate appropriate sample sets and variant
detection methods. It is important to design studies that are suitable for MDGA’s sensitivity
and resolution limits. For example, the MDGA cannot be used to detect very rare variants
or to find the exact locations of CNV junctions.
Well-designed studies do not guarantee the production of good quality data since
sample preparation or hybridization errors can occur. Several computational methods are
available for assessing the quality of MDGA data. These include visualizing the array to
look for hybridization abnormalities and assessing the SNP genotyping and CNV calling
results using metrics like SNP call rates, the presence of heterozygous SNP calls underlying
CNV losses, the presence of CNVs in genes unlikely to vary in copy number, and BAF
drift, LRR SD, and WF values. Ultimately, even if computational assessment indicates
good quality data, experimental confirmation is necessary to ensure that true genomic
alterations were identified. Preferably, non-hybridization-based methods would be used for
confirmation to avoid similar errors that occur with hybridization-based methods like
microarrays.
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Chapter 3

3

CNV Diversity in Inbred and Wild Mice Detected by the
Mouse Diversity Genotyping Array

A version of this chapter’s broad survey of mouse genomes for CNVs has been published
in Locke et al., BMC Genomics (2015)1.

3.1 Background
The house mouse, Mus musculus, has a long history linked with humans as a commensal
species2,3 and as a valuable animal model of human biology and disease4–6, yet there are
many aspects of its basic biology left to uncover. One such aspect, which is explored in
this chapter, is the contribution of copy number variants (CNVs) to mouse genetic diversity
and to phenotypic traits important for species adaptation, evolution, and use as a model
organism. M. musculus is known to be a phenotypically and genetically diverse species
being comprised of three major subspecies in the wild3 and including numerous laboratory
strains which were genetically manipulated and bred to express specific traits7. M.
musculus subspecies are sufficiently diverse genetically that hybrid sterility and reduced
fertility have been known to occur8–11. One of the contributors to the genetic diversity in
M. musculus is CNVs12,13. CNVs can alter phenotypes by modifying expression levels of
protein-coding genes and regulatory or noncoding elements14,15. Deleterious phenotypes
will be selected against in a mouse population while phenotypes that confer an advantage
to fitness are more likely to remain or expand within a population. An exception to this is
the intentional introduction and maintenance of deleterious variants in mice by humans, to
create a variety of genetically and phenotypically different mouse models of human
biology and disease4,16,17. The genetic diversity of a mouse model can be increased by
using wild-derived strains, which capture the genetic diversity of the three major mouse
subspecies in natural populations, or by breeding wild-derived strains with classical
laboratory strains (usually domesticus) of interest18.
An important part of understanding why there are genetic differences among
members of the M. musculus species is understanding its history. The musculus,
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domesticus, and castaneus subspecies of M. musculus diverged sometime around ~350500 thousand years ago19,20. Ancestral M. musculus populations are thought to have lived
in the north of the Indian subcontinent and dispersed to other parts of the world from there3.
Today, this species can be found world-wide with different subspecies being predominant
in certain regions. After M. musculus subspecies divergence, the subspecies are thought to
have independently evolved commensalism following the rise of human agrarian
societies7. As a human commensal species, M. musculus movement often followed human
movement and this allowed for the establishment of populations where none would be
expected due to large natural barriers such as oceans. During the Viking Age for example,
mouse stowaways travelled with European colonizers, and this resulted in the
establishment of M. m. domesticus populations in Iceland and Greenland (later replaced by
Danish M. m. musculus)2.
M. m. musculus is commonly found in a region ranging from central Europe to
northern China and in Greenland, while M. m. castaneus is common in southeast Asia3,21.
M. m. domesticus has the greatest range and can be found in western Europe, the
Mediterranean basin, Africa, North and South America, and Australia21. Another mouse
subspecies was thought to be present in Japan, M. m. molossinus, until DNA studies
showed that Japanese mice have mostly M. m. musculus DNA along with some M. m.
domesticus and M. m. castaneus DNA22,23. Mice in New Zealand are hybrids of all three
mouse subspecies representing mouse populations from different regions of Europe and
Asia24. Subspecies hybrids can be found in hybrid zones where the subspecies ranges meet
and overlap. Isolated populations of house mouse subspecies can be found where there are
natural barriers between the subspecies. One such example is the Himalayan mountains
which separate M. m. musculus and M. m. castaneus populations21.
In addition to natural barriers isolating mouse subspecies, there are also biological
barriers that can interfere with hybridization of subspecies. M. m. musculus and M. m.
domesticus, for example, were found to have divergent urinary odors occurring in allopatric
European populations and the divergence was more pronounced in regions where the two
subspecies come in contact with each other25. It is suspected that the urinary odors play a
role in mating and that the presence of different proteins in the mouse urine is responsible
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for the divergent odors. This may suggest that genetic differences between the mouse
subspecies are contributing to differences in odor production and detection, and
preferences for certain odors, leading to interference with hybridization.
Although mating can occur between subspecies, genetic incompatibilities can affect
the offspring fitness by causing hybrid sterility8. Hybrid mating experiments between M.
m. musculus and M. m. domesticus reveal that hybrid males are sterile if they inherit a M.
m. musculus X chromosome while hybrid females are not affected26. Sex chromosome
incompatibilities are not the only genetic contributors to infertility. The autosomal PRdomain containing 9 (Prdm9) gene was found to play a role in hybrid sterility with fertility
levels being affected by which alleles are present and the number of copies of Prdm927.
Prdm9 is highly polymorphic in M. musculus populations28. During meiosis, Prdm9
initiates meiotic recombination by promoting double strand break (DSB) formation near
its DNA binding sites29. Sterile mouse hybrids have defects in meiotic prophase following
the DSB formation and different Prdm9 alleles influence each other’s behaviour regarding
DSBs, but the defects causing sterility can be reversed by introducing altered Prdm9 alleles
into the mouse hybrids30. In all, it has been found that multiple genomic loci can
independently impact hybrid fertility due to genetic differences between subspecies at
those loci.
Within the same subspecies, genetic variation was found between different wild
populations of house mouse, with CNVs being a large contributor to this variation12. When
multiple mice have a CNV overlapping the same genomic region, that region is referred to
as a CNV region (CNVR). CNVRs that overlap large segmental duplications have been
found to vary more in copy number in mice than those that do not overlap segmental
duplications, and they are enriched for nonessential, environmentally-responsive genes
including those with functions related to olfaction, production of urinary proteins, as well
as production of proteins with unknown functions12. CNVRs that do not overlap segmental
duplications are thought to be under stronger selective constraints, since these CNVRs
contain CNVs that are smaller, less frequent, and linked to Mendelian disease genes.
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With inbred mice, many classical laboratory strains share a predominantly M. m.
domesticus background but their genome has been modified through generations of
inbreeding and selection for specific traits. Many laboratory mice have been selectively
bred for traits related to human health with numerous strains being used as models of
cancer, complex and single gene diseases, and for determining gene function (e.g. gene
knockouts)31–33. Genetic differences among laboratory strains also contribute to differences
in non-pathogenic traits like taste thresholds and macronutrient selection preference
(related to taste)34,35.
CNVs are known to contribute to some genetic differences in laboratory mice. For
example, an Ide (insulin-degrading enzyme) gene duplication can be found segregating in
C57BL/6J mice36. Likewise, a-defensin gene diversification occurring through tandem
duplication has been observed specifically in C57BL/6 mice and results in an increased
variety of antimicrobial peptides24. CNV studies of laboratory mice have found CNVs that
are enriched for genes with functions related to the immunity, olfaction, and pheromone
detection38,39.
Due to inbreeding over numerous generations and having a small founding
population, classical laboratory mice do not capture the extent of genetic diversity
occurring in wild populations of mice7. Thus, wild-derived mouse lines were established
to introduce greater genetic variation and novel phenotypes40. The genetic variation among
lines, particularly from a single nucleotide polymorphism perspective, has been shown to
be greater in wild-derived strains than classical laboratory strains17,41. Similarly, the
contribution of CNVs to genetic diversity is expected to be greater in wild-derived mice
than classical laboratory mice.
In this study, the CNV landscape is characterized in hundreds of M. musculus
individuals from a variety of genetic backgrounds. CNV differences within and between
multiple mouse cohorts are identified using the Mouse Diversity Genotyping Array42, with
an aim of gaining insight into potential phenotypic impact and relevance to adaptation and
evolution in natural and laboratory environments. This chapter is divided into two studies,
1) a broad survey of mouse genetic diversity and 2) a comparison of genetic diversity
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between mouse cohorts. The broad survey tests a CNV detection pipeline on a large mouse
dataset and assesses its variant detection capabilities by experimentally confirming putative
CNVs. This survey will characterize the CNVs in a diverse group of M. musculus samples
that includes multiple subspecies, a variety of inbred laboratory mice, and wild mice.
Reported here, is the CNV analysis of 351 mice, representing 290 strains that have not been
studied for CNVs previously.
The mouse cohort comparison study uses a refined dataset that focuses on the
comparison of three mouse cohorts: classical laboratory (CL) strains, wild-derived (WD)
inbred strains, and wild-caught (WC) mice. These cohorts were selected to study how
differences in genealogy, breeding schema, origins of genetic diversity, and housing shape
the CNV landscape of a mouse genome. In comparison to the broad survey, the mouse
cohort comparison study uses 10 addition WD samples and 14 additional WC samples. CL
strain duplicates were excluded for a total of 114 CL strains selected for study, each with
different breeding and phenotype selection histories but all are predominantly M. m.
domesticus. In this study, there is a greater emphasis on the differences between classical
CL, WD, and WC mouse cohorts with respect to CNV characteristics (e.g. number, length,
state, hotspots, genic content), and the potential implications for adaptation and evolution.
Genetic variants that are recurrent in CL cohort are predicted to be associated with
the shared M. m. domesticus background, husbandry practices, and adaptation to living in
a laboratory environment. Since the WC cohort includes multiple M. musculus subspecies
from different geographical regions, WC diversity is predicted to be associated with the
inclusion of different subspecies and the different geographic environments. Recurrent
CNVs that are either subspecies-specific or geographically-specific may be observed for
the WC cohort. The WD cohort also includes multiple subspecies, but unlike with WC
mice, WD mice are inbred laboratory strains. The CNVs in this cohort are likely shared
with mice in the CL and WC cohorts, resulting from inheritance given common ancestry
or from selection pressures given similar environments. The WC and WD cohorts are
predicted to have the greatest genetic diversity due to greater diversity in environments and
the inclusion of different subspecies. The WC and CL cohorts are expected to have the
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fewest CNVs in common given their histories in different environments and the different
genealogies for the two cohorts.

3.1.1

Research goal, central hypothesis, and specific objectives

Research goal: The overall goal of this study is to broadly characterize the CNV landscape
of Mus musculus using the MDGA, and to expand on this initial study by identifying CNV
differences within and between mouse cohorts that can be further studied to gain insight
into the CNV origins, phenotypic impact and relevance to adaptation and evolution in
natural and laboratory environments.
Central hypothesis: First, given that CNVs are heritable, different mice of different strains
and origins will have different CNV profiles reflecting similarities and differences in
genealogy. Second, given evidence of the phenotypic impact of CNVs, the profile of CNVs
will differ between mouse cohorts that differ in environment and phenotypic selection.
The specific objectives of the board survey are:
1. To identify CNVs, using a filtered probe list containing both SNP probes and IGPs, in
Mus musculus samples from different lines, subspecies and geographic locations.
2. To use genes that are unlikely to vary in copy number as a measure of false CNV
discovery.
3. To characterize CNV differences and impacted gene pathways between CL and WC
mouse cohorts.
4. To evaluate the reliability of the candidate CNV detection method via confirmation of
select genic CNVs by ddPCR.
The specific objectives of the mouse cohort comparison study are:
1. To identify CNVs in CL, WD, and WC Mus musculus samples using the stringently
filtered probe list recommended in Locke et al1.
2. To use genes that are unlikely to vary in copy number as a measure of false CNV
discovery.
3. To characterize CNV differences and impacted gene pathways in and between CL,
WD, and WC cohorts.

85

3.2 Materials and methods
3.2.1

Samples

Publicly available Mouse Diversity Genotyping Array CEL files were downloaded from
the Center for Genome Dynamics at The Jackson Laboratory43. The CEL files for the broad
mouse survey contain raw array intensity data for mouse tail samples from 120 CL strains,
58 WD strains, 10 consomic strains, one congenic strain, 44 BXD recombinant inbred
strains, 40 CC-UNC G2:F1 strains, 55 F1 hybrids of inbred strains and 23 WC mice, for a
total of 351 samples (Appendix 3A). Consomic strains are inbred mice that contain one
entire chromosome from a different mouse strain44. Congenic strains are generated to
contain a particular marker from another mouse strain44. BXD recombinant inbred strains
contain approximately equal amounts of genetic material from a C57BL/6 and DBA/2
strain background44. CC-UNC G2:F1 mice are the first generation of collaborative cross
mice generated at the University of North Carolina by breeding eight extant and genetically
diverse laboratory strains together to create recombinant inbred lines45,46. For the mouse
cohort comparison study, CEL files for 110 CL strains without strain duplicates, 37 WC
mice, and 68 WD mice were selected for analysis (Appendix 3B).

3.2.2

CNV identification

The probe list provided in Additional file 2 of Locke et al.1 was used for SNP genotyping
and CNV calling in the broad survey while the more stringently filtered list, provided in
Additional file 7 of Locke et al. was used for the mouse cohort comparison study. Genotype
calls were generated using the BRLMM-P algorithm implemented in Affymetrix® Power
Tools47 using default parameters as specified by Genotyping Console48, which includes
quantile normalization. To pass SNP genotype call rate requirements, CL mouse samples
in the mouse cohort study, but not the broad survey, were required to have an overall call
rate greater than 97%. Low call rates are expected for WD and WC samples1,49, so call rate
was not used as an exclusion criterion for these samples.
A canonical genotype clustering file was generated and used to calculate Log R
Ratio (LRR) and B allele frequency (BAF) values using the PennAffy package50.
PennCNV was used to generate PFB (population frequency of the B allele) reference files
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from the dataset for each study51. A GC model file, containing the percent GC content of
the 1 Mb region surrounding each marker (or the genome-wide average of 42% GC
content, if this could not be calculated) was generated using KentUtils52 and an in-house
script based on the reference genome used for the broad survey (UCSC:mm9) and the
mouse cohort study (UCSC:mm10).
CNVs were detected with PennCNV using default parameters and GC model
correction53. CNVs on the X chromosome were detected in a separate run of PennCNV
using the –chrX option. Calls were filtered to be 500 bp to 1 Mb in length, have at least
three markers, have a marker density of 0.00013 markers/bp, have a log-R ratio standard
deviation below 0.35 and have a B-allele frequency drift below 0.01. CNV data for the
broad survey are provided in Appendices 3C-E. CNV calls for the mouse cohort study are
provided in Appendices 3F and 3G.
For the mouse cohort study, CL samples failing to meet the inclusion criteria, based
on their autosomal CNV calls, were excluded from all subsequent analyses (five samples
failed: MA/MyJ, NONcNZO10/LtJ, C57BL/10ScSnJ, C57BL/10ScNJ, GR/J). The failing
samples were included in the phenogram section for comparison to the SNP data since the
SNP genotyping threshold was met. The MDGA cannot always capture the diversity from
wild-type samples and is therefore more likely to fail to meet inclusion criteria for WD and
WC samples than CL strains. As such, WD and WC failing samples were not excluded
from analysis. Mouse samples were also not excluded from subsequent analysis if their
Chromosome X CNV calls failed quality controls because X chromosome calling requires
special treatment51 so the CNV calls for the X chromosome may less reliable than autosome
calls. In addition, sex prediction by PennCNV is more suitable for Illumina arrays when
using default parameters than for Affymetrix arrays54.

3.2.3

Figure construction and statistical analysis

Boxplots were generated in R (v3.2.4) using the Boxplot function. Figure 3-2 was
generated using the ggplot2 (v3.1.0) package and the geom_point and geom_density
functions. Wilcoxon and Kruskal-Wallis tests were performed with R using the
stat_compare_means function from the ggpubr (v0.2) package.
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3.2.4

CNV recurrence and CNV landscape plot visualization

Recurrent CNVs were identified using the default overlap percentages (40% for a merge,
and 99% for a family) and reciprocal overlap in HD-CNV55. Recurrent CNVs must be
found in at least two mice within a dataset, regardless of cohort, and they are not required
to share the same copy number state. Genomic regions containing recurrent CNVs are
referred to as CNV regions (CNVRs) in this chapter. Appendix 3C lists broad survey CNVs
as unique (also known as singleton CNVs) or recurrent. For the mouse cohort study, the
number of CNVRs detected by HD-CNV, was represented with a Venn diagram generated
in R with the venneuler package (v1.1.0). Each CNVR count includes multiple CNVs and
CNVs can be included in more than one CNVR.

3.2.5

Concordance with previous studies

Data for concordance analysis for the broad survey were downloaded from the Database
of Genomic Variants56 or from supplementary tables depending on availability1. Overlap
analysis at 20% reciprocal overlap was performed using the intersect function of Bedtools
(version 2.17.0)57. The copy number state of the call was not considered; the presence of a
call in a previous study was considered evidence that variability occurs in this region.
Chromosome X was excluded from analysis since many studies did not have CNV data for
this chromosome.
To identify CNVs in the mouse cohort study that were observed in the broad survey,
the genome coordinates from the Locke et al.1 CNVs were converted to the newer genome
build (GRCm38/mm10) using the UCSC Genome Browser LiftOver tool. Nine positions
could not be updated due to sequence additions or deletions within the region. CNVs that
overlapped by at least 1 bp with the Locke et al. CNVs were labeled as “previously
observed”. Overlapping CNVs were identified using in-house Python scripts.

3.2.6

Genes unlikely to harbour copy number losses

In-house scripts were used to determine if CNVs overlapped “control” genes unlikely to
vary in copy number (Appendix 2G). The genes used in overlap analysis in the broad
survey from the list in Appendix 2G can be identified by “Locke et al” and “Gatesy et al”

88

in the source column. All genes in Appendix 2G were used for overlap analysis in the
mouse cohort study. A CNV to be considered to be overlapping a control gene if there was
an overlap of at least 1bp between the CNV and a control gene.

3.2.7

Confirmation of select CNVRs by droplet digital PCR
(ddPCR)

For the broad survey, nine genic CNVRs found in C57BL/6J mice were selected for CNV
confirmation by ddPCR in five C57BL/6J, five CBA/CaJ and four DBA/2J inbred mice
(Appendix 3H). C57BL/6J and CBA/CaJ mouse samples came from Dr. Kathleen Hill’s
laboratory (Appendix 3I) and DBA/2J mice were provided by Dr. Shiva Singh. For
C57BL/6J mice, DNA was extracted from tail samples, with the exception of C57BL/6J
mouse 2, where ear clip tissue was used. DNA was extracted from the cerebellum for
DBA/2J mice and tail samples for CBA/CaJ mice. For each CNVR, one TaqMan® Copy
Number Assay (Thermo Fisher Scientific, Waltham, Massachusetts, USA) was selected
for a gene overlapping that CNVR. Overall, nine gene assays were conducted for the 14
mice with inclusion of two technical replicates per DNA sample. A TaqMan® Copy
Number Reference Assay (Thermo Fisher Scientific, Waltham, Massachusetts, USA) for
the transferrin receptor gene (Tfrc) was used as a reference with an expected copy number
of two. Negative controls lacking DNA template were included for each gene assay,
including the reference gene.
Prior to ddPCR, DNA samples were extracted using the Wizard® Genomic DNA
Purification Kit (Promega, Madison, Wisconsin, USA), assessed for quantity using a
NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts,
USA) and diluted to approximately 8 ng/μl. The DNA was then fragmented by centrifuging
140 μl of DNA sample at 16,000xg for 3 min in a QIAshredder column (Qiagen, Venlo,
Limburg, Netherlands) to prohibit inaccuracies in copy number detection due to tandem
duplications not efficiently sorted in the ddPCR assay58.
Each 20 μl PCR reaction contained 8 μl of DNA template (~4 ng/μl), 10 μl of the
ddPCR™ Supermix for Probes (Bio-Rad, Hercules, California, USA), 1 μl of the FAM™
dye-labelled TaqMan® assay for the gene target of interest, 1 μl of the VIC® dye-labelled
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TaqMan® reference assay. Droplets were generated by a QX200™ droplet generator (BioRad, Hercules, California, USA). A C1000 Touch™ thermal cycler (Bio-Rad, Hercules,
California, USA) was used to perform PCR using the following program: 1 cycle at 95°C
for 10 min, 45 cycles of denaturation at 95°C for 30 s, annealing and extension at 60°C for
1 min and enzyme deactivation at 98°C for 10 min. Droplets were read using a QX200™
droplet reader and analyzed with QuantaSoft™ software (Version 1.7.4.0917; Bio-Rad,
Hercules, California, USA).

3.2.8

Gene analysis

Gene annotations consistent with the broad survey reference genome (UCSC:mm9) and
the mouse cohort study reference genome (UCSC:mm10) were downloaded from Ensembl
BioMart59,60. Genes found in CNVs were identified using in-house scripts. The Database
for Annotation, Visualization and Discovery (DAVID) Functional Annotation tool was
used to identify gene ontology (GO) term enrichment for genes overlapping CNVs61,62.
DAVID versions 67 and 68 were used for the broad survey and the mouse cohort study,
respectively. DAVID automatically excludes redundant genes from its analysis. The three
GO

categories

“GOTERM_BP_FAT”,

“GOTERM_CC_FAT”,

and

“GOTERM_MF_FAT” were used to identify the most relevant GO terms for each broad
survey gene list. Occasionally, pseudogenes can be “resurrected” and produce translated
products63. For this reason, pseudogenes classified as having a protein-coding biotype by
Ensembl were included in the gene analysis. For the mouse cohort study, the default
“GOTERM_BP_DIRECT” category was used to identify the most relevant biological
process GO terms for each gene list. The gene lists were comprised of genes that were
completely encompassed by CNVs in the mouse cohorts.
Ingenuity® Pathway Analysis’ Core Analysis64 was used to determine disease and
biological function networks for genes overlapping CNVs from the broad survey. Direct
and indirect relationships with a maximum of 35 focus molecules per network were
included. Human, mouse and rat genes were included. The confidence level was set to
include experimentally observed relationships between focus molecules as well as
predicted relationships that have a high confidence. Molecule relationships with
endogenous chemicals were excluded.
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3.2.9

Genetic distance matrices and phenogram generation

SNP genetic distance was calculated based on pairwise genotype differences at SNP loci.
All four genotype categories were used in the calculations: AA, AB, BB, and No Call. To
calculate pairwise CNV genetic distance, probes underlying a CNV call were assigned the
state of that CNV, while probes not underlying a CNV call were assigned a default state
value of two. Distance matrices were generated using R (v3.2.4). From the distance
matrices (Appendix 3J), phenogram files were constructed in R using the BIONJ function
in the APE package (v3.4) and saved in Newick format. The Newick files were uploaded
to Figtree (v1.4.2) to generate coloured phenogram images.

3.3 Results
3.3.1

Broad survey

3.3.1.1

CNVs detected

For 334 samples passing quality control criteria, a total of 9,634 CNVs were identified on
the autosomes, with an average of 29 CNVs per sample (Table 3-1). On the X chromosome,
1,218 CNVs were found (Appendix 3D), with an average of four CNVs per sample. Calls
across all samples affect 6.87% (169.9 Mb) of the autosomal genome or 8.15% (215.2 Mb)
when including calls on the X chromosome.
Strains classified as CL strains have a mean of 0.065% (1.6 Mb) of the autosomes
affected by CNVs, 0.065% (1.7 Mb) when the X chromosome was included. The mean
autosome and genome percentage affected for the WD strains (0.15% or 3.6 Mb and 0.14%
or 3.8 Mb, respectively) and WC mice (0.14% or 3.5 Mb and 0.14% or 3.8 Mb,
respectively) were significantly different than the CL strains (P < 0.01, Mann–Whitney
test).
The CNVs on the autosomes have an average length of 54,037 bp, with a median
length of 26,340 bp. The majority (81%) of CNV calls are between 1 kb and 100 kb. Gains
are significantly larger than losses (P < 2.2 × 10−16, Mann–Whitney test), where gains have
a median length of 36,708 bp compared to losses at 20,091 bp. Copy-state-zero losses are
significantly smaller than copy-state-one losses (P < 2.2 × 10−16, Mann–Whitney test),
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where copy-state-zero losses have a median length of 13,766 bp compared to copy-stateone losses at 26,980 bp. Losses outnumber gains by a ratio of 1.42:1 on the autosomes
(Table 3-1) and only the CL cohort has more gains than losses. Unlike the CL and WC
cohorts which have roughly twice as many state-one CNVs as state-zero CNVs, the WD
cohort has approximately twice as many state-zero CNVs as state-one CNVs.
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Table 3-1. Autosomal CNV losses and gains in laboratory strains and wild-caught mice.
Number of
Samples

Number of
CNV calls

All Mice

334

Classical Inbred

Sample Group

Copy Number Stateb

Loss/Gainc

0

1

3+

9,634 (29)a

1,995 (6)

3,661 (11)

3,978 (12)

1.42

114

2,824 (25)

424 (4)

867 (7)

1,533 (13)

0.84

Wild Derived

52

2,611 (50)

1,214 (23)

594 (11)

803 (15)

2.25

Wild Caught

19

969 (51)

231 (12)

491 (26)

247 (13)

2.92

C57BL/6J

8

90 (11)

0 (0)

38 (5)

52 (6)

0.73

C57BL/6NJ

6

46 (7)

5 (1)

23 (4)

18 (3)

1.56

a

Values in parentheses are the average number of CNVs per sample.

b

Copy number is determined in reference to the diploid standard with 0 indicative of loss of paternal and maternal copies; 1 and 3+

indicate single copy loss and the occurrence of duplication events respectively.
c

Loss/Gain is the total number of deletions (0 and 1 copy-state call counts) divided by the number of gains (3+ copy-state call counts)
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3.3.1.2

Genic content and analysis

A majority (65.7%) of CNVs within the dataset entirely encompass at least one gene, are
entirely encompassed by a gene, or partially overlap with at least one gene. The three main
Ensembl classification types, excluding regulatory elements, for regions that overlap CNVs
are protein-coding genes (76%), pseudogenes (11%) and multiple classes of RNAs (10%).
The percentage of CNVs containing protein-coding genes in the CL mice (76.7%) is higher
than in the WC mice (54.2%).
Overall, protein coding genes were found in a higher percentage of gains (88.8%
of gain calls overlapped a protein coding gene region) than losses (55.6%). Pseudogenes
were also found to overlap a higher percentage of gains (18.0%) than losses (13.9%), as
were RNAs (18.2% vs 7.1%) and antisense gene regions (5.1% vs 2.6%).
The most common CNV (when considering events with the same start and end
position in each sample) is in 66 mice on Chromosome 17 and contains the Tmem181c-ps
pseudogene (Table 3-2). Almost all (93%) CL mice with this CNV have a gain, while all
WC mice have a single-copy loss. The second most common CNV (Table 3-2) contains
two pseudogenes, Ear-ps7 and Ear-ps10, as well as two protein-coding genes, Ang5 and
Ang6. This CNV was observed only as a copy number state of either zero or four and both
states existed in CL and WC cohorts. This CNV occurred most frequently in the BXD
cohort.
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Table 3-2. Most common CNVs detected by the Mouse Diversity Genotyping Array in a set of 334 Mus musculus samples.
Number of
mice with
the CNV
66

Mixed

chr14:44540155-44579921

43

Mixed

chr17:35383895-35392718

41

Gain

chr11:116603748-116629092

40

Mixed

chr4:122366514-122382286
chr7:111681502-111683670

38
35

Loss
Mixed

chr4:111790559-111972640

35

Gain

chr17:30593663-31058945

34

Gain

chr5:114856193-114895051

34

Gain

chr14:20443929-20587951

34

Gain

Genomic location of CNV
chr17:6635443-6646618

a

CNV
state

Gene name (Gene symbol; Gene type)a
Transmembrane protein 181 C, pseudogene (Tmem181c-ps; ps)
Angiogenin, ribonuclease A family, member 5 (Ang5; pc), Eosinophilassociated, ribonuclease A family, pseudogene 7 (Ear-ps7; ps),
Eosinophil-associated, ribonuclease A family, pseudogene 10 (Earps10; ps), Angiogenin, ribonuclease A family, member 6 (Ang6; pc)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 39B (Ddx39b; pc),
histocompatibility 2, Q region locus 4 (H2-Q4; pc)
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-Nacetylgalactosaminide alpha-2,6-sialyltransferase 1 (St6galnac1; pc),
Predicted gene 11735 (Gm11735; ps)
RIKEN cDNA 9530002B09 gene (9530002B09Rik; pc)
Tripartite motif-containing 30E, pseudogene 1 (Trim30e-ps1; ps)
Selection and upkeep of intraepithelial T cells 4 (Skint4; pc), Predicted
gene 12820 (Gm12820; ps), predicted gene 12815 (Gm12815; ps),
selection and upkeep of intraepithelial T cells 3 (Skint3; pc)
BTB (POZ) domain containing 9 (Btbd9; pc), predicted gene 9874
(Gm9874; pc), glyoxalase 1 (Glo1; pc), dynein, axonemal, heavy chain
8 (Dnahc8; pc)
Ubiquitin protein ligase E3B (Ube3b; pc), methylmalonic aciduria
(cobalamin deficiency) cblB type homolog (human) (Mmab; pc),
mevalonate kinase (Mvk; pc)
Predicted gene 17030 (Gm17030; ps), nidogen 2 (Nid2; pc)

Gene names are as in Mouse Genome Informatics Symbol. Gene types are one of: Protein coding (pc), RNA type as listed, or
pseudogene (ps)
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CNV differences were observed in samples from the same mouse strain. Six of
eight C57BL/6J mice have an extra copy of the insulin-degrading enzyme (Ide) gene and
half of the C57BL/6J mice have an extra copy of the fibroblast growth factor binding
protein 3 (Fgfbp3) gene. None of the C57BL/6NJ mice have the Ide or Fgbp3 gain. All
eight C57BL/6J mice in this study also have CNV gains overlapping most of Skint4, NLR
family, pyrin domain containing 1B (Nlrp1b), and solute carrier family 25, member 37
(Slc25a37), although none of these genes were encompassed completely by a CNV like
Ide and Fgfbp3. Single-copy losses overlapping predicted gene 9765 (Gm9765) and Btbd9
are also common (found in > 50% of samples). The Skint4 two-copy gain is also in all six
C57BL/6NJ mice.
When only considering genes completely encompassed by CNVs and CNVs
completely encompassed by genes (complete overlap), the top gene enrichment terms
differed between WC and CL mice (Table 3-3). Across CL mice, only the gene ontology
(GO) terms for gains are significant, while in WC mice, GO terms for both losses and gains
are significant. The most significant GO term across classical laboratory mice is “antigen
processing and presentation of peptide antigen” (Padj = 3.26 × 10−10). Most of the top GO
terms for CL mice are related to immunity or structural organization of the genome. Across
WC mice, GO terms related to olfaction are significant for losses while GO terms related
to pheromone response are significant for gains.
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Table 3-3. Top DAVID Gene Ontology terms for genic CNVs detected in classical laboratory and wild-caught mice.
Mouse
cohort
Classical
Classical
Classical
Classical
Classical
Classical
Classical
Classical
Wild caught
Wild caught
Wild caught
Wild caught
Wild caught
Wild caught
Wild caught
Wild caught
Wild caught
Wild caught
Wild caught
Wild caught
a

CNV
state
3+
3+
3+
3+
3+
3+
3+
3+
1
1
1
1
1
1
1
1
3+
3+
3+
3+

Gene Ontology term (Category )

Involved genes
(% total)

Fold
enrichment

Antigen processing and presentation of peptide antigen (BP)
Antigen processing and presentation (BP)
MHC protein complex (CC)
Nucleosome (CC)
Nucleosome assembly (BP)
Protein-DNA complex assembly (BP)
Nucleosome organization (BP)
Chromatin assembly (BP)
Sensory perception of chemical stimulus (BP)
Sensory perception (BP)
Neurological system process (BP)
Cognition (BP)
Olfactory receptor activity (MF)
Sensory perception of smell (BP)
G-protein coupled receptor protein signaling pathway (BP)
Cell surface receptor linked signal transduction (BP)
Pheromone binding (MF)
Odorant binding (MF)
Response to pheromone (BP)
Pheromone receptor activity (MF)

16 (1.95)
22 (2.68)
17 (2.07)
16 (1.95)
17 (2.07)
17 (2.07)
17 (2.07)
17 (2.07)
71 (26.59)
72 (26.97)
78 (29.21)
72 (26.97)
62 (23.22)
61 (22.85)
76 (28.46)
79 (29.59)
13 (5.39)
13 (5.39)
13 (5.39)
13 (5.39)

13.08
7.23
9.19
7.25
6.66
6.4
6.4
6.48
5.16
4.44
4.02
4.21
4.81
4.73
3.5
2.74
15.33
14.17
13.92
11.13

a

BP, Biological Process; CC, Cellular Component; MF, Molecular Function

Padj
(BenjaminiHochberg)
3.26E-10
1.24E-09
5.60E-09
5.12E-07
1.81E-06
2.02E-06
2.02E-06
2.06E-06
1.46E-30
1.74E-27
2.25E-27
3.88E-26
1.10E-24
8.03E-24
4.46E-23
1.50E-17
9.35E-09
1.20E-08
1.03E-07
1.36E-07
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Ingenuity Pathway Analysis (IPA) gene groupings into top diseases and functions
networks show differences between WC and CL mice for CNVs completely within or
completely containing a gene, although the distinction is not as clear as with DAVID
(Appendix 3K). A total of 45 networks with an IPA score not less than 10 were identified.
More networks are affected by gains (28) than by losses (17) and, in particular, by gains
across the CL strains (22). “Lipid metabolism” is among the top biological functions for
an IPA network associated with gains across WC mice and is not found for CNVs in CL
mice. Conversely, CL mice have a network associated with “carbohydrate metabolism” in
gains, as well as “amino acid metabolism” in one-copy losses.
Development terms were found in 23 of the 45 networks associated with CNV
regions and included cellular development, tissue development and the development of a
variety of systems (e.g. neurological, hematological, gastrointestinal). For all genes present
in the mouse (Ensembl:67), 34 out of 50 of their associated networks when analyzed as a
whole with IPA include development terms.
Across mouse strains, networks involved in “endocrine system development” are
associated with gains in WC mice and with state-zero losses in CL mice. Networks
involved in “cardiac system development” are only associated with gains in CL mice and
not associated with CNVs in WC mice. Networks involved in “inflammatory response” are
associated with CNVs (both in losses and gains) in the CL mice, but not in the WC mice.
Networks involved in “cell mediated immune response” were found to be associated with
gains in both CL and WC mice.

3.3.1.3

Genes unlikely to harbour copy number losses

Mouse CNVs that were detected by the MDGA did not overlap 26 gene regions that are
conserved in copy number across mammalian species (Appendix 2G)65. For autosomal
genes that are unlikely to contain losses, a partial loss of one copy of Col7a1 was detected
in three mice. Two male mice are partially missing the Cask gene on the X chromosome
(approximately 33% and 6.5% missing).
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3.3.1.4

Droplet digital PCR confirmation of select genic CNVRs

For a total of 252 ddPCR confirmation assays, 242 (96%) were in agreement with MDGA
predictions (Appendices 3H and 3L). There was no discordance between ddPCR technical
replicates. Predicted intra-strain differences in Fgfbp3 copy number were also confirmed
by ddPCR assays, for the C57BL/6J samples. Inter-strain differences in copy number state
for CNVRs affecting haloacid dehalogenase-like hydrolase domain containing 3 (Hdhd3),
selection and upkeep of intraepithelial T cells 3 (Skint3), and glyoxalase 1 (Glo1) genes
were also confirmed by ddPCR. Three of nine ddPCR gene assay results (B4galt3,
Ide and Fgfbp3)

matched

the

predicted

state

for

all

three

mouse

strains. Skint3 and Trim30e-ps1 copy number states were zero for all CBA/CaJ and
DBA/2J mice when a state of two was predicted. However, the MDGA predicted a copy
number difference of two for Skint3 and Trim30e-ps1 when comparing CBA/CaJ and
DBA/2J to C57BL/6J, so ddPCR results were considered to confirm MDGA predictions.
The gains predicted for Hdhd3 in CBA/CaJ and DBA/2J mice were detected by ddPCR
and called as a state of six in both strains. Skint3 ddPCR copy number states were found to
be increased by one for all three mouse strains when compared to the predicted states.
Contrary to array-based predictions, ddPCR targeting intelectin-1 (Itln1) determined that
copy number states did not differ from two, in the five C57BL/6J mice tested.

3.3.2
3.3.2.1

Mouse cohort comparison study
CNV number, state and length in three mouse cohorts

In total, 4,718 autosomal and 683 Chromosome X CNVs were detected, and passed
filtering criteria, for 210 mouse samples (Appendices 3F and 3G). For autosome CNVs,
WD mice had the highest median number of CNVs, which was two-fold higher than the
CL strain median while there was no difference for the median number of X chromosome
CNVs between WD and CL cohorts (Table 3-4). WC mice had a three-fold lower median
number of X chromosome CNVs than the WD and CL cohorts and an intermediate
autosome CNV median. WC mice had the greatest range in the total number of CNVs
detected per mouse (7-98 CNVs) when compared to WD mice (12-75) and CL mice (4-80;
Fig. 3-1).
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Table 3-4. Summary statistics for autosome and Chromosome X CNVs detected in classical laboratory, wild-derived, and wildcaught mice.
Genomic
location

Autosomes

Chr. X

a

Mouse
cohorta

Total
number of
samples

Samples with
at least one
CNV

Total
number of
CNVs

Average
number of
CNVs

Median
number of
CNVs

Min, max
number of
CNVs

CNV
gains
(%)

CL

105

105

1706

16

15

4, 67

54

WD

68

68

2098

31

30

9, 72

34

WC

37

37

914

25

21

7, 90

3

CL

105

95

361

3

3

0, 15

92

WD

68

65

240

4

3

0, 11

75

WC

37

25

82

2

1

0, 8

54

CL, Classical laboratory strains; WD, wild-derived strains; WC, wild-caught mice
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Figure 3-1. Number of CNVs detected for classical laboratory, wild-derived, and wildcaught mice. The box plots show the median number of CNVs with the quartiles,
minimum and maximum non-outlier values, and outliers. Asterisks indicate significant pvalues of <0.001 (***) or <0.0001 (****) for Wilcoxon tests performed following a
Kruskal-Wallis test (p = 7 x 10-16).
CL mice have a higher ratio of gains-to-losses than do either WD or WC mice, by
1.6- and 1.8-fold respectively (Fig. 3-2). All cohorts have a higher proportion of CNV gains
on the X chromosome than on the autosomes and the greatest difference is seen in the WD
mice, which have a 2.2-fold increase in CNV gains on the X chromosome when compared
to the autosomes (Table 3-4). WC and CL mice both have 1.7-fold more gains on the X
chromosome than on the autosomes.
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Figure 3-2. Number of CNV gains and losses for classical laboratory, wild-derived,
and wild-caught mice. Individual data points represent a single sample within the classical
laboratory (pink circle), wild-derived (light green), and wild-caught (dark green) mouse
cohorts. The center dotted line indicates where a data point will lie if a sample has an equal
number of CNV gains and losses. The dotted lines above and below the center line indicate
where data points will lie if the sample has 75% losses with 25% gains and 75% gains with
25% losses, respectively. The top density plot shows the distribution of CNV gains for each
cohort while the right-side density plot shows the distribution of losses.
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For all cohorts, the median length is longer for autosomal CNV gains than the
median length for CNV losses (Fig. 3-3). The WD cohort has the greatest fold difference
in length between gains and losses where gains are 2.2-fold longer in median length. CL
and WC cohorts had a similar length difference between gains and losses, at 1.6- and 1.5fold respectively. The same pattern for median length was observed between gains and
losses for Chromosome X CNVs, except the fold difference was much higher at 4.9-, 7.7, and 8.5-fold for CL, WD and WC mice, respectively. Significant differences in the mean
CNV length were observed for all autosomal intra- and inter-cohort comparisons while for
the X chromosome CNVs, there were significant differences observed only at the intracohort level.
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Figure 3-3. Length of CNV gains and losses for the autosomes and X chromosomes of
classical laboratory, wild-derived, and wild-caught mice. Classical laboratory, wildderived, and wild caught mouse cohorts are represented by CL, WD, and WC, respectively.
CNVs are groups by autosomal gains (dark blue), autosomal losses (light blue),
Chromosome X gains (dark yellow), and Chromosome X losses (light yellow). The box
plots show the median number of CNVs with the quartiles, minimum and maximum nonoutlier values, and outliers. P-values of > 0.5 (ns), £ 0.01 (**), £ 0.001 (***), and £ 0.0001
(****) are indicated for Wilcoxon tests performed following a Kruskal-Wallis test for the
autosome (p < 2.2 x 10-16) and X chromosome data (p < 2.2 x 10-16).
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3.3.2.2

Regions with recurrent CNVs and singleton CNVs

When considering all cohorts combined, 67% of CNVs were recurrent (Fig. 3-4). For a
CNV from one mouse sample to be considered recurrent, it must reciprocally overlap a
CNV from at least one other mouse sample by at least 40%, and the copy number states of
the overlapping CNVs are permitted to differ. A genomic region containing recurrent
CNVs is defined here as a CNV region or CNVR. WD mice had 3.2 times more cohortspecific CNVRs than WC mice and 1.2 times more CNVRs than CL mice. A similar
number of CNVRs were shared between the WD and WC cohorts, and the WD and CL
cohorts. In contrast, 3.1 times fewer CNVRs were shared between CL and WC mice. The
CNVRs are not uniformly distributed across the mouse genome.
A total of 1,783 singleton CNVs (<40% reciprocal overlap) were identified (Table
3-5). WD mice have double the number of singletons CL mice have (1.97-fold more) and
more than double the number of singletons WC mice have (2.2-fold more). When a more
stringent singleton cutoff of 0% reciprocal overlap is applied, the majority of CL (91.1%),
WD (90.4%), and WC (89.0%) CNVs that were singletons at the 40% overlap, remain
singletons. At 0% and 40% reciprocal overlap respectively, CL strains had the fewest
singletons as a cohort (20% and 22%), the WC cohort had the greatest (38% and 41%) and
the WD cohort had slightly fewer singleton CNVs than the WC cohort (35% and 39%).
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Wild caught

53

Classical
laboratory

Wild derived

Figure 3-4. CNVRs in classical laboratory, wild-derived, and wild-caught mice.
Classical laboratory, wild-derived, and wild-caught mouse cohorts are represented in pink,
light green, and dark green colours, respectively. A CNV is considered to be recurrent if it
has at least 40% reciprocal overlap with another CNV of any state in a different sample.
Genomic regions containing recurrent CNVs are CNV regions (CNVRs). CNVs include
autosome and Chromosome X CNVs.
Table 3-5. Number of singleton CNVs present on the autosomes and X chromosome
for classical laboratory, wild-derived, and wild-caught mouse cohorts, as determined
using <40% reciprocal overlap and 0% overlap criteria.
Mouse
cohort

Autosomal
Chr. X
Singletons
Singletons
(<40% overlap) (<40% overlap)

Autosomal
Singletons
(0% overlap)

Chr. X
Singletons
(0% overlap)

Classical

438

24

399

22

Wild derived

868

44

788

36

Wild caught

385

24

351

23
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3.3.2.3

Genetic distance

The CNV-based genetic distance between mouse pairs groups some mice with common
ancestry together but it does not recapitulate known genealogy as well as SNP-based
genetic distance does (Fig. 3-5). The SNP-based genetic distance shows a clear division in
genetic distance between the CL samples and the WD and WC samples, which do not have
clear cohort divisions. The MOR/RkJ WD mouse is genetically most similar to the C57BL
strains according to SNP-based genetic distance calculations, but this is not unexpected
because MOR/RkJ contains some C57BL/6J ancestry66. CNV-based genetic distance does
not show any clear cohort grouping.

CNV

SNP

Figure 3-5. Phenograms depicting relationships between mice, as determined using
pairwise genetic distances calculated for all autosomal CNVs in 210 mice and
autosomal SNPs in 215 mice. The mouse samples are coloured by cohort where pink
indicates classical laboratory strains, light green represents wild-derived mouse strains and
dark green is used for wild-caught mice. Samples C57BL/6NCr, C57BL/6NCrl, and
C57BL/6NTac are listed as C57BL/6NCl, C57BL/6Crl, and C57BL/6Tc, respectively, in
Appendix 3B.
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When looking at CNV-based genetic distance values, the average intra-cohort
genetic distance is lowest within the CL cohort, although it is very similar to the WD and
WC cohorts (Table 3-6). The average inter-cohort genetic distance is similar when
comparing the CL and WD cohorts and the CL and WC cohorts. The average inter-cohort
genetic distance is slightly greater between the WD and WC cohort samples. SNP-based
genetic distance shows that the average genetic distance within the CL cohort is two times
lower than the average intra-cohort genetic distance for the WD and WC cohorts. The
greatest average inter-cohort genetic distance is between CL and WC mice and lowest
between CL and WD mice. The minimum and maximum genetic distance values indicate
that CL mice are genetically more similar to each other than to mice in other cohorts. In
contrast, some mice in the WD and WC cohorts are more genetically similar to mice from
other cohorts than to mice within their cohorts. In comparison to CNV-based genetic
distance values, the SNP distance values are greater by 100-fold indicating that there are
more SNP differences between samples than CNV differences.
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Table 3-6. Average CNV- and SNP-based genetic distances within and between classical laboratory, wild-derived, and wildcaught mouse cohorts.
Variant type used
for genetic distance
calculations

Mouse cohort

Classical
Copy number variant

Wild derived
Wild caught
Classical

Single nucleotide
polymorphism

Wild derived
Wild caught

Average intra-cohort
genetic distance
(min, max)
2.57´10-3
(1.06´10-4, 1.45´10-2)
2.97´10-3
(4.91´10-4, 1.20´10-2)
2.92´10-3
(2.11´10-4, 1.86´10-2)
1.89´10-1
(1.84´10-3, 2.36´10-1)
3.86´10-1
(2.17´10-2, 5.91´10-1)
3.91´10-1
(3.03´10-2, 5.68´10-1)

Average inter-cohort genetic distance (min, max)
Classical

Wild derived

Wild caught

-

2.85´10-3
(3.20´10-4, 1.71´10-2)

-

-

2.90´10-3
(3.78´10-4, 1.75´10-2)
3.07´10-3
(5.64´10-4, 2.03´10-2)

-

-

-

-

3.84´10-1
(2.54´10-2, 5.58´10-1)

-

-

4.67´10-1
(2.50´10-1, 5.72´10-1)
4.01´10-1
(1.33´10-1, 6.00´10-1)

-

-

-
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3.3.2.4

Genes unlikely to vary in copy number

Of the 5401 detected CNVs, 99% did not overlap, to any degree, with genes that were
unlikely to vary in copy number. The full list of genes checked for CNV overlap used can
be found in Appendix 2G. Of the 47 CNVs that did overlap these genes only four had a
copy number state of zero (Appendix 3M). However, none of the four CNVs completely
overlapped these genes with the percentage of gene overlap ranging from 0.5-20.5%.

3.3.2.5

Concordance between mouse cohort comparison study
and broad survey

Of the autosomal CNVs detected in this study, 522 (11%) CNVs, were not observed in the
broad survey. However, the majority of these novel CNVs (68%) were found in samples
not used in the study. When only comparing the same samples from both studies, 167
autosomal CNVs from 94 mice, were novel in the mouse cohort comparison study. For the
X chromosome CNVs, 15% of CNVs were not found in the broad survey. However, unlike
for autosomes, the majority (68%) of these novel CNVs were detected in samples used in
both studies. In total, 71 novel CNVs were detected in 39 mouse samples in the mouse
cohort comparison study.

3.3.2.6

Genic content

Within the WD and WC mouse cohorts, there were fewer CNVs overlapping at least one
complete gene (Table 3-7). The CL cohort has an equal number of genic and non-genic
CNVs. The majority of genic CNVs in the CL and WD mouse samples were gains while
approximately the same proportion of WC genic CNVs were gains and losses. The top
ranked gene ontology (GO) terms for genes overlapping CNVs differ between CL and wild
mouse samples (Table 3-8). CL mice had CNV losses and gains in genes with terms related
to epigenetics, like nucleosome assembly and methylation. CL CNV losses were found in
genes with antigen-related functions. Nucleosome assembly is also found as a top GO term
in WD CNV gains. Unlike with the CL cohort, the WD cohort has gene enrichment for
sensory perception of smell, also found in the WC cohort. The WC cohort genes are also
enriched for pheromone response in both CNV losses and gains.
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Table 3-7. Genic CNV gains and losses in classical laboratory, wild-derived, and
wild-caught mice.
Mouse
cohort

Genic CNVsa

Non-genic CNVs

Gain

Loss

Gain

Loss

Genic CNVs
(% of total)

Classical

773 (73%) b

286 (27%)

482 (48%)

526 (52%)

51

Wild derived

529 (57%)

399 (43%)

363 (26%)

1047 (74%)

40

Wild caught

224 (49%)

236 (51%)

108 (20%)

428 (80%)

46

a

Genic CNVs overlap at least one whole gene

b

Percentage of gains in genic CNVs
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Table 3-8. Top Gene Ontology terms for CNV gains and losses in classical laboratory, wild-derived, and wild-caught mouse
cohorts.
Mouse
cohort

CNV
states

Losses
Classical
laboratory
Gains

Losses
Wild
derived
Gains

Losses
Wild
caught
Gains

GO term (biological process)
Nucleosome assembly
Antigen processing and presentation
DNA methylation on cytosine
Nucleosome assembly
DNA methylation on cytosine
Positive regulation of gene expression, epigenetic
Sensory perception of smell
G-protein coupled receptor signaling pathway
Detection of chemical stimulus involved in sensory
perception
Sensory perception of smell
G-protein coupled receptor signaling pathway
Nucleosome assembly
Sensory perception of smell
G-protein coupled receptor signaling pathway
Response to pheromone
Response to pheromone
Cell adhesion
Glutathione metabolic process

Number of
genes

P-value

Padj
(BenjaminiHochberg)

25
16
13
25
13
13
105
109

1.40E-16
4.30E-12
1.10E-11
9.40E-18
2.70E-12
4.20E-12
1.40E-69
2.00E-56

2.00E-13
3.90E-09
6.60E-09
1.60E-14
2.20E-09
2.30E-09
6.50E-67
4.70E-54

16

1.40E-08

2.10E-06

71
83
17
67
74
18
10
23
7

3.80E-17
7.80E-14
3.10E-10
1.50E-33
4.70E-29
2.70E-16
2.60E-04
3.80E-04
4.40E-04

4.60E-14
4.80E-11
1.30E-07
5.20E-31
8.30E-27
2.60E-14
2.90E-01
2.20E-01
1.80E-01
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3.4 Discussion
3.4.1

Broad survey

3.4.1.1

CNVs detected

The percentage of the reference mouse genome affected by CNVs detected in this study
(6.87-8.15%) falls within the range found in other studies which found between 1.2%67 and
10.7%68 of the reference genome affected by SVs and CNVs, respectively. In comparison
to WD (0.15%) and WC (0.14%) mice in this study, the percent of the genome affected
was higher in other studies for WD mouse samples (3.4%)67 and WC samples (10.7%)68.
CL mice had a lower percentage (0.065%) of the genome affected by CNVs than WD or
WC mice, which would be expected with inbreeding practices leading to reduced interstrain and intra-strain genetic diversity. These values are all affected by the sample size,
capture technology and diversity of samples, which differ between studies. The amount of
the mouse genome affected by CNVs is greater than that reported for dog (1.08%)69, cattle
(1.61–4.60%)70,71 and swine (4.23%)72 but is similar to that reported for humans (3.7%,
7.6%, 12%)73–75.
The higher ratio of CNV losses to gains observed in this study is consistent with a
previous study76. The larger median CNV length of gains, compared to losses, is consistent
with the idea that large genomic gains are less likely to be deleterious than losses and thus
more likely to be present in the genome, particularly for genic CNVs77. Similarly, a
significant size difference between copy-state-zero and copy-state-one losses was
observed, where the median length of copy-state-one CNVs is approximately double that
of copy-state-zero CNVs. A complete loss of a genomic region is more likely to be
deleterious if it is large because it is more likely to overlap regions that code for important
biological functions.

3.4.1.2

Genic content and analysis

While reduced genetic diversity is expected in CL mice, CNVs can arise even in wellestablished strains like C57BL/6J mice. Watkins-Chow and Pavan78 found dosagesensitive Ide and Fgfbp3 copy number gains segregating in the Jackson Laboratory
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C57BL/6J colony with the occurrence of the gains having increased in the colony since the
mutation was predicted to have arisen, sometime after 1994. The Ide and Fgfbp3 gains in
C57BL/6J samples were confirmed by ddPCR in our study as well. The intra-strain CNV
differences that were detected by the array continue to support intra-strain CNV differences
as important contributors to divergence from isogeneity53. This divergence from
isogeneity, however, can only occur in certain regions of the genome and is dependent on
the mutation type. For example, few losses were expected to occur in regions important for
biological function as they are likely to be deleterious79. Thus, to some extent, dosage
sensitive genes can be used to assess the quality of CNV calls.
Recurrent detection of specific CNVs by different research groups may indicate a
mutation hotspot in a region of the genome or inheritance through relatedness (e.g. same
supplier), but it is also important to consider the reference genome used when generating
CNV calls. The C57BL/6J strain is commonly used as a reference. CNV gains that overlap
with Skint4, Nlrp1b, Slc25a37, Ide and Fgbp3 in the study were called as CNV losses in
non-C56BL/6J laboratory strains in previous studies38,39,68,80–84. Similarly, the CNV losses
in Btbd9 were called as CNV gains in previous studies38,76,81–84. Gm9765, which appears
as a loss in this study’s C57BL/6J mice, appeared as an gain in inbred mice in six other
studies38,76,81–84, while one study found a mix of losses and gains in this region68. This may
indicate that the CNVs overlapping with these six regions (excluding Gm9765) are
widespread in some C57BL/6J mouse stocks and using this mouse strain as a reference
(expected copy number state of two) may result in incorrect CNV states reported in other
strains.
Gene ontology analysis, using DAVID, showed differences in gene enrichment
between mouse cohorts. Laboratory mouse strains are frequently bred to display specific
immunity or disease phenotypes85 and this may in part explain the GO term enrichment
across the CL mouse strains for immunity-related terms. Olfaction- and pheromone-related
genes, which can assist mice with social interactions and gaining information about their
environment86, are not highly enriched in analysis of GO terms for CL mouse strains,
consistent with their laboratory breeding history and less diverse ancestry. Similar to copy
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number variation, SNP variation in pheromone receptors is lower in CL mice when
compared to WD mice87.
Using IPA, an overrepresentation of lipid metabolism genes has been shown in
CNV regions in WC mice68. Different sets of metabolism genes were overrepresented in
CL mouse CNVs: carbohydrate metabolism genes in gains and amino acid metabolism
genes in losses. This difference may indicate copy number variation as an adaptive change
to diet between WC mice and CL strains. In humans and dogs, the copy number of the
amylase (AMY1, AMY2B) gene was found to vary and in dogs is also found to be amplified
over wolves, conferring adaptation to a starch-rich diet88,89. Across all of the samples, there
is only one gain in the mouse ortholog to these genes (Amy1, Amy2), found in the YBR/EiJ
CL strain, so there is no evidence for an adaptive change to diet involving CNVs in the
mouse amylase genes within this sample mouse population.
Since many development-related genes are present in the mouse genome, it is not
unexpected for development-related IPA networks to appear for the detected CNVs. The
types of developmental genes that are overrepresented differ between mouse cohorts
although it is not clear if the differences result from factors including but not limited to
environmental influences and sampling biases (e.g. sample size, inter-cohort differences in
subspecies composition, and genetic relatedness).
Some CNV calls may differ by strain due to strain-specific SNPs preventing the
hybridization of probes and the target DNA. As a result, a bias in gene enrichment may be
present depending on how closely related a mouse is to the probe design reference. Biases
in gene enrichment can also occur with large gene families or if there are many genes
associated with specific Gene Ontology terms. These biases can be overcome in programs
like DAVID by inputting all of the genes in the mouse genome as a “background” for
statistical analysis.

3.4.1.3

Genes unlikely to harbour copy-number losses

The autosomal genes A disintegrin and metallopeptidase domain 17 (Adam17)90, cyclindependent kinase 8 (Cdk8)91, collagen type VII alpha 1 (Col7a1)92, delta like canonical

115

Notch ligand 1 (Dll1)93, DNA methyltransferase 3B (Dnmt3b)94, dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1a (Dyrk1a)95, embryonic ectoderm development
(Eed)96, elastin (Eln)97, enhancer of zeste 2 polycomb repressive complex 2 subunit
(Ezh2)98, insulin-like growth factor 1 (Igf1)99, laminin alpha 5 (Lama5)100, mediator
complex subunit 1 (Med1)101, mediator complex subunit 21 (Med21)102, mediator complex
subunit 24 (Med24)103, mediator complex subunit 30 (Med30)104, peroxisomal biogenesis
factor 7 (Pex7)105, Pbx/knotted 1 homeobox (Pknox1)106, 3-phosphoinositide dependent
protein kinase 1 (Pdpk1)107, solute carrier family 2 (facilitated glucose transporter) member
1 (Slc2a1)108, SUZ12 polycomb repressive complex 2 subunit (Suz12)109,110, VPS35
retromer complex component (Vps35)111, and transferrin receptor (Tfrc)112 are known to
cause deleterious phenotypes when gene expression levels are reduced and may be lethal
when inherited at a zero-copy state or one-copy state, depending on the gene. Therefore,
losses in these gene regions, particularly state-zero losses, are not expected to be inherited
or arise early in development and be present in the adult mouse. Although three mice appear
to have partially lost one copy of Col7a1, unlike a zero-copy loss, a single-copy loss
of Col7a1 is not lethal92. Mice in this latter case are expected have a normal phenotype if
gene expression levels are high enough92. As expected, no losses were detected in any of
the other autosomal genes listed above.
A number of genes on the X chromosome cause deleterious phenotypes when
deleted or inactivated113, including apoptosis-inducing factor mitochondrion-associated
1 (Aifm1)114, aminolevulinic acid synthase 2 erythroid (Alas2)115, APC membrane
recruitment 1 (Amer1, synonyms Wtx and Fam123b)116, BCL6 interacting corepressor
(Bcor)117, calcium/calmodulin-dependent serine protein kinase (MAGUK family; Cask)118,
cullin 4B (Cul4b)119, phenylalkylamine Ca2+ antagonist (emopamil) binding protein
(Ebp)120, filamin alpha (Flna)121, glucose-6-phosphate dehydrogenase X-linked
(G6pdx)122, glycerol kinase (Gyk)123, inhibitor of kappaB kinase gamma (Ikbkg)124, methyl
CpG binding protein 2 (Mecp2)125, mediator complex subunit 12 (Med12)126, X-linked
myotubular myopathy gene 1 (Mtm1)127, NAD(P) dependent steroid dehydrogenase-like
(Nsdhl)128, OFD1 centriole and centriolar satellite protein (Ofd1)129, phosphatidylinositol
glycan

anchor

biosynthesis

class

A

(Piga)130, and

porcupine

O-
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acyltransferase (Porcn)131,132. The partial loss of the Cask gene in two mice may be a true
biological event because although a knockout of Cask is lethal, mice are still viable even
if Cask expression has been reduced by ~70%118. Losses up to 4761 bp in length have been
found in Cask67 and a large CNV loss covering the entire Cask gene was identified in an
aCGH study133. As long as some degree of the functioning Cask gene is maintained in the
mouse it is possible for Cask to acquire mutations or be lost in a cell population.
There are several possible explanations for observing gene losses that contribute to
deleterious phenotypes. The losses could be false positive calls or could be due to off-target
mutations in the samples that prevent the sample DNA from binding to the array probes.
In other cases, a potentially deleterious genic loss could have arisen in a mouse, but it is
not harmful to the individual because it occurred after a specific developmental time point,
in a tissue where it is not vital for proper function, or it is present in a clonal size insufficient
to produce a negative phenotype. The following genes were also reported to overlap losses,
over 500 bp in size, in previous studies67,68,83,134: Adam17, Cdk8, Dnmt3b, Dyrk1a, Eed,
Ezh2, Lama5, Med21, Pdpk1, and Pex7, as well as on the X chromosome38,67,83: Aifm1,
Bcor, Cask, Cul4b, Ebp, Flna, G6pdx, Gyk, Ikbkg, Mecp2, Nsdhl, and Porcn. The reports
for the genes listed above do not provide an integer copy number state, so it is likely that
the reported losses in these gene regions are one-copy-state losses since single-copy losses
or minimal expression of each of these genes can be tolerated in mice.

3.4.1.4

Droplet digital PCR confirmation of select genic CNVRs

Biological validation, such as qPCR, would normally be performed using the same DNA
samples. Since we did not have access to those exact samples, strain-matched mice were
used instead since mice of the same strain are related and there is a possibility that the
CNVs selected for confirmation may have been inherited in the lineage. Confirmation of
select genic CNVs in classical inbred strains is a first step toward biological validation and
future work could be expanded include more CNVs and to evaluate their phenotypic
impact.
The high rate of CNV confirmation (96%) in mouse samples that differed from
those used on the array, can be partially attributed to the occurrence of strain-specific
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CNVs. For example, two of the CNVRs selected for confirmation are known to contain
genes Ide and Fgfbp3 that vary in copy number within the C57BL/6J mouse strain78.
Alternatively, not all strain-specific CNVs are found in every individual of that strain, so a
copy number state of two (“default” state) is also considered to be an acceptable alternate
state for confirmation purposes, thereby increasing the probability that a CNV state can be
“confirmed”. In the case of Skint3 in DBA/2J mice, a copy number state of two was
predicted by the array, but ddPCR results showed a state of zero. Complete losses of Skint3
have been previously observed in DBA/2J mice135. Notably, any differences from the
predicted copy number states are not necessarily indicative of MDGA performance given
that different mice were used for the microarray and ddPCR-based determinations.

3.4.2

Mouse cohort comparison study

3.4.2.1

CNVs detected

Among the three cohorts, WD mice had the greatest number of CNVs, which is consistent
with findings in the Locke et al1 study, which includes ~85% of the samples used in the
mouse cohort comparison study. WD mice are laboratory strains that have greater interstrain genetic heterogeneity than CL strains, so the increased number of CNVs may have
artificially resulted from breeding practices intended to maintain higher genetic diversity
than CL mice136. At the same time, sibling mating has occurred with WD mice, leading to
reduced heterozygosity, and the WD mice may also be gaining CNVs common to CL
strains, as a result of positive selection for variants with higher fitness in mouse facility
environments136. Further genomic studies would be required to determine if the increased
number of CNVs in WD mice is due to animal husbandry, the genetic diversity of the
founding wild animals and animals used in maintaining the stock, or some other reason.
In general, inbreeding is associated with reduced genetic diversity and CL strains
have been maintained through inbreeding for many generations. Inter-line genetic
relatedness can be attributed to founder effects and a small number of related founders.
Intra-strain homogeneity can be valuable in that it helps reduce confounding factors arising
from genetic variation in research studies. Many CL strains are known for having specific
traits and were intentionally bred to study disorders caused by different mutations4. Some
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mouse strains are used to model diseases that are known to have genomic instability, such
as cancer and therefore could have a number of structural alterations that is higher than
expected with other disease models or with normal development137–139. This may have been
the case with CL samples which are outliers in the cohort with respect to number of CNVs
detected. The MRL/MpJ sample for example, which had the highest number of CNVs in
the mouse cohort study (80 CNVs; 100 CNVs in the broad survey), is prone developing
lupus and differences in anergic B cell gene expression have been identified between the
MRL/MpJ strain background and the C57BL/6J strain, which is not prone to developing
lupus140. The differentially expressed genes were involved in functional networks relating
to the regulation of cell growth, signalling and apoptosis140. It has yet to be determined if
the high number of CNVs in the MRL/MpJ sample is characteristic of this strain as a result
of genetic background or if it is disease-associated, or both.
Given that CNV gene gains are generally thought to result in milder phenotypes
than losses and strong purifying selection against genic CNV losses, but not gains, has been
observed in a eukaryote species77, it was expected that all mouse cohorts would have more
CNV gains than losses. However, only CL mice were found to have more gains than losses.
More losses than gains were also found in all but one of 59 sequenced samples assessed in
a study of wild-caught domesticus and musculus mice (including wild-caught mice bred
for one or two generations)13. Losses were generally found to be more frequent in studies
of other organisms as well, including silkworms141, dogs142, goats143, and cattle144, and are
thought be found more frequently due to mutation mechanism biases and biases in the
detection technology used141,143. The mouse cohort comparison study also showed the
median length of CNV losses to be smaller than gains for all cohorts and this length
difference was larger for Chromosome X CNVs. The reason for this difference in length
has yet to be determined, although it is possible that large deletions are more likely to be
deleterious than large gains and therefore are negatively selected against. A study of CNVs
in wild-caught mice found that, although more numerous, losses generally impacted a
smaller proportion of the genome than gains, which indicates that many losses are small in
size13. In humans, the CNV length was found to be associated with pathogenicity, since
pathogenic CNVs for both gains and losses were longer on average than benign CNVs,
thereby impacting more of the genome145. Pathogenic CNV losses were also found to

119

outnumber pathogenic gains by ~3-fold while benign CNVs were made up of slightly more
gains than losses145, further providing support that CNV losses are more likely to be
deleterious than gains.

3.4.2.2

CNV recurrence

The CNV diversity was predicted to be the greatest in the WC cohort because of the
heterogeneous makeup of the samples in this cohort which included mice from different
geographical regions and multiple subspecies, and these captured mice were not inbred for
numerous generations like CL mice. This diversity was reflected in the percentage of
singleton (non-recurrent) CNVs in this cohort, which is the highest among the three
cohorts. Likewise, the WC cohort had the highest maximum genetic distance between two
mice, although the average genetic distance was similar to the WD cohort. In contrast, the
CL cohort mostly had recurrent CNVs, some of which appear to be specific to a mousestrain or lineage and may have resulted from random mutations that arose in the lineage
and were passed on or they may have been selected for in the generation of a mouse strain
due to phenotypic impact. An example of this is the Ide gain in C57BL/6J mice78. The high
level of CNV recurrence in the CL cohort is evident from the pairwise genetic distance
values which show lower intra-cohort diversity for CL mice than WC or WD mice. WD
mice had a similar number of singletons as WC mice, indicative of genetic diversity within
the cohort. However, the WD cohort also had 167 and 166 CNVRs shared with the WC
and CL cohorts, respectively. These shared CNVs may be the result of shared ancestry or
they could be variants that arose independently and were positively selected for in the wild
or laboratory environments.
The WC and CL cohorts shared more than 3-fold fewer CNVRs than the WD cohort
shared with either of these cohorts. This suggests that the WD mice are more closely related
to mice in the other two cohorts, either as a result of shared genealogy or shared
environmental influence on the genome, while the WC and CL mice had less in common.
Overall, there were more CNVRs shared by all three cohorts than by any two alone. Some
of these recurrent CNVs may be specific to mouse subspecies, since multiple subspecies
or mixtures of subspecies can be found within the cohorts. If shared among all subspecies,
recurrent CNVs may have arisen in ancient ancestors and could be informative about the
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evolutionary history of mice. Alternatively, recurrent CNVs may have arisen
independently in individuals from each cohort in mutation hotspots in the genome.
CNVRs that overlap large segmental duplications are more likely to contain CNVs
that are variable in copy number between individuals and overlap environmentally
responsive genes while CNVRs outside of segmental duplications are more likely to
contain pathogenic CNVs12,146. Several CNVRs observed in this study have been identified
in other studies, including the regions that contain the Itln1 and Hjurp (Holliday junction
recognition protein) genes, which have roles in metabolism and chromosome segregation
during cell division, respectively12,147. The genomic context of CNVRs and regions with
unusual CNV distribution patterns should be looked at in depth in future studies to
determine potential mechanisms of CNV formation and phenotypic impact. CNV
landscape plots, described in Chapter 3B, can be used to aid in the visual identification of
major CNVRs and unusual CNV distribution patterns.

3.4.2.3

Genic content of CNVs and analysis

The predicted functional impact of genic CNVs differed between mouse cohorts. Similar
to the DAVID results in the broad survey, the CL mice had CNVs in genes with functions
relating to immunity like “antigen processing and presentation”, and to epigenetic
regulation like “nucleosome assembly”. The highest ranking, gene ontology terms for
CNVs in the WD and WC cohorts, included terms related to olfaction and pheromone
response, and were also observed for the WC samples in the broad survey. This is
consistent with a previous study which found that copy number variable regions in wild
mouse populations generally contained genes relevant to environmental and behavioural
interactions, such as vomeronasal and olfactory receptor genes12. Pheromone response
which is important for mouse mate selection, and influencing sexual behaviour and
reproductive function148, would be expected to be more diverse in natural mouse
populations where a choice of potential mates is available than in laboratory mice which
have mates selected for them by humans to create and maintain inbred lines. Likewise, the
ability to detect a wide range of scents via olfaction is important in the wild for obtaining
food149,150 and avoiding predators151,152, neither of which is a concern for laboratory mice
since they live in control environments. Many laboratory mouse strains have been created
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to express disease-related traits4, so it is expected that immunity-related terms would
appear in this cohort.
The G-protein coupled receptor signaling pathway found in the WD and WC mouse
cohorts is likely to have an important role in adaptation and evolution. The reason for this
is that these proteins belong to a protein superfamily and their common function is in acting
as receptors for signals for different biological pathways relating to olfaction, pheromone
detection, taste, regulation of metabolism, reproduction, development, and more153. Due to
the numerous functional roles of genes associated with the G-protein coupled receptor
signaling pathway, genes impacted by CNVs will need to be identified individually to
determine what specific biological pathways and functions are associated with each cohort
but broadly fall under the G-protein coupled receptor signaling pathway category.

3.4.2.4

Genes unlikely to harbour copy-number losses

Very few CNV losses occurred in genes that were predicted to be unlikely to vary in copy
number, particularly if the CNV state was zero. Where state-zero-losses of control genes
did occur, the losses covered 20% or less of the gene. The presence of such losses may not
have phenotypic consequences if the losses arise during a period where their expression is
not vital for survival (e.g. after development). The CNV that results in a 20% loss of a gene
was found in the CL mouse, TSJ/Le, in the Tcf7l2 gene. Had this loss disrupted the gene
function, the mouse would have been severely hypoglycemic and would have died
perinatally154. Furthermore, the CNV breakpoints are approximations of the real CNV
breakpoints so the loss may overlap less than 20% of the gene. Additional experiments
would be required to confirm that the array is detecting biological events but the low
presence of CNVs in control genes is consistent with where CNV losses would be less
likely to occur.

3.4.2.5

Confirmation of CNV data

Since the data for this study was produced using publicly available MDGA data from an
online source, there is no way to directly confirm the array findings using the DNA from
those specific samples. Instead, the same mouse strains could be tested to identify strainspecific CNVs, as was done in the broad survey.
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In the broad survey, Hdhd3 and Glo1 CNV gains were identified in CBA/CaJ and
DBA/2J samples and confirmed using ddPCR. In the current study, the same gains were
detected again in these mouse samples. DdPCR was also performed to confirm CNV gains
in Ide, Fgfbp3, and Skint3, all of which also appeared as gains in the C57BL/6J sample in
this study. Nlrp1b, B4galt3, and Trim30-ps1 appeared either as a state of two or as gains in
the eight C57BL/6J mice in the broad survey and as a state of two in the mouse in this
study. A loss of a copy of Itln1 was found in C57BL/6J samples in both studies.
Further support for the accuracy of array data is the genetic distance information
generated from the SNP genotyping data. In the phenogram representing the genetic
distance relationships between mice, the CL mouse samples cluster together while the WD
and WC samples are clustered together. Related mouse strains were also found to cluster
together, which indicates genetic similarity. The WC mouse samples group together by
mouse subspecies, consistent with a previous study on some of these mouse samples21. One
WD mouse sample, MOR/RkJ was found to cluster with the C57BL strains, which was not
expected. However, MOR/RkJ and MOR/Rk mice consistently cluster with C57BL-type
strains in other SNP-based studies66,155. These findings support the inclusion of C57BLtype strains in the MOR/RkJ ancestry.
Two other outliers on the SNP-based phenogram are the CL strains, CE/J and SM/J,
which are found on their own branches. The background of these two strains likely
accounts for the increased genetic distance from the other classical laboratory strains. The
CE/J mouse originated from a wild mutant mouse that was trapped in Illinois in 1920 and
then inbred for many generations to become a CL strain156. The SM/J mouse was created
in 1939 using seven different inbred mouse stocks and selectively bred for a small size
phenotype157. Didion et al (2013) also observed segregation of CE/J and SM/J from the
other CL strains and attributed this to the highly mixed background of these mice, which
includes large contributions from a WC mouse in the CE/J strain21.
The CNV phenogram shows some related mice clustering together but there is not
a clear distinction between the CL and wild cohorts like there is when using SNP-based
genetic distance. This lack of clustering based on known genealogy is likely due to
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insufficient numbers of strain-specific CNVs, which is not an issue with SNP genotype
data. SNP information is regularly used to determine genetic relationships in a variety of
organisms.

3.5 Conclusion
The microarray is a valuable tool for large-scale analysis and when analyzed with rigour
can provide insight into SNP and copy number variation. This study provides researchers
with a CNV detection pipeline that has been tested on a large, publicly available dataset of
Mus musculus samples and was confirmed using computational and PCR-based
approaches.
In the broad survey, differences were found in the genes affected by putative CNVs
between WC and CL mice, most notably in genes related to lipid, carbohydrate and aminoacid metabolism, as well as immunity, pheromone response and olfaction. This supports
the hypothesis that CNVs play a role in increasing genetic diversity and have phenotypic
impacts that when shaped by selective pressures confer adaptation.
The mouse cohort study expanded on the findings in the broad survey and identified
cohort-specific differences in CNV number, state and genes impacted. CNV length is not
a defining characteristic among the cohorts, suggesting that the CNVs arose in samples
from the three cohorts via common mechanisms of CNV formation. Further analysis is
required to determine if there is a biological significance behind the differences in CNV
number and state between cohorts. The gene pathways impacted by CNVs in CL, WD, and
WC cohorts have associations consistent with the histories of these mice with respect to
their environments and breeding histories.
In future studies, recurrent CNVs could be studied in detail from a cohort and
subspecies perspective, to identify evolutionary-relevant mutations by finding cohort- or
subspecies-specific CNVRs and determining if there are dosage-sensitive elements
contained within those regions that can impact phenotypes. Dosage-sensitivity of a gene
can be determined by confirming the predicted copy number state through ddPCR and then
measuring levels of the transcribed product with a gene expression microarray or with RNA
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sequencing. The mechanism of CNV formation in regions of interest can also be
determined by sequencing the breakpoint junctions and searching for repetitive or
homologous regions, or nucleotide deletions and additions that are known to be associated
with specific mechanisms of CNV formation. Uncharacterized genomic elements in
recurrent CNVs could be characterized through various functional genomics approaches to
determine their function and if they are dosage sensitive. For example, a region of interest
could be sequenced and checked for the presence of transcription-associated sequences like
open reading frames, followed by measuring levels of predicted transcript and translated
product. Protein or RNA function can be predicted through ortholog comparisons and
verified with gene knockout experiments. Any future MDGA-based experiments should be
carried out on samples where tissues are available for confirmation of microarray results
using methods not based on hybridization.
Overall, the two studies in this chapter presented an established CNV detection
pipeline, introduced a method to visualize the distribution of CNVs across a genome, and
characterized CNVs in a large variety of M. musculus individuals, including three mouse
cohorts, from the perspective of CNV number, state, length and genomic context.
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3B

Visualizing the Distribution of CNVs across a Genome
with CNV Landscape Plots

3B.1

Background

An informative way to view CNVs across the genomic landscape is to plot them at
chromosomal base pair positions, similar to the plot presented in Figure 1 of Cutler et al.
(2007)1. This CNV landscape plot has advantages over Gephi-based visualization of HDCNV output in that it shows the genomic locations and copy number states of CNVs in
each sample with easy recognition of singletons and CNVRs that are specific to a mouse
strain or cohort, or that are shared by multiple mouse groups. Here, an example CNV
landscape plot of CNVs detected on Chromosome 17 in the mouse cohort comparison
dataset is presented alongside the corresponding HD-CNV Gephi image for comparison.

3B.2

Materials and methods

The mouse samples used here are described in section 3.2.1. CNV identification was
performed as described in section 3.2.2. Recurrent and singleton CNVs were determined
using HD-CNV, described in section 3.2.3. HD-CNV output was converted into a
chromosome image using the Fruchterman-Reingold layout in Gephi2. To visualize CNV
recurrence across individual chromosomes, a timeline-style plot was generated in R using
the geom_curve() function in ggplot2 (v2.1.0).

3B.3
3B.3.1

Results
Visualization of CNV spatial landscape of Chromosome 17

In Figures 3B-1 and 3B-2, several regions with recurrent CNVs, also known as copy
number variant regions (CNVRs), can be seen. Region A contains CNVs from all mouse
cohorts, as does region C1. Regions C1 and C2 in Figure 3B-1 flank the ATP-binding
cassette transporter G1 (Abcg1) and trefoil factor 3 (Ttf3) genes, and correspond with
region C in Figure 3B-2, which cannot be clearly identified as two separate merge regions
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at that scale. Region C appears to be a major CNV hotspot in Mus musculus since it is
present in many mice from all three cohorts. Region D has CNVs that are recurrent mostly
in the CL cohort, although one WD sample is included as well.

C2
D
B
C1

A

Figure 3B-1. Gephi-based visualization of HD-CNV output showing Chromosome 17
CNV merges and singletons for classical laboratory, wild-derived, and wild-caught
mouse samples. Each node (circle) represents a CNV and nodes that are connected by
edges (lines) indicated CNVs that overlap reciprocally by at least 40%. The more CNVs
that are involved in a merge region, the warmer the node colours are while cool colours
indicate fewer CNVs in a merge. Merge regions A-D correspond with regions A-D in
Figure 3B-2.
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Figure 3B-2. Distribution of CNV gains and losses across Chromosome 17 for classical
laboratory, wild-derived, and wild-caught mouse samples. Regions A-D correspond
with merge regions A-D in Figure 3B-1. Different colours represent CNV gains (yellow),
state-one-losses (light blue), and state-zero-losses (dark blue).

3B.3.2

CNV spatial landscape analyses for autosomes and
Chromosome X

A visual inspection of the autosomal landscape plots (data not shown) reveals 21 CNVRs
that are shared by mice in all three cohorts. There are also six regions where CNVs
commonly occur in both WD and WC mice. No large multi-sample CNVRs are shared by
only CL and WD or WC mice, based solely on visual inspection. Nine genomic regions
were found to have cohort-specific CNVRs, seven of which were unique to the CL cohort
and were predominantly gains among the CL samples. The X chromosome (Fig. 3B-3) has
over 10 CNVRs between and within the mouse cohorts, with almost all of these regions
having CNV gains. CNV losses on the X chromosome are noticeably more common in the
WD and WC cohorts, in comparison to the CL cohort. CNVRs on the X chromosome are
difficult to quantify visually due to the large number of CNVs detected on this chromosome
and would be better suited for HD-CNV analysis. Strain-specific CNVRs were observed
as well, including a region on Chromosome 9 (Fig. 3B-4) where recurrent gains can be
found in the 129-type strains.
The CNV landscape plots also revealed an unusual distribution of CNV occurrence
on five autosomes of the PWK x Domesticus F1 sample, where many CNVs were found
somewhat uniformly distributed either in regions of an autosome or across the entire
autosome. Such a pattern can be observed in other samples within the dataset, like on
Chromosome 8 (Fig. 3B-5A) of the RDS10105 WC sample, but only PWK x Domesticus
F1 has this pattern on multiple chromosomes. Other CNV distribution patterns can be
observed as well, such clustered gains made up of two or more closely-spaced, large CNV
gains (Fig. 3B-5B) and paired, small CNV gains and deletions where a CNV gain is located
almost immediately next to a CNV loss or vice versa (Fig. 3B-5C).
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Genome Position (Mb)

Figure 3B-3. Distribution of CNV gains and losses across Chromosome X for classical
laboratory, wild-derived, and wild-caught mouse samples. Different colours represent
CNV gains (yellow), state-one-losses (light blue), and state-zero-losses (dark blue).
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Figure 3B-4. Distribution of CNV gains and losses across Chromosome 9 for classical
laboratory, wild-derived, and wild-caught mouse samples. Different colours represent
CNV gains (yellow), state-one-losses (light blue), and state-zero-losses (dark blue).
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Figure 3B-5. Examples of three CNV distribution patterns (A-C) across a mouse
chromosome. Different colours represent CNV gains (yellow), state-one-losses (light
blue), and state-zero-losses (dark blue). Dark red asterisks indicate a gain closely followed
by a loss. Light green asterisks indicate a loss closely followed by a gain.

3B.4

Discussion

When CNVs from the mouse cohort comparison study are plotted on CNV landscape plots,
several CNVRs that involved a large number of CNVs are revealed. In total, there are at
least 21 of these CNVRs shared among M. musculus samples in all three cohorts, as well
as over 15 regions that are specific to two cohorts, one cohort, or a mouse strain. HD-CNV
analyses detected far more CNVRs (see section 3.3.2.2), but it is not possible to visually
identify all these CNVRs from the CNV landscape plot. In general, the CNV landscape
plot is more useful in identifying major mutation hotspots and CNVRs in a large dataset,
such as Regions A and D on Chromosome 17. The plot is also highly informative about
general CNV distribution patterns across the mouse genome. HD-CNV Gephi images are
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most helpful in visualizing the number of singletons and recurrent CNVs but they are not
informative about the nature of the CNVs nor do they allow for visual identification of
CNV occurrence patterns along the chromosome landscape. Following CNVR
identification in the mouse cohort comparison dataset, the next step would be to examine
the genomic context of the CNVRs in order to determine the mechanisms of CNV
formation and impact on phenotype or biological relevance.
Given a sufficient sample size for pattern observation, the CNV landscape plot can
be used for data visualization with any genome and for any mutation type, provided that
the genomic positions of the CNVs are known. Furthermore, the CNV landscape plot can
be used in conjunction with HD-CNV output to visualize merged regions and singletons
across each chromosome. In all, the CNV landscape plot is a useful tool in assisting with
visual identification of mutation hotspots in a genome and CNVRs relevant to adaptation
and evolution. This type of CNV plot may also prove to be valuable in identifying mutation
signatures in disease studies involving unstable genomes, such as cancer, and in mutagen
exposure studies, such as exposure to ionizing radiation which is known to cause increased
CNV formation3.

3B.5
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Chapter 4

4

Somatic Mosaicism and de novo CNVs in a C57BL/6J
Mouse Family

4.1 Background
The presence of two or more genetically distinct cell populations within an individual, is a
common phenomenon known as mosaicism, which can impact phenotypes, in some cases
causing deleterious effects. Somatic mosaicism, which occurs postzygotically in somatic
cells1 via multiple mechanisms, including imperfect DNA replication, and exogenous and
endogenous mutagen exposure2,3, has been shown to be widespread in normal human
tissues4–6. Mosaicism can also occur in the germline, in which case it is referred to as
germline mosaicism7. Unlike somatic mutations, mutations in the germline can impact
offspring. The proportion of cells with a given de novo (i.e. postzygotic) mutation is largely
dependent on when the mutation arose. CNVs in mice were observed to arise as early as in
the first division following zygote formation, and although CNVs were not found in all
preimplantation embryos, there was a general pattern of increasing CNV numbers as
preimplantation embryos continued to grow in cell number and develop8. Similarly,
chromosomal mosaicism was found in approximately half of human embryos, with a
pattern of increasing frequency of mosaic embryos with embryo progression through the
developmental stages9. A mutational event that occurs when a two-cell embryo is formed
can result in genotypic differences between half of an individual’s cells, if the mutation
does not reduce cell fitness, and could have potential phenotypic implications for the
affected individual if genes or regulatory regions are impacted10,11. Early-occurring
mutations may lead to mosaicism in both the soma and germline if arising prior to the
separation of the soma and germline7, resulting in gonosomal mosaicism. In such a case,
there is potential for the phenotype to be impacted in both the affected individual and the
individual’s offspring7. Due to its association with different diseases, mosaicism has been
commonly studied from a human disease perspective. There are comparatively fewer
studies on mosaicism occurring with normal development in healthy individuals.
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Mosaicism can lead to several potential consequences depending on several factors
including but not limited to the mutation type, location (i.e. genomic content), and
proportion of cells affected12,13. With respect to mutation type, aneuploidy mutations are
more likely to cause severe phenotypic consequences than smaller genome alterations or
point mutations since they affect a larger region of the genome that includes numerous
genes and regulatory elements. One of the most commonly known examples of aneuploidy
in humans is Trisomy 21 and it can be found in a mosaic form. The severity of the affected
person’s symptoms is dependent on the proportion of cells containing the extra
Chromosome 21 and if a full third chromosome or partial copy, similar to a CNV gain, is
present14,15. Other chromosomal aneuploidies can be lethal when inherited but can produce
less severe consequences if a small proportion of the person’s cells are affected, as is the
case with trisomy 18 mosaicism16. Smaller genomic alterations like CNVs are also
contributors to genome mosaicism between17,18 and within6 normal human tissues and do
not always result in negative phenotypes. De novo CNVs are estimated to affect
approximately 30% of normal human skin fibroblast cells and between 13-40% of human
frontal cortex neurons4,6, making somatic mosaicism a common phenomenon in normal
human tissues.
The observation that CNV mosaicism can occur in normal tissues without
phenotypic consequences can be explained by several reasons. First, some genes have
tissue-specific or time-specific expression and are not needed in the tissue or during the
time point when the CNV arises. For example, of 19,628 putative protein coding genes in
humans for which there is transcriptome data available in major organs and tissue types,
7,367 genes are expressed in all tissues and 7,835 have tissue-specific or related tissue
group-specific expression patterns19. Even if CNVs overlap genic or non-coding elements
that are expressed, the elements might not be dosage sensitive (i.e. expression is dependent
on copy number), so there may not be any impact on phenotype for gains or partial losses.
Individual cells that acquire mutations that disrupt vital cell functions will die or stop
dividing, resulting in the loss of these mutant cells from proliferating cell populations20,21.
Furthermore, the presence of cancer-causing mutations does not always result in the
development of cancer. An example of this was observed in the human eyelid where more
than 25% of cells in the normal human eyelid epidermis were found to contain known
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cancer-causing mutations as a result of UV exposure, yet still appeared to be maintaining
normal functions22. Although the reason for why the cells are not presenting malignant
phenotypes was not determined in the study, it has been proposed that the cellular
microenvironment is an important factor the development of cancer and genetic mutations
alone, within the context of the eyelid epidermis, are not sufficient to cause cancer23. The
microenvironment is an important area of study in cancer research and multiple studies
have shown the impact of the microenvironment on both allowing and preventing cancer
initiation and progression24,25.
In contrast to mutations that do not impact phenotypes because of their timing or
location in a specific cell type or tissues, some mutations are linked to different diseases
because they generate different phenotypes depending on the cell or tissue type and the
developmental timing of the origin of the mutation. For example, a study sampling brain
and skin tissue from individuals with Sturge-Weber syndrome found that a specific
nonsynonymous point mutation in the guanine nucleotide-binding protein G(q) subunit
alpha (GNAQ) gene is associated with this neurocutaneus disorder and likely occurs early
in fetal development26. This same mutation occurring later and in a different cell type,
melanocytes, is linked to uveal melanoma risk27.
When attempting to find a genetic link to a phenotype, it is important to account for
possible somatic mosaicism. If the mutations are tissue-specific in tissues that are hard to
access, such as the brain, then the mutations might not be detected when a sentinel tissue
such as blood, saliva or skin is used for disease testing. In one case, a CNV gain present in
approximately 20% of neurons, was enough to cause brain dysfunction (i.e.
hemimegalencephaly)28. This CNV gain was discovered in a post-mortem brain and likely
would not have been discovered in the living individual if sentinel tissues were tested
instead of the brain tissue. It is possible that many disease-causing mutations are missed
even when the appropriate tissue is selected, because of low-level mosaicism that is below
the detection threshold of the technology used.
De novo CNV discovery is heavily dependent on the technology used, making the
true number of de novo CNVs present in an individual’s tissues and cells difficult to
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ascertain. Estimates of the minimum detectable level of mosaicism using SNP microarray
technology range from <5-20% depending on the array resolution and probe types,
algorithms used, amount of tissue or number of cells examined, the heterogeneity level of
the cell population, and type of mutation being assayed29–32. Alternatively, sequencing
strategies offer high depth of coverage and single-nucleotide resolution allowing for the
detection of rare, low frequency events in cell population or even individual CNV events
in a single cell6,33,34. While there are multiple CNV mosaicism detection approaches
available, the most appropriate choice will be dependent on cost limitations and what
research question needs to be answered. There are also several additional challenges when
studying mosaicism in humans, including but not limited to, the low availability of multiple
human tissues, limitations to conducting family studies, and the difficulty in controlling for
the subject’s environment and genetic background.
For this study, a cost-effect MDGA approach is used to identify somatic mosaicism in
multiple healthy tissues from the parents and sons of a C57BL/6J mouse family. The
MDGA has not been used previously in a study of somatic mosaicism occurring with
normal development in a mouse family. The C57BL/6J strain was selected as it is a highly
inbred strain that is commonly used by mouse researchers and it is most compatible with
the MDGA, which was built based on the C57BL/6J reference genome35. With a family
study, genetic variants can be compared between parents and siblings to help establish
when the variants may have arisen. The use of multiple tissues for each individual can help
identify tissue-specific mutations, and examining tissues derived from different
developmental germ layers can help establish when the variants arose. Overall, this study
will establish what a normal CNV profile looks like across the genomes of multiple healthy
tissues in a C57BL/6J mouse family.

4.1.1

Research goal, central hypothesis, and specific objectives

Research goal: The purpose of this study is to characterize the CNV landscape in multiple,
normal tissues of family members of a commonly used laboratory mouse strain to
determine the contribution of CNVs to somatic mosaicism occurring with normal
development.
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Central hypothesis: CNVs that are inherited in family members or arise spontaneously
within an individual mouse during postzygotic development can be detected using MDGA
analysis.
The specific objectives of this chapter are:
1. To detect and characterize putative CNVs in both parents and three sons of a single
C57BL/6J mouse family across four tissues in the parents and six tissues in the sons.
Predictions: Based on CNV data from eight C57BL/6J tail samples, presented in the broad
survey in Chapter 3 and Locke et al.36, there should be an average of 11 CNVs per mouse
for the mouse family tail samples. This average increases to 14 if Chromosome X CNVs
are included. It is also predicted that there will be more gains than losses since 57% of
autosomal CNVs detected in the eight samples were gains. All the Chromosome X CNVs
found in the eight C57BL/6J samples were gains and are therefore predicted to be gains in
the C57BL/6J mouse family in this analysis. Considering previous findings in C57BL/6J
samples, copy number gains of the Ide gene are likely to be found since these mouse
samples also came from The Jackson Laboratory.
2. To determine what the level of de novo CNV occurrence is within an individual mouse
and to determine if there are tissue-specific CNVs.
Predictions: Most CNVs detected are predicted to be recurrent across different tissues
within an individual mouse. Given that somatic mosaicism is a common phenomenon, it is
predicted that the MDGA will detect some de novo CNVs given that a sufficient clonal size
is present, but it is unknown if tissue-specific CNVs will be detected. Recurrent CNVs are
expected to be shared among members of the mouse family due to inheritance.
3. To confirm the presence of select candidate CNVs in the biological samples using
ddPCR.
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4.2 Materials and methods
4.2.1

Samples

All mouse housing, care and animal use procedures were approved by Western
University’s Animal Care Committee (Appendix 3I). One family of C57BL/6J mice,
consisting of a sire (identifier number 1), dam (identifier number 2), and three adult sons
(numbers 3-5), was used in this study. The mice were euthanized by CO2 asphyxiation
according to approved protocols and exsanguinated via cardiac puncture. Tissues were
harvested, frozen in liquid nitrogen and stored at -80°C. The tissues chosen for this study
were selected based on collectively representing different compositions of cells derived
from different embryological germ layers. The selected tissues were hippocampus
(ectoderm), lung (endoderm), bladder (mesoderm), and tail (mesoderm and ectoderm) for
all five mice, and in addition, kidney (mesoderm), and pancreas (endoderm) from the three
sons. A tail sample from a C57BL/6J mouse not related to the family, a tail sample from a
CBA/CaJ mouse, and a DBA/2J brain sample (provided by Dr. Shiva Singh), were also
included in this study for comparison to the mouse family and were used for ddPCR
confirmation of select candidate CNVs.

4.2.2

DNA extraction

The DNA was extracted according to the Wizard® Genomic DNA Purification Kit protocol
(Promega, Madison, Wisconsin, USA), with two modifications: 1) tissues were digested
by proteinase K for 24-48 hours, and 2) RNAse digestion was used for all tissues. DNA
quantity and purity were assessed using a NanoDrop 2000c spectrophotometer (Thermo
Fisher Scientific, Waltham, Massachusetts, USA). DNA preparation and hybridization to
the Mouse Diversity Genotyping Array were performed according to the standard
protocol37 at the London Regional Genomics Centre (Robarts Research Institute, London,
Ontario, Canada). MDGA hybridization data were outputted in a CEL file format.

4.2.3

Genotyping and CNV detection

Genotyping was performed using Affymetrix Power Tools’ (APT)38 BRLMM-P algorithm,
and default parameters as specified by Genotyping Console39, which includes quantile
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normalization. Following a summarization step using APT, the Log R Ratio (LRR) and B
allele frequency (BAF) values were generated using the PennAffy package40. CNV calls
were made using PennCNV41 with GC model correction. The GC model file was generated
using in-house scripts and KentUtils42, and was based on the mouse reference genome
(UCSC:mm10). CNV calls on the X chromosome were generated separately using the –
chrX option in PennCNV. The first round of genotyping and CNV calling used a reference
set of 313 mice36 to create a canonical genotype clustering file for use with the PennAffy
package, as well as the Population Frequency of B Allele (PFB) file used with PennCNV.
However, only eight of twenty-six samples had a log-R ratio standard deviation (LRR SD)
that met the cutoff by having values below 0.35, for the autosomes (Appendix 4A). The
samples passing the LRR SD cutoff were also below the B-allele frequency drift (BAF drift
<0.01) and waviness factor (WF <0.05) cutoffs. Confirmation of select CNVs based on this
dataset was low (see section 4.3.1), so CNV calling was performed again with
modifications so that data did not produce false positive calls, based on the ddPCR results.
The quality of the calls was improved when using a different reference set (214
classical laboratory mice with more females), and only SNP probes. With those
modifications, all samples passed the LRR SD and WF cutoffs but only nine samples were
below the BAF drift cutoff (Appendix 4A). All SNP genotype call rates were above 99%
for every sample and CNVs that failed to be confirmed by ddPCR did not appear in this
dataset. The CNV dataset created using the 313 sample reference file will be referred to as
dataset 1 and the CNV dataset created using the 214 sample reference file will be referred
to as dataset 2.

4.2.4

DdPCR confirmation

DdPCR was performed using nine TaqMan® Copy Number Assays (Thermo Fisher
Scientific, Waltham, Massachusetts, USA), selected based on results from dataset 1: Hoxa1
(Mm00563305_cn), Hoxa2 (Mm00563310_cn), Hoxa3/5 (Mm00736986_cn), Hoxa13
(Mm00563296_cn),

Glo1

(Mm00735212_cn),

Ide

(Mm00496897_cn),

Fgfbp3

(Mm00630217_cn), Skint3 (Mm00735949_cn), and Itln1 (Mm00534147_cn). Six
additional gene assays were selected to confirm CNVs from dataset 2: Slamf9
(Mm00736858_cn), Lama2 (Mm00307917_cn), Ebf1 (Mm00734275_cn), Loxl2

156

(Mm00611995_cn), Mum1l1 (Mm00631824_cn), and Map3k7 (Mm00735116_cn). The
transferrin receptor gene (Tfrc) was used as the diploid copy number reference and notemplate controls were used in all assays. Gene assays were selected to test a mixture of
CNV gains, losses, singletons and recurrent CNVs. Control samples with no expected gains
or losses, according to the MDGA results, were used for each gene assay in addition to
samples for which a CNV was called.
DNA quantity and quality were assessed prior to ddPCR, using a NanoDrop 2000c
spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA), and diluted
to approximately 8 ng/μl. Then, the DNA was fragmented by centrifuging 140 μl of DNA
sample at 16,000xg for 3 min in a QIAshredder column (Qiagen, Venlo, Limburg,
Netherlands).
The PCR mixture for a single reaction contained 5 μl of DNA template, 5 μl of
PCR-grade water, 12.5 μl of the ddPCR™ Supermix for Probes (Bio-Rad, Hercules,
California, USA), 1.25 μl of the FAM™ dye-labelled TaqMan® assay for the gene target of
interest, 1.25 μl of the VIC® dye-labelled TaqMan® reference assay. Additional water was
used instead of template DNA or gene assay solution for controls. 20 μl of the PCR mixture
was used for droplet generation and PCR. Droplets were generated by a QX200™ droplet
generator (Bio-Rad, Hercules, California, USA). PCR was carried out in a C1000 Touch™
thermal cycler (Bio-Rad, Hercules, California, USA) with the following program: 1 cycle
at 95°C for 10 min, 45 cycles of denaturation at 95°C for 30 s, annealing and extension at
60°C for 1 min and enzyme deactivation at 98°C for 10 min. Droplets were read using a
QX200™ droplet reader and analyzed with QuantaSoft™ software (Version 1.7.4.0917;
Bio-Rad, Hercules, California, USA).

4.3 Results
4.3.1

CNVs detected and ddPCR confirmation

From dataset 1, 112 autosomal and 25 Chromosome X CNVs were detected (Appendix
4B). From this dataset, nine genic regions were selected for ddPCR confirmation. The
genic regions included targets within the Hoxa cluster, which is predicted to be present as
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a copy number loss, and targets confirmed as CNVs in Chapter 3 that were also predicted
to be CNVs in the mouse family samples. Losses were predicted in a region on
Chromosome 6 that spans several Hoxa cluster genes in the pancreas and bladder of mice
4 and 5, with the CNV loss starting at Hoxa2 or Hoxa3, depending on the sample, and
ending at Hoxa13. Hoxa1 ddPCR assays consistently showed a state of two in tested
samples (Fig. 1). Copy number states for Hoxa2 and Hoxa3/5 were between 1.5 and 2,
while copy number states for Hoxa13 were generally between 1 and 1.5. There was a trend
of decreasing copy number state with increasing gene proximity to Hoxa13, observed for
mice 1 and 5 (Fig. 1). For three mice (C57BL/6J, DBA/2J, and CBA/CaJ) not related to
the C57BL/6J mouse family, the copy number state for Hoxa13 was lower than an expected
default state of two and ranged between 1.5 and 1.77.
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Mouse ID, Gene Assay, and Tissue
Figure 4-1. DdPCR-based copy number states for Hoxa genes in multiple tissues from a C57BL/6J mouse family and three
unrelated mice. Hoxa13 (H13) results are shown in dark green while ddPCR states for Hoxa1 (H1), Hoxa2 (H2), and Hoxa3/5 (H3)
are shown in light green. Individual mice are represented by a number if they are members of the C67BL/6J family, where 1, 2 and 3 to
5 represent the sire, dam and three sons, respectively. Letters are used to indicate individuals not related to the mouse family (B for
C57BL/6J, C for CBA/CaJ, and D for DBA/2J). The letters above the bars indicate samples for which no MDGA data were available
(n), samples for which a copy number state of two is expected based on array findings (t), and samples for which a copy number state
of one is expected based on array findings (o). The bars show the average state of two technical replicates, with the exception of bars
marked with an asterisk which represent one assay. Error bars represent standard deviation and were used when the average was
calculated from two, three (bold lowercase letter), or four (bold, underlined lowercase letter) separate ddPCR assays for the same gene
and sample.
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CNV losses that overlapped Glo1 and Itln1 were also detected by the array in several mouse
samples, yet all tested samples showed a default copy number state of two (Fig. 4-2). Likewise, a
Skint3 gain that was identified in the lung of mouse 3, could not be confirmed with ddPCR. Copy
number gains for the Ide and Fgfbp3 genes were confirmed in mouse 2. An Ide gain was also
identified in the kidney of mouse 5, although it was not identified as a CNV by the MDGA.
Overall, the confirmation rate for CNV gains and losses for non-Hoxa regions was 23.5%. Hoxa
gene assay results are excluded from the confirmation rate because the copy number state for most
samples is neither a one nor a two.
For dataset 2, 70 autosomal and 38 Chromosome X CNVs were identified (Appendix 4C).
CNVs from dataset 1, that failed to be confirmed by ddPCR, were not present in dataset 2. Six
CNV gene regions were selected for confirmation. These regions represented a mixture of copy
number states and were found to differ between tissues or mouse samples. Four of the selected
genes (Ebf1, Lama2, Map3k7, and Slamf9) were predicted as copy number losses but none could
be confirmed by ddPCR (Fig. 4-2). Mum1l1 (chr. X) was predicted as a gain in the lung of mouse
3 and kidney of mouse 5. Like the CNV losses, this gain could not be confirmed as a CNV using
ddPCR.
A CNV gain was detected on Chromosome 14 in all tissues of every mouse family member.
This CNV overlapped Synb and Entpd4 but as no assays were available for these genes, a gene
neighbouring this CNV region, Loxl2, was selected for confirmation. Loxl2 could not be confirmed
as a gain. In all, no CNV gains or losses from dataset 2 could be confirmed.
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4.4 Discussion
Among the tail samples, the highest average number of CNVs was for dataset 1 when
counting both autosomal and Chromosome X CNVs. This average number of CNVs was
six, which is much lower than the predicted average of 14 CNVs per C57BL/6J tail
sample36. However, the lowest number of CNVs detected for one of the eight C57BL/6J
samples was also six, indicating that an average of six CNVs for the mouse family could
be within the normal range. More mouse samples would be needed to firmly establish the
normal range of the number of CNVs present in healthy C57BL/6J mice.
Predictions for the proportion of gains to losses were met for dataset 1. It was
predicted that the majority (57%) of CNVs detected would be gains for the autosomes and
that all Chromosome X CNVs would be gains. For dataset 1, 61% of autosomal CNVs
were gains and all Chromosome X CNVs were gains. For dataset 2, 50% of the autosomal
CNVs were gains and all Chromosome X CNVs were gains.
Unfortunately, several arrays failed to pass quality control criteria and the CNV
confirmation rate was low for both sets of data. The CNVs that were confirmed, like gains
of Ide and Fgfbp3, are already known to be widespread in C57BL/6J mice43, so it was a
possibility that they would be present in the mouse family. Gains of Ide were confirmed to
be a copy number of four in the dam (mouse 2) and the sire (mouse 1) likely had a copy
number state of two for Ide since one son (mouse 5) was found to have an Ide copy number
of three. Further ddPCR experiments would be required to confirm the copy number status
of Ide in the other two sons and the sire.
Although there were issues with the quality of the data, an unexpected biological
event was discovered. A Hoxa13 loss was detected in dataset one and ddPCR assays for
this gene consistently returned copy number states that were in-between one and two, for
all samples tested except bladder of mouse 4, which had a copy number state of one. A
similar pattern was observed in tissues from three unrelated mice of different backgrounds
(C57BL/6J, CBA/CaJ, and DBA/2J). A copy number state between one and two is
consistent with the presence of a mixed cell population where some cells have a Hoxa13
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loss and some cells have two copies of Hoxa13. Hoxa13 is unlikely to be inherited as a full
loss because it can cause embryonic lethality44. Surviving Hoxa13-/- mice have been
recovered when the genetic contribution of the C57BL/6J background in the mice is at least
87.5%, however, these mice are infertile, and exhibit hypodactyly, syndactyly, and stiffness
when walking45. Mice with a high contribution of C57BL/6J to the genetic background and
one functional Hoxa13 copy do not exhibit visible autopod skeletal defects and are capable
of producing offspring. In 129/SV strains of mice or in mice with lower background
contributions of C57BL/6, varying degrees of hypodactyly and syndactyly of the forelimbs
and hindlimbs have been observed with a Hoxa13+/- genotype, with greater disruption of
Hoxa13 function being associated with increased phenotype severity44. All of the mice in
the C67BL/6J family appeared phenotypically normal, and it is likely that the mice
inherited two normal copies of Hoxa13 which, based on array findings, may have been lost
in a subpopulation of cells as an example of postzygotic somatic mosaicism.
An emergent hypothesis that is consistent with findings is that Hoxa13 losses may
have occurred early in development, after limb development, as a non-random,
“programmed” deletion. Programmed genomic deletions, which typically occur in the form
of chromatin diminution or elimination, are known to occur in over 100 multicellular
animal species from nine taxonomic groups, as well as single-cell ciliates and can serve
different purposes46. In sea lampreys and the nematode Acaris suum, ~20% and ~13% of
the somatic genome, respectively, is deleted during early development to create distinct
genomes and transcriptomes between the germline and soma47,48. Many of the deleted
lamprey genes have roles in germline development and pluripotency47. Similarly, 85% of
the deleted genes in A. suum are expressed during gametogenesis (65%) or early
embryogenesis (20%)48. Sciarid flies undergo three tissue-specific types of chromosome
elimination which serve to determine the sex of the embryo and to develop gametes49. Like
many eliminated genes, Hoxa13 has functions important for organism development, and
has been shown to be required for autopod development44 and placental function50 in mice.
It is unknown what biological purpose it would serve for Hoxa13 or neighbouring Hoxa
genes to be deleted in somatic cells during early development. An alternative explanation
for the Hoxa13 deletions is that there is no programmed modification of Hoxa13, but rather,
this region is a mutational hotspot that is susceptible to replication- or transcription-induced

163

deletions. The presence of low copy repeats like segmental duplications and self-chains,
for example, can facilitate repeat-induced replication errors leading to CNV formation51.
On the other hand, repetitive DNA sequences are also commonly associated with
programmed chromosome diminution, as the majority of eliminated DNA sequences are
repetitive46.
To determine the mutational mechanism for CNV losses in the Hoxa cluster, the
breakpoint junctions of the CNVs need to be identified and sequenced. Given that all
Hoxa1 ddPCR assays indicated a copy number state of two, it can be assumed that one
breakpoint junction occurs between Hoxa1 and Hoxa13. For some samples, Hoxa2 and
Hoxa3 had lower copy number states than Hoxa1 but higher than Hoxa13 which may
suggest the presence of multiple deletion initiation or end points within the Hoxa cluster
region.
Initial Hoxa13 ddPCR results for mice not related to the C57BL/6J family suggest
that the occurrence of Hoxa13 losses might be a widespread phenomenon in M. musculus.
Further testing of multiple tissues from individuals of different strains and subspecies will
need to be conducted to determine how prevalent Hoxa13 losses are in mice. Detailed
analysis of different tissues can also assist in delineating the cell lineages affected and the
developmental timeline. Screening mouse embryos at different developmental stages for
Hoxa13 losses would help establish if Hoxa13 losses occur early in development and are
present as a minority cell population in all germ layer lineages or if the deletions are more
likely to independently arise numerous times, in multiple cell populations. Early Hoxa13
losses might not result in a deleterious phenotype if not enough cells are affected for gene
expression levels to meet a phenotypic threshold. No study to-date has observed intra-tissue
losses of this gene in multiple tissues in all members of a mouse family. Further work can
be extended to determine the mutational mechanism and purpose of Hoxa13 deletions and
to determine what proportion of the mouse genome regularly undergoes such alterations.

4.5 Conclusion
Ultimately, this study was unable to examine somatic mosaicism in a mouse family due to
technical issues that may have occurred during the DNA preparation or hybridization

164

process. To gather the data again will require DNA from the mouse family members to be
hybridized to new set of MDGA arrays. Alternatively, different technology like sequencing
could be used to identify somatic mosaicism in mice. Since this study was completed, there
has been significant progress in the methods used to study how mutations arise in cell
lineages of mice. By using CRISPR technology to insert known DNA sequences called
“barcodes” into mouse embryos, deletion and insertion mutations can be tracked through
cell lineages and developmental germ layers of a whole mouse52. In the future, the mouse
family study could be expanded upon by using methods with higher resolution and
sensitivity, and including more families, a greater variety of tissues and subpopulations of
cell, and more mouse strains or subspecies.
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Chapter 5

5

Characterization of the CNV Landscape in a Mouse
Model of Breast Cancer with Lung Metastasis in the
Presence and Absence of Rhamm

5.1 Background
Although the MDGA was designed to detect genetic variation in normal mouse tissues1, it
may prove to be a useful tool in detecting genetic variation associated with cancer.
Currently, its application in detecting structural variation in tissues with genomic
instability, like cancer tissues, has been limited2. Conversely, numerous human, SNP
microarray-based studies have been conducted to study genomic structural alterations, like
copy number alterations and aneuploidy, in cancer3–6. Like with human studies, the use of
SNP-based microarrays in mouse models of cancer may help expand our understanding of
the role of genetic alterations in cancer. Copy number alterations cause the disruption of
normal cell function by increasing, decreasing, or preventing the expression of dosagesensitive genes, and thereby contributing to various cancer characteristics like initiation
timing and location, tumour cell metabolism, tumour growth, ability to metastasize, and
response to treatment7–12.
Numerous mouse models of human cancer have been developed to help fill in gaps
in human studies and the design of mouse models of cancer has been constantly improving
to help increase the predictive value when compared to human-based studies13. Mouse
models of human breast cancer are among some of the most common animal cancer models
and can be generated in several ways, the earliest being generated through a transgenic
approach where foreign, oncogenic DNA is integrated into the genome14,15. One example
of an oncogenic transgene is a mouse mammary tumour virus (MMTV) promoter paired
with a polyoma middle T-antigen (PyMT) gene, which is used to model luminal breast
cancer with lung metastasis16. MMTV is active in estrogen-sensitive tissues such as the
mammary epithelium where it drives the expression of the oncogenic PyMT which
simulates growth signaling pathways, resulting in unregulated cell division and the
development of mammary gland primary tumours and secondary tumours in the lungs16–
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. Other cancer models can be generated through the use of various combinations of

promoters and oncogenes. The whey acidic protein (WAP) promoter for example, drives
gene expression in the mouse mammary gland epithelium like MMTV, but unlike with
MMTV which is activated during puberty16, WAP is responsive during pregnancy under
the influence of multiple lactogenic hormones and continues after weaning19. WAP can be
used to create a model of breast cancer when paired with the simian virus 40 (SV40) T/t
antigen, a protein which inactivates the tumour suppressors p53 and Rb20. Ectopic
expression of the SV40 T/t antigen has been used to create over 20 different transgenic
cancer models affecting the bladder, liver, retina, skin, intestines, stomach, and mammary
glands20. Mouse cancer models can also be created in several other ways that do not require
the introduction of a transgene, including but not limited to mutagen or carcinogen
exposure, knockouts of tumour suppressor genes, and the use of human tumour
xenografts15,21.
Cancer cells routinely exhibit several common properties termed “hallmarks”.
Three of these hallmarks are sustained proliferation, genomic instability, and escape from
apoptosis22. It was proposed by Macheret and Halazonetis (2015)22 that DNA replication
stress should be included as another hallmark of cancer. DNA replication stress is
connected to the previous three hallmarks since sustained cellular proliferation induces
DNA replication stress which in turn can lead to genomic instability, such as the formation
of CNVs, and some of these de novo mutations may alter normal cell phenotypes allowing
them to escape from apoptosis22. DNA replication stress in yeast has been observed to
induce high rates of both large (e.g. aneuploidy and CNVs) and small genomic alterations
(point mutations and small insertions/deletions), with tandemly repeated genes like
ribosomal RNA genes being particularly susceptible to deletions23. The observed genomic
alteration preferentially occurred in regions with slow-moving replication forks, with some
alterations conferring a selective growth advantage to cells23. Cancer-associated copy
number alterations that confer an advantage for growth are important for the development
of some cancer types while passenger mutations can help elucidate the mechanisms behind
genomic instability22.
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The roles of genomic alterations in certain cancers are thought to be important to
tumorigenesis and cancer progression since multiple recurrent and syntenic copy number
alterations have been found between a mouse model of T-cell lymphoma and multiple
human cancers, suggesting the existence of genetic modifications and biological pathways
that are common between cancers across and within species24. This finding is further
supported by Rennhack et al. (2018) who found that copy number alterations are very
common in 27 major models of breast cancer and although there is a high degree of
heterogeneity, there are many conserved gene copy number alterations within and between
mouse and human tumors that are associated with tumour progression and secondary
tumour characteristics like histological appearance, metastatic potential, and oncogenic
singalling25. It was also noted that not all mouse models had equal amounts of genomic
instability, which differed based on the cancer driver, promoter, and mouse strain used25.
Copy number alteration differences are known to exist between primary and
secondary tumours26–28. For some cancers, there are greater mutation constraints in the
primary tumours, possibly due to microenvironment effects or requirements to maintain
specific functional pathways29. Depending on how early or late in primary tumour
development metastasis-capable cells develop and metastasize, and on how quickly new
subpopulations arise in the primary and metastatic tumours, more or fewer genetic
similarities may be detected between the two tumour types30. If only one subpopulation of
a primary tumour is capable of metastasizing, the initial metastatic tumour cell population
will have less genetic diversity than the primary tumour31. The level of heterogeneity in a
metastatic tumour may increase as the tumour continues to grow and acquire mutations,
leading to increased genetic distance between the primary and metastatic tumours31. In a
study of human colorectal cancer with liver metastasis, the discordance in average copy
number between the primary tumour and metastases was 22%, leading the authors to
proposed that due to substantial genomic differences, different treatment strategies may be
required for primary tumors and metastasis tissue26.
In this study, the MDGA is used to assess the CNV landscape of mammary gland
primary tumours and lung with metastasis in an MMTV-PyMT mouse model of luminal
breast cancer, in the presence and absence of the receptor for hyaluronan-mediated motility
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(Rhamm) gene. RHAMM is a receptor for hyaluronan (HA) and has intracellular and
extracellular functions relating to normal cellular function and cancer. Inside the cell, one
important function of RHAMM is to localize to the centromeres during mitosis and
maintain mitotic spindle integrity32. RHAMM normally resides intracellularly but it can be
exported to the cell surface to bind HA in response to wounding and cytokine signalling33.
Extracellularly, RHAMM can promote cell motility and invasion through the use of MEK1
and ERK1/2 kinases via association with CD44, the main HA receptor, and subsequent
activation of MEK1 and ERK1/2 kinases34,35. Elevated RHAMM expression is associated
with poor clinical outcome in the majority of breast cancers36 and high levels of HA binding
to RHAMM are associated with increased breast cancer invasiveness and lung metastases,
but lower proliferation37.
A lack of Rhamm expression in cells causes multi-pole mitotic spindles, aberrant
chromosome segregation, and inappropriate cytokinesis during mitosis38. Crossing Rhamm
knockout mice to the MMTV-PyMT mouse model of luminal breast cancer leads to a
significant increase in the number of metastasis nodules in the lung compared to wild-type
MMTV-PyMT mice (unpublished). The increased metastases observed in Rhamm-/- mice
suggests that elevated genomic instability in the absence of Rhamm expression is a driver
for tumour progression. The association between loss of Rhamm expression and genomic
instability makes this cancer model suitable for studying genome structural alterations.
The MDGA has been used previously to study copy number alterations in a mouse
model of breast cancer. Standfuss et al.2 found that there was an increase in copy number
alterations in primary tumours in transgenic mice that developed breast cancer in
comparison to mammary gland tissue from two non-transgenic mice, of the same strain,
that did not develop cancer. Transgenic mammary gland tissue that was collected prior to
tumour development showed fewer copy number alterations than tumour samples but more
alterations than normal tissue.
There are several differences between the Standfuss study and this study. Standfuss
et al. used a WAP-SVT/t-driven cancer model with outbred mouse strains and included
WAP-SVT/t breast cancer derived cell lines, while this study used an MMTV-PyMT
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cancer model in inbred mouse strains with Rhamm-/- and wild-type genotypes. The results
of the Standfuss study and this study are not expected to be very similar since cancer
models using different oncogenic drivers have been observed to have different CNV
profiles, and even when the same cancer driver is used in a mouse model of breast cancer,
the use of different background strains can produce copy number differences25. Similarities
between the two studies include the use of a small sample set of six mice and neither study
used adjacent normal tissue for comparison to cancer tissue. However, the Strandfuss study
assessed copy number alterations at different stages of tumorigenesis up to the
development of primary tumours, while our study assesses genetic differences occurring
with different Rhamm genotypes and between primary tumours and metastasis in the same
animal. The study in this chapter advances beyond Standfuss et al. by being the first to use
both SNP probes and IGPs for CNV detection with the MDGA, which increases the MDGA
resolution and genic representation. The increased resolution, as well as the use of filtered
probe lists is expected to allow for the more reliable detection of CNVs, particularly of
genic CNVs, as well as help in the detection of smaller CNVs that can be missed at a low
resolution.

5.1.1

Research goal, central hypothesis, and specific objectives

Research goal: The purpose of this study is to 1) assess the utility of the MDGA in the
context of tumorigenesis and metastasis, specifically in an MMTV-PyMT mouse model of
breast cancer using wild-type and Rhamm-/- mice, and 2) to analyze CNV differences with
different Rhamm-/- genotypes and cancer tissue types (primary tumour or tissue with
metastases).
Central hypothesis: Given that genomic instability is a hallmark of cancer, primary
tumours and lung tissue with metastases will have more CNVs than normal tissues. If
metastatic capabilities are specific to a subset of primary tumour cells with a given
genotype, then the primary tumor will have more CNV diversity than metastatic tumours
and there will be more inter-animal variability in CNV profiles of primary tumours versus
metastatic tumours. Given the phenotype of increased metastases in Rhamm-/- mice,
primary tumour and metastatic tumour samples will have Rhamm genotype-specific CNV
profiles which may include increased genomic instability.
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The specific objectives are:
1. To identify CNV differences between primary tumours and lung with metastasis in
wild-type and Rhamm-/- MMTV-PyMT mouse samples.
2. To confirm the presence of select candidate CNVs in the biological samples using
ddPCR.

5.2 Materials and methods
5.2.1

Samples

Mouse MDGA CEL files and DNA samples were provided our collaborator, Dr. Eva
Turley. All six mice used in this study are female, carry an MMTV-PyMT transgene, and
are of a mixed FVB/N and C57BL/6 background (E. Turley, personal communication).
Three of the mice have a Rhamm-/- genotype and are represented by numeric identifiers:
10.4, 45.2, and 63.1. The three wild-type mice are represented by the numeric identifiers
36.1, 36.2, and 76.3. All mice developed mammary gland primary tumours that
metastasized to the lungs. For each mouse, DNA was isolated from a primary mammary
gland tumour and from normal lung tissue that contained metastatic tumours. In total, there
are four sample groups in this study: wild-type primary tumour (WP), wild-type lung with
metastasis (WM), Rhamm-/- primary tumour (RP), and Rhamm-/- lung with metastasis
(RM). The metastasis samples also contain surrounding normal tissue since it was not
feasible to extract only the individual metastasis nodules.

5.2.2

MDGA hybridization

Mouse DNA was prepared by C. Tolg. MDGA hybridization was performed at the London
Regional Genomics Centre (Robarts Research Institute, London, ON) according to
instructions in the Affymetrix® Genome-Wide Human SNP Nsp/Sty 6.0 manual39. The
resulting CEL files were then used for SNP genotyping and CNV identification.

5.2.3

SNP genotyping and CNV identification

M.E.O. Locke generated SNP genotypes and CNV calls by using the BRLMM-P algorithm
implemented in Affymetrix® Power Tools40 using default clustering parameters as
specified by Genotyping Console, and included median normalization and artifact
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reduction, as recommended for cancer samples by the Affymetrix® Genotyping Console
4.0 User Manual41. Analysis was limited to a stringent probe list42. A canonical genotype
clustering file42 was used to calculate Log R Ratio (LRR) and B allele frequency (BAF)
values using the PennAffy package43. A GC model file, containing the percent GC content
of the 1 Mb region surrounding each marker (or the genome-wide average of 42% if this
could not be calculated) was generated using KentUtils44 and an in-house script based on
the reference genome (UCSC:mm9). CNVs were detected with PennCNV using default
parameters, a Population Frequency of B Allele (PFB) file based on a collection of
reference strains42 and GC model correction45. Calls were not filtered based on length or
number of markers, as all passed the minimum criteria of at least a 500 bp length and more
than 10 markers underlying the call. Samples were not excluded based on the standard
deviation of the LRR values or B allele frequency drift. The CNV calls are available in
Appendix 5A.

5.2.4

Select genic CNV confirmation by droplet digital PCR
(ddPCR)

A recurrent CNV region located on Chromosome 7, was selected for confirmation by
ddPCR in all 12 samples. Two TaqMan® Copy Number Assays (Thermo Fisher Scientific,
Waltham, Massachusetts, USA) for the Ilk/Rrp8 (Mm00216640_cn) and Taf10
(Mm00232271_cn) genes, which overlap the CNV region, were used for confirmation.
Additionally, a Rhamm TaqMan® Copy Number Assay (Mm00344889_cn) was used to
confirm the copy number state of Rhamm in each mouse sample. The transferrin receptor
gene (Tfrc) was used as the diploid copy number reference for the Ilk, Taf10 and Rhamm
assays. No-template controls were used in all assays and there were two technical replicates
for each assay.
DNA quantity and quality were assessed prior to ddPCR, using a NanoDrop 2000c
spectrophotometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA), and diluted
to approximately 8 ng/μl. Subsequently, the DNA was fragmented by centrifuging 140 μl
of DNA sample at 16,000xg for 3 min in a QIAshredder column (Qiagen, Venlo, Limburg,
Netherlands).
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Each PCR reaction, with the exception of negative controls, contained 5 μl of DNA
template, 5 μl of PCR-grade water, 12.5 μl of the ddPCR™ Supermix for Probes (Bio-Rad,
Hercules, California, USA), 1.25 μl of the FAM™ dye-labelled TaqMan® assay for the gene
target of interest, 1.25 μl of the VIC® dye-labelled TaqMan® reference assay. 20 μl of the
PCR mixture was used for droplet generation and PCR. Droplets were generated by a
QX200™ droplet generator (Bio-Rad, Hercules, California, USA). PCR was carried out in
a C1000 Touch™ thermal cycler (Bio-Rad, Hercules, California, USA) with the following
program: 1 cycle at 95 °C for 10 min, 45 cycles of denaturation at 95 °C for 30 s, annealing
and extension at 60 °C for 1 min and enzyme deactivation at 98 °C for 10 min. Droplets
were read using a QX200™ droplet reader and analyzed with QuantaSoft™ software
(Version 1.7.4.0917; Bio-Rad, Hercules, California, USA).

5.2.5

SNP and CNV phenogram construction

SNP distance was calculated by totaling the number of loci where pairs of samples did not
share the same genotype call and dividing by the total number of SNP loci. Loci where
both mice had a No Call genotype were not counted as a difference. For pairwise CNV
distance calculations, SNP and IGP markers were assigned the copy number state (0, 1, 2,
or 3+) that they called as their “genotype”. The total number of CNV genotype differences
between pairs of samples was divided by the total number of SNP and IGP loci to obtain
CNV genetic distance values. SNP and CNV distance matrices are available in Appendix
5B. The genetic distance matrices were used to construct a phenogram file using the BIONJ
function of the APE package (version 3.3) for R (version 3.2.2), which implements the
algorithm described by Gascuel et al46. The phenogram file was saved in Newick format
and uploaded to Figtree (v1.4.2) to generate coloured phenogram images.

5.2.6

Tissue-specific CNVs

Tissue-specific CNVs within a mouse were identified using inhouse scripts. If a CNV in
one mouse tissue overlapped to any degree with another CNV in a different tissue of the
same mouse, regardless of copy number state, it was considered to be recurrent within the
mouse. Conversely, CNVs that did not overlap any CNVs in a different tissue within the
same mouse were considered to be tissue-specific CNVs (i.e. somatic mutations). It is
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important to note that the inherited copy number state is unknown. Therefore, in cases
where the copy number state of the same locus differs between two tissues of the same
mouse, either one or both of the tissues sampled may contain a de novo CNV.

5.2.7

Recurrent gene gains and losses and IPA networks

Genic annotation used to identify the genic content of CNVs was obtained from Ensembl’s
BioMart (Ensembl genes 67, NCBIM37). Protein-coding genes, non-coding genes, and
pseudogenes that completely overlapped CNVs of the same state, in all three samples of a
group (shared Rhamm genotype and tumour type), were considered to be recurrent within
that group (Appendix 5C). Lists of recurrent gene gains and losses were made for each of
the four groups. The four sample groups were wild-type primary tumour (WP) samples,
wild-type metastasis (WM) samples, Rhamm-/- primary tumour (RP) samples, and
Rhamm-/- metastasis (RM) samples.
Each gene list was inputted into the Ingenuity® Pathway Analysis (IPA) Core Analysis
(Qiagen, Venlo, Limburg, Netherlands) program. IPA identifies relevant relationships,
functions and pathways for inputted datasets such as gene lists. IPA parameters were set to
include: direct and indirect relationships with a maximum of 35 focus molecules per
network, mouse genes only, an “experimentally observed” confidence level, and the
Ingenuity Knowledge Base Genes only reference set. “Endogenous Chemicals” was not
selected since the focus of this study is on genetics aspects rather than metabolomics.

5.3 Results
5.3.1

CNVs detected

Across 12 cancer samples, 665 CNVs were identified (Appendix 5A). CNV genetic
distances do not show samples clustering together by mouse or genotype (Fig. 5-1). There
is no readily apparent relationship between the samples. In contrast, SNP distances are
greater between different mice than between two tissues of the same mouse and the samples
also cluster by genotype (Fig. 5-1).
Primary tumours in Rhamm-/- and wild-type mice have greater inter-animal
variation in the number of CNVs detected than do metastatic tumour samples (Table 5-1).
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Rhamm-/- metastatic tumour samples have 1.4-fold more CNVs on average, with more
inter-animal variation in the number of CNVs, than wild-type metastatic tumour samples.
Cancer samples range from having 1.6- to 3.2-fold more CNVs, on average, than normal
tail samples which have an average of 25 CNVs per sample (Table 5-1). In contrast to
normal samples, which have slightly more gains than losses on average, all cancer samples
have more losses than gains (Table 5-1; Fig. 5-2).
Rhamm-/- primary tumour samples have the smallest CNVs, with the average length
being less than half the size of CNVs found in any other cancer sample group, and closest
in size to C57BL/6J normal tail tissue samples (Table 5-1). By plotting the length
distribution of the CNVs for each sample, it is evident that only the Rhamm-/- primary
tumour samples all consistently have a high proportion of smaller CNVs and this is not
seen with the metastasis samples and only seen in one wild-type primary tumour sample
(Fig. 5-3). Wild-type primary tumour samples were found to have the longest average CNV
length but also had the greatest inter-animal variation (Table 5-1). The average CNV size
of metastasis samples is similar between genotypes (Table 5-1; Fig. 5-3). All cancer groups
have longer CNVs, on average, than do normal tissues (Table 5-1).
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CNV

SNP

Figure 5-1. Phenograms representing CNV- and SNP-based pairwise genetic distance between mouse samples from four groups:
Rhamm-/- primary tumour, Rhamm-/- lung with metastasis, wild-type primary tumour, wild-type lung with metastasis. Rhamm-/primary tumour (RP) and lung with metastasis (RM) samples are coloured in blue while green indicates wild-type primary tumour (WP)
and lung with metastasis (WM) samples. The numeric values in the sample labels represent the individual mouse identifier number.
Scale bars represent genetic distance.
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Table 5-1. Summary of averages for CNV numbers, length, state, and genic classification, in cancer and normal sample
groups.
Number
of
samples

Average number
of CNVs per
mouse

Average CNV
length (bp)
per group

Gains
(%)

Genic
(%)

Genic gains
(%)

Rhamm-/- primary
tumour

3

79 ± 46

91,239 ± 16,525

3.16 ± 4.03

62.08 ± 7.57

3.25 ± 3.61

Wild-type primary
tumour

3

46 ± 42

272,356 ± 134,633

14.86 ± 23.90

71.46 ± 4.31

15.82 ± 26.01

Rhamm-/- lung with
metastasis

3

56 ± 21

235,703 ±77,512

14.15 ± 6.93

75.79 ± 7.98

8.11 ± 3.47

Wild-type lung with
metastasis

3

41 ± 9

229,280 ± 46,936

11.94 ± 3.93

74.92 ± 6.56

8.22 ± 4.18

114

25 ± 14

52,490 ± 18,840

51.28 ± 17.54 23.87 ± 11.23

59.11 ± 28.94

C57BL/6J normal tail
tissue42

8

11 ± 4

76,469 ± 19,760

57.54 ± 13.76 43.66 ± 11.65

58.12 ± 15.36

FVB/NJ normal tail
tissue42

1

28

46,279

Sample group

114 classical laboratory
mouse normal tail
tissue42

Averages are presented along with standard deviation.

53.57

17.86

40
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Figure 5-2. Number of CNV gains and losses detected in primary tumour and lung
with metastasis samples from three wild-type and three Rhamm-/- mice. Gains are
shown in dark blue while losses are shown in light blue. Each mouse is represented by a
numeric identifier.
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Figure 5-3. CNV length distribution for primary tumour and lung with metastasis
samples from three wild-type and three Rhamm-/- mice. Primary tumour data are
coloured in blue and lung with metastasis data are coloured in green. Individual mice are
represented by the numeric identifiers at the top of the figure.
Cancer samples have a similar percentage of genic CNVs on average at around 7176%, except for Rhamm-/- primary tumour samples, which have 62% genic CNVs (Table
5-1). In contrast, 18-44% of CNVs in normal tissues are genic, depending on the sample
group (Table 5-1). A high proportion of genic CNVs in cancer samples are losses, ranging
from 84-97% genic losses, depending on the sample group. For normal tissues, more genic
CNV gains than losses were observed in 64% of the 114 mouse samples.
Here, a CNV is defined as tissue-specific if it is present in only one of two tissues
of an individual mouse. The majority of CNVs (68-97%) in the wild-type and Rhamm-/mice are tissue-specific within an individual mouse (Fig. 5-4). The proportion of tissuespecific CNVs detected in a particular tissue type, did not appear to be dependent on
genotype.
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Figure 5-4. Tissue-specific CNVs in the primary tumour and lung with metastasis
tissue of wild-type and Rhamm-/- mice. Dark green bars represent primary tumour data
and light green bars represent lung with metastasis data. Each mouse is represented by a
numeric identifier. Values over each bar indicate the number of CNVs represented by the
bar.

5.3.2

Droplet digital PCR confirmation of select genic CNVs

The ddPCR results confirmed that the Rhamm gene was knocked out in Rhamm-/- samples
and was present as a copy number state of two in wild-type samples (Fig. 5-5). Based on
MDGA results, Ilk and Taf10 were predicted to have a copy number state of two in all
samples except in Rhamm-/- primary tumours. These genes were not confirmed to be a copy
number state of one in Rhamm-/- primary tumour samples. Instead, there appears to be a
mixture of genotypes present in the cell population with a subset of cells carrying the
deletion. Furthermore, several other samples also appear have lost copies of Ilk and Taf10
in a subset of the cell population sampled within the tissue sample.
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Figure 5-5. Copy number state of Ilk, Taf10, and Rhamm genes as detected by ddPCR in wild-type primary tumour, wild-type
lung with metastasis, Rhamm-/- primary tumour, and Rhamm-/- lung with metastasis mouse tissues. Bars are coloured according
to sample group (genotype and tumour type). Each mouse is represented by a numeric identifier on the x-axis and primary tumour and
metastatic tumour tissues are represented by “P” and “M”, respectively.
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5.3.3

CNV genic analysis

Genic CNVs, especially genic losses, are found in the majority of cancer samples which is
in contrast to normal tissue samples where the majority of CNVs detected are not genic
(Table 5-1). For each of the four cancer sample groups, recurrent CNV-affected
pseudogenes, non-coding genes and protein-coding genes can be found that are common
to all samples within the groups (Appendix 5C). Rhamm-/- primary tumour samples have
more genes in common that are impacted by CNVs than wild-type primary tumour samples
do. More specifically, Rhamm-/- primary tumour samples had eight recurrent CNV regions
overlapping 48 protein-coding or non-coding genes, while only six protein-coding or noncoding genes, all in one CNV region, were affected by CNVs in the three wild-type primary
tumour samples.
The top IPA network for the 48 shared Rhamm-/- genes is “connective tissue
development and function, tissue morphology, cellular growth and proliferation” (Table 52). Vascular endothelial growth factor B (Vegfb), a regulator of Rhamm is found in this
network but Vegfb-containing CNVs were also found in some wild-type samples. Only
three genes, integrin-linked kinase (Ilk), ribosomal RNA processing 8 methyltransferase
homolog (yeast; Rrp8), and TATA-box binding protein associated factor 10 (Taf10), were
unique to Rhamm-/- primary tumours as copy number losses and not found to vary in copy
number in any other sample. These genes were completely encompassed by a single CNV,
which also partially overlapped the dynein heavy chain domain 1 (Dnhd1) and tripeptidyl
peptidase I (Tpp1) genes. Wild-type primary tumour samples did not have any groupspecific genes.
Although an Ilk loss was not observed in Rhamm-/- metastasis samples, the top
canonical pathway for this cancer group in IPA was “ILK Signaling” (p = 1.43 x 10-5) and
included insulin receptor substrate 3 (Irs3), protein phosphatase 1 regulatory inhibitor
subunit 14B (PPP1R14B), ribosomal protein S6 kinase polypeptide 4 (RPS6KA4), and
VEGFB. Rhamm-/- metastasis samples shared CNVs affecting 31 genes in six genomic
regions. Wild-type metastasis samples shared 20 genes, also in six genomic regions. In
Rhamm-/- metastasis samples, only snoMe28S-Cm3227 (snoRNA) was unique to that
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group, while in wild-type metastasis samples, AC161763.1 (miRNA), ABCE maturation
factor (LTO1), and cyclin D1 (Ccnd1) were unique and not found in Rhamm-/- metastasis
samples. The top Rhamm-/- metastasis network is immune-related cell signaling (Table 52), and the top wild-type metastasis network is cell function related to cancer and injury
response. The remaining top networks for both metastasis groups only had one associated
focus molecule.
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Table 5-2. Top three Ingenuity Pathway Analysis “diseases and functions” terms for
gene networks describing recurrent genic CNVs within each cancer sample group.
Group

Rhamm-/primary
tumour

Wild-type
primary
tumour

Rhamm-/metastasis

Wild-type
metastasis

a

IPA
Scorea

Number
of Focus
Moleculesb

39

17

12

7

2

1

Carbohydrate Metabolism, Small Molecule
Biochemistry, Post-Translational Modification

3

1

Amino Acid Metabolism, Post-Translational
Modification, Small Molecule Biochemistry

3

1

Cancer, Gastrointestinal Disease, Hepatic System
Disease

2

1

14

6

3

1

Tissue Morphology, Organ Development,
Reproductive System Development and Function

3

1

Cancer, Cell-To-Cell Signaling and Interaction,
Immunological Disease

16

7

Cellular Function and Maintenance, Cancer,
Organismal Injury and Abnormalities

3

1

Tissue Morphology, Cellular Development, Tissue
Development

3

1

Amino Acid Metabolism, Post-Translational
Modification, Small Molecule Biochemistry

Top Diseases and Functions
Connective Tissue Development and Function,
Tissue Morphology, Cellular Growth and
Proliferation
Digestive System Development and Function,
Hepatic System Development and Function,
Inflammatory Response

Cell-To-Cell Signaling and Interaction,
Hematological System Development and Function,
Immune Cell Trafficking
Cell-To-Cell Signaling and Interaction,
Hematological System Development and Function,
Immune Cell Trafficking

The IPA score is equal to -log10 of the p-value
Number of genes that were inputted into IPA by the user and are present in the top diseases
and functions network
b
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5.4 Discussion
The MDGA was able to provide information regarding the number, size, state and gene
content of CNVs in cancer samples. Comparisons of CNVs in cancer tissues and normal
tissues revealed differences in cancer CNV profiles from normal CNV profiles with respect
to CNV number, length, state, and genic content. Contrary to predictions, there is no clear
association between the number of CNVs detected in either the presence or absence of
Rhamm expression. However, the absence of Rhamm expression is associated with
alterations to the primary tumour genome that were not observed in metastasis tissue or
with a wild-type genotype, particularly in respect to the high proportion of smaller CNV
losses. With respect to CNV length only, Rhamm-/- primary tumour CNVs are more similar
to normal tissues than to other cancer samples. Rhamm-/- primary tumours also have
multiple genic CNVs shared between samples within the group that are associated with
IPA disease and function terms relevant to cancer while the wild-type primary tumours
have more diversity in genic CNVs impacted, suggesting that Rhamm-/- absence in the
microenvironment leads to selection for specific phenotypes resulting from genotypic
changes. This genotype-specific difference was not observed with metastasis samples,
possibly because of the presence of normal tissue and a difference in the lung verses
mammary gland microenvironment. As predicted, confirmation of select CNV targets
revealed that there are SNP microarray sensitivity limitations for genetically heterogeneous
samples, such that small mutant clones cannot be detected. Ideally, tumour subpopulations
should be isolated and characterized for CNVs using CNV-detection methods appropriate
for small sample sizes. Regardless of its limitations, the MDGA provided important leads
to follow up on relating to the influence of Rhamm-/- on the CNV landscape, possibly
through tissue microenvironment changes that lead to selection for specific phenotypes
associated with the detected genotypes.

5.4.1

CNVs detected

The genetic distance between cancer samples can differ greatly based on which mutation
types are used in the calculations (e.g. SNPs or CNVs), the algorithm or model used, and
if the sample is genetically heterogeneous or if more homogeneous cell subpopulations are
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used47. When using SNPs, the genetic distance between cancer samples reflected the
known genetic relationships between the samples. On the other hand, CNV genetic distance
showed that the genetic variation acquired by the cancer samples exceeds the shared,
inherited genetic variation in a way that the known relationships are not observed when
looking at the CNV phenogram. The absence of sample clustering by animal in the CNV
phenogram would suggest that there is high intra-animal copy number variation in
cancerous tissues, regardless of Rhamm genotype. However, the SNP genetic distance
values are larger than CNV genetic distance values, which means that there is a larger
contribution from SNPs to genetic differences between the samples than there is from
CNVs.
Differences between SNP and CNV genetic distance values and how closely they
represent known genetic relationships are a result of SNP and CNV frequency in the
genome and how that is applied to genetic distance calculations. SNP genetic distance is
calculated for hundreds of thousands of single-nucleotide loci while CNV genetic distance
is dependent on CNV number, length and state. Assuming that the majority of the genome
is a copy number state of two in all individuals, a sample would need to have a great number
of small CNVs with mixed states to achieve a high level of uniqueness and thereby
distinction from other samples – similar to SNPs. Within a mouse, the CNV landscape
between two tissues would have to be very similar for the tissues to cluster together since
genetic distance can be greatly impacted by small differences in CNV number, length or
state. If there is a high incidence of de novo or tissue-specific CNVs in tissue samples, as
can occur with cancer or mutagen exposure, the genetic distance will be greater than for
tissues that only contained inherited CNVs.
The number of CNVs detected in the cancer samples exceeded what is typical of
normal mouse tissues, in some cases by more than four-fold. This observation of high CNV
levels in cancer is not found in all cancer studies as mutation profiles can vary based on
cancer type10,48. In a study on human colorectal cancer49, the median number of CNVs was
found to be similar between individual tumours (480 CNVs, with a range of 7-969 CNVs)
and matched normal tissue (383 CNVs, with a range of 3-762 CNVs). A large range in
CNV number was also found in the cancerous tissues of the six mice, unlike the CNV range
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for normal mouse samples, which was far smaller. In the human colorectal cancer study49,
there were more than 4-times the number of CNVs detected overall in cancer samples than
normal samples - similar to the findings in the mouse study presented here. A larger sample
size of primary and secondary tumour samples with matched normal tissue will be needed
in future experiments to determine if the high CNV loads detected in the MMTV-PyMT
mice are representative of this particular cancer model or if these six mice are outliers and
other mice would have lower CNV loads.
Tissue-specific copy number alterations were detected in all tissues of this study
and are a common occurrence with cancer tumorigenesis and metastasis29,50. The number
of mutations that arise in a tissue can depend on many factors including, but not limited to,
which genes are affected (e.g. mutation repair genes), tissue type, and microenvironment.
Ben-David et al51 found that aneuploidy and large copy number alterations become
dominant as non-invasive lesions progress to invasive carcinomas in SV40 Tag-induced
cancer, but that an increase in chromosomal aberrations is not associated with PYMTrelated metastasis development. The authors also found recurrent copy number alterations
that are unique to specific breast cancer drivers51. Recurrent CNVs should be studied at a
cell subpopulation level within the primary tumours and compared to isolated metastasis
tumours to identify chromosomal changes that promote tumorigenesis and metastasis.
However, higher resolution technology is required to study cell subpopulations since the
MDGA only reports the most abundant copy number state.
One of the most striking differences when comparing cancer samples to normal
tissues is the high number of CNV losses observed with cancer. Generally, genic losses are
more likely to be deleterious than gains, particularly when there is a loss of genes necessary
for cell function. Therefore, CNV losses are not expected to be prevalent in healthy tissues.
However, sometimes losses are advantageous. In hematopoietic cancer stem cells from a
Pten-/- mouse model of leukemia, loss of ribosomal DNA regions was counterintuitively
associated with increased cell proliferation, rRNA production and protein synthesis52.
Alternatively, copy number losses could be neutral, they could contain tumour suppressor
genes that would contribute to tumour progression if gene copies are lost, or they could
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confer minor fitness disadvantages to cells but are linked to a strong cancer driver and are
therefore not selected against.
Although there were no clear genotype-specific differences regarding the number of
CNVs detected by the array, genotype-specific differences were observed when looking at
the length of CNVs in primary tumour samples. In the absence of Rhamm, primary tumour
CNV losses were found to be smaller than in wild-type primary tumours, but still larger
than CNVs in healthy mice. This difference was not seen in metastatic tumour samples,
possibly because of the presence of some normal tissue and a different microenvironment
in the lung than in the mammary gland. Alternatively, it is possible that the successfully
metastasizing cells had a genotype that did not contain many of the CNV losses present in
the primary tumour samples. Small losses that are genotype specific may share a common
mechanism. The mechanisms known to generate smaller deletions include: double-strand
breaks associated with elevated reactive oxygen species and this being more likely with
open DNA53. Therefore, the wild type and Rhamm-/- groups could be examined for
differences in chromatin structure which may result from differing levels of transcription
or influences on histone activity. The level of DNA accessibility and susceptibility to
damage can be determined using a DNase I footprinting assay. Other assays could be
applied to test for genotype-specific, mutation repair deficiencies.
Aneuploidy was not detected by the MDGA, even though it is known to occur in
the absence of RHAMM38. Aneuploidy would not be detectable by the array unless a large
proportion of the cells had the same chromosomal gain or loss.

5.4.2

Droplet digital PCR confirmation of select genic CNV regions

Confirmation of selected recurrent CNVs revealed a limitation of microarrays when used
with cancer samples or any sample that is a composite of subpopulations with different
CNV genotypes. The MDGA is only capable of calling whole number CNV states from
zero to four while ddPCR can detect a mixture of copy number states, such as a state of
1.5. In a genome, a copy number state can only exist as a whole number. A state of 1.5
could appear if there is mosaicism in a population of cells where some cells have a CNV
loss while others do not, so an averaged copy number state is detected. In this event, ddPCR
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would make a copy number call in between whole-number states, while the MDGA would
round the state up or down to a whole number. CNV detection is often more problematic
in cancerous tissues than in normal tissues because of the heterogeneous genetic makeup
of tumours54,55.
The MDGA has the capability to detect a knockout of Rhamm since there are probes
present in that region of the genome. However, no state zero CNVs were detected in the
entire dataset. This may have occurred for a few reasons such as uneven or excessive
staining, or it could be due to highly variable fluorescence intensities that can occur with
cancer samples or can arise from unequal sample application during hybridization56–58.
Visual images of the arrays showed hybridization abnormalities like the presence of curved
line artifacts across the arrays which would likely cause high variation in fluorescence
intensities. Therefore, as with any technology based on massively parallel hybridization,
conclusions drawn from the array data require additional experimental confirmation. In this
study, ddPCR analysis did successfully confirm the Rhamm genotype of the samples.

5.4.3

CNV genic analysis

Due to the heterogeneous nature of cancer tissues and microarray limitations, additional
confirmation of the results is required, particularly when attempting to assign cancerrelated roles to genes. For examples, the CNV region containing Ilk, Rrp8, and Taf10,
which are genes that have been implicated in cancer, was identified by the MDGA as a
copy number loss in Rhamm-/- primary tumour samples. However, ddPCR results suggest
that the samples contain cell populations with mixed copy number states of two or lower.
This intra-sample heterogeneity cannot be captured by the MDGA, which is limited to
calling whole-number CNV states.
Ilk, Rrp8, and Taf10, are found contiguously and partially overlapping each other
on Chromosome 7 and were detected as a copy number state of one in all three Rhamm-/primary tumour samples using MDGA analysis. This CNV confirmed as a copy number
state of less than two, but more than one, by ddPCR in all Rhamm-/- primary tumour
samples. Although other samples also had a copy number state less than two for this region,
there was no other sample group wherein all the samples showed this loss. Ilk, Rrp8, and
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Taf10 may impact cancer proliferation, apoptosis resistance, and growth, respectively, and
might contribute to some Rhamm-/--specific phenotypes like increased lung metastases.
During mitosis, ILK forms a complex with an integrin receptor, α-Parvin and
Dynactin-2/1 to orient mitotic spindles59.When Ilk is knocked out, mitotic spindles become
more randomly oriented leading to changes in the axis of mitosis and subsequently
allowing cells to grow outside of their normal cell layer. With less cell-cell contact limiting
cell division, cells are able to proliferate more rapidly and spread outside of their normal
layers. ILK has overlapping regulatory pathways with RHAMM as they both act as
regulators of ERK1/2 Map kinases38,60, which are commonly involved in cancer61. ILK and
RHAMM are also involved in fibronectin (FN1) regulation. RHAMM is an up-regulator
of Fn1 when associated with E2F162, and ILK is required for the induction of FN1
fibrillogenesis63. Fibronectin is important for cell adhesion and invasion64, including for
metastatic breast cancers65. What impact the combination of ILK reduction and RHAMM
absence has on fibronectin and cell behaviour remains to be determined.
Ribosomal RNA-processing protein 8 (RRP8) is thought to be a methyltransferase
in the energy-dependent nucleolar silencing complex (eNoSC). One established function
of eNoSC involves sensing the energy status in a cell, and when energy levels are low, it
will suppress rRNA transcription and ribosome biogenesis through histone acetylation and
methylation to prevent energy deprivation-dependent apoptosis66. Rrp8 heterozygous
deletions have been found in several different cancers and reduced expression is thought
to play a role in tumor formation and poor survival in breast cancer67.
TAF10 is also involved in transcriptional regulation and required for mouse
embryogenesis and cell cycle progression68, and erythropoiesis69. TAF10 is a component
of multiple complexes including TFIID, a general transcription factor which binds TATA
boxes, and TATA box-binding protein-free TAF-containing complexes like TRTC, PCAF,
and STAGA, which also have roles in regulating transcription70–72. In addition, TAF10 can
directly associate with estrogen receptors (ER) and when it is knocked down, there is a
significant reduction in estradiol-induced repression of the folate receptor-α (Folr1) P4
core promoter73. With Taf10 deleted in the Rhamm-/- primary tumour cells, Folr1 repression
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through ER would be reduced. Since Folr1 expression helps triple negative (ER-, PR-,
HER2-) breast cancer cells increase folate uptake and grow in vitro, it was suggested that
Folr1 could be targeted in cancer treatments74.
The CNV loss encompassing Ilk, Rrp8 and Taf10 could not have been inherited as
a complete loss (copy number = 0) since at least one copy of Taf10 is required for mouse
embryogenesis68. Whether or not a loss of this region plays an important biological role in
the MMTV-PyMT model studied here remains to be seen. An L1-family LINE located
between exons in Dnhd1, as well as several SINEs and LTRs may provide mechanisms for
CNV formation in this region.
Wild-type primary tumours had many mouse-specific CNVs, as the three primary
tumour samples only shared one CNV, and this shared CNV was not unique to this cancer
group. The high level of unique CNVs in wild-type primary tumours and the contrasting
high levels of CNV recurrence in Rhamm-/- primary tumours may indicate
microenvironment differences that result in selection for phenotypes, produced by specific
CNV genotypes, in the absence of RHAMM. The idea that Rhamm absence or presence
can influence the tumour microenvironment is plausible since there is emerging evidence
that suggests the tumour microenvironment can be modified by different gene alleles75.
Furthermore, the tumour microenvironment is hypothesized to be involved in the
development of highly malignant cells through a combination of selection and education
(characteristic alteration) of tumour cells76. A larger sample size and additional
experiments would be required to ascertain if the microenvironment influences the
genotype of the cells and what advantages are conferred to the primary tumour as a result
of the selection for specific genotypes.
In Rhamm-/- metastasis samples, no CNVs containing protein-coding genes were
unique to the group. SnoMe28S-Cm3227 was unique to Rhamm-/- metastasis samples but
its association with cancer has not been studied. In wild-type metastasis samples,
AC161763.1, LTO1, and Ccnd1 were unique to the group and observed as losses.
AC161763.1, also known as brain cytoplasmic RNA 1 or Bc1, is a lincRNA77 that promotes
TGF-β-induced smooth muscle cell differentiation when knocked down and acts as a
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suppressor of differentiation when overexpressed78. Overexpression of LTO1 but not
under-expression, as would be expected with a loss, has been commonly observed in
cancer79. Ccnd1 is a cell cycle regulator whose reduced expression has been linked to
resistance to breast cancer80 and reduced tumour incidence in teratoma-susceptible mice81.
The role that genic CNVs play in relation to cancer in this study’s metastasis samples
cannot be determined solely from SNP microarray data, especially because the metastasis
samples contain a mixture of normal and cancerous tissue.

5.5 Conclusion
In this study, cancer samples differed in CNV landscape in comparison to normal, healthy
tissues. Primary tumour samples had a greater inter-animal variability in the number of
CNVs detected than did metastasis samples. The absence of Rhamm is associated with the
presence of small CNVs in primary tumours but not in lung tissue with metastasis or in the
wild-type tissue samples. This is suggestive of different CNV mutation mechanisms in the
primary tumour tissue in the presence and absence of Rhamm. Based on CNV recurrence
and genic analysis, an absence of Rhamm is now hypothesized to produce a
microenvironment where there is selection for a specific cell phenotype.
This study was designed as a pilot study to determine if the MDGA could be used
for CNV detection with cancer samples and if it could be used, then the goal was to identify
and characterize differences between wild-type and Rhamm-/- cancer tissue. Although
microarray technology is limited in its ability to detect copy number variants in tissue
samples composed of heterogeneous cell populations, the MDGA was able to identify
differences in comparison to normal tissues and between cancer groups in regard to CNV
number, size, state, recurrence and genic content. To explore the CNV landscape in more
depth, larger sample sizes, the use of normal tissue adjacent to assayed tumour samples,
higher resolution technology, and focusing on cell subpopulations within tumours is
recommended. This study shows the utility of the MDGA in searching for general mutation
patterns, between cancer groups, that could be further investigated to identify mutational
mechanisms and genes associated with specific cancer phenotypes.
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Chapter 6

6

Summary and Discussion

The overall goal of this thesis was to identify CNVs in inbred and wild mice, using the
Mouse Diversity Genotyping Array (MDGA), and to explore the CNV landscape of Mus
musculus from the perspectives of evolution and adaptation, normal development, and
cancer. To accomplish this goal, a CNV detection pipeline for the MDGA needed to be
developed and tested on a sample dataset. Once a reliable pipeline was established, the
MDGA could be used to characterize the CNV landscape in different mouse subspecies,
multiple normal tissues within an individual mouse, and in primary tumour samples
compared to metastasis tissue. The outcome of the first thesis aim of developing a CNV
detection pipeline, was the generation of lists of filtered probe lists recommended for use
in CNV detection, updated probe annotation files, and the collection of a list of genes,
predicted have conserved copy number states, for use in the assessment of CNV call
reliability. It was also shown that the MDGA probes were not designed as carefully as the
Genome-Wide Human SNP Array 6.0 probes. However, filtering of the MDGA probes
increases SNP genotyping performance and is predicted to improve CNV genotyping.
Cross-species MDGA hybridization data showed that MDGA use is not limited to M.
musculus but has the potential to be a SNP and CNV detection tool for Mus genus samples
and may be of more limited use for genotyping distantly related rodents like H. glaber.
Cross-species hybridization studies using the MDGA would require identifying which
probes are usable in the species of interest by determining which probe sequences are
present in the reference genome, and reannotation of the probe genomic positions is
necessary for accurate CNV genotyping in a species other than M. musculus.
The developed MDGA CNV detection pipeline was first used in a broad, mouse
survey study where CNVs were shown to commonly occur in the genomes of M. musculus
individuals, with 9,634 CNVs being detected in 334 mouse samples. The reliability of the
pipeline for CNV detection was established by putative CNV confirmation by ddPCR.
Indirect confirmation of CNVs on strain-matched samples suggests that some CNVs may
be strain-specific. CNVs were also found to impact different genes and biological pathways
in classical laboratory strain and wild-caught mouse cohorts that appear to be linked to
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differences in their respective environments and mate selection. As predicted, these data
imply that some adaptive traits can be conferred through variation in gene copy number,
although experiment confirmation of these findings is required. The discovery of CNV
differences between the classical laboratory strains and wild-caught mice led to the
development of the mouse cohort study to further explore mouse cohort differences in CNV
landscapes.
The mouse cohort study compared the CNV landscapes in classical laboratory,
wild-derived, and wild-caught mouse cohorts. The differences in gene pathways between
the classical laboratory strains and wild-caught mice were similar to findings in the broad
survey study. The wild-derived strain cohort, which was not assessed for CNV genic
content in the broad survey study, was found to have gene pathway overlap between both
the classical laboratory and wild caught cohorts. These data may show how CNV-affected
gene pathways are altered through the process of creating inbred laboratory strains. A
useful tool that came out of this study to assist with future identification of cohort-specific
CNVs and mutation hotspots in the mouse genome was the CNV landscape plot. Given a
sufficient sample size for pattern observation, the CNV landscape plot can be used for data
visualization with any genome and for any mutation type, provided that the genomic
position is known. Furthermore, the CNV landscape plot can be used in conjunction with
HD-CNV output to visualize merged regions and singletons across each chromosome.
After looking at CNV differences between mice, where all the data originated from
tail samples, the next aim was to characterize the CNV landscape between multiple tissues
of individual mice. However, low data quality provided too many false positives to
accurately characterize the CNVs in the sample tissues from members of a C57BL/6J
mouse family. A ddPCR confirmation of some of the putative CNVs detected may have
uncovered a mutational hotpot or programmed deletion in the Hoxa gene cluster, which
always included Hoxa13. This deletion was not only present in all tested C57BL/B6 mice
and tissue samples, but also appeared to be occurring as somatic mosaicism at the intratissue level. Evidence of Hoxa deletion mosaicism was also found in two other M.
domesticus laboratory strains and in a C57BL/6J mouse unrelated to the mouse family. The
significance of a Hoxa13 gene loss is that it is unlikely to be inherited without causing
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embryonic lethality or some level of abnormal development, depending on if the deletion
is a copy state of zero or one, respectively, and depending on the mouse genetic
background. The emergent hypothesis from this data is that this deletion is a case of
nonstochastic somatic mosaicism. Future testing of is required to determine if the data
show a developmentally-programmed deletion in a developmentally-relevant gene, within
the context of specific tissues.
The final thesis aim was to study CNVs in the context of tumorigenesis and
metastasis. Using an MMTV-PyMT mouse model of breast cancer with either a knockout
of Rhamm or a wild-type genotype, the CNV profile was characterized for mammary gland
primary tumours and lung tissue with metastasis for six mice. CNV profiles in cancer
samples were found to differ from normal tissues and have greater numbers of CNVs,
particularly genic losses. Among the four cancer tissue groups, the CNV profiles of
Rhamm-/- primary tumour samples were unique in having smaller CNV deletions than the
other groups. This would suggest that different mutational mechanisms are forming CNVs
in the presence and absence of Rhamm. Furthermore, the higher frequency of recurrent
CNVs, or greater genetic homogeneity, among Rhamm-/- primary tumour samples
compared to samples with a wild-type genotype suggests that Rhamm absence may be
altering the microenvironment so that certain cancer cell genotypes are selected for. In the
absence of positive selection for a specific phenotype and genotype, primary tumours
would be expected to have greater genetic heterogeneity. Overall, this study shows the
utility of the MDGA in cancer research and provides further leads to explore relating to the
impact of Rhamm absence on the CNV landscape of the cancer genome, particularly in the
mechanisms of CNV formation and role of recurrent, genic CNVs.

6.1 Study limitations
There are several limitations for the studies described in this thesis that could be improved
upon in future studies. When the MDGA probe lists were filtered, the impact of the filtering
was assessed indirectly via SNP genotype call rate changes without additional biological
confirmation. Following filtering and overall increases in SNP genotype, some poorly
performing SNP probes that returned only “No Calls” remained. This could result from
probe properties that were not filtered, like the presence of mononucleotide repeats or GC
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content, or for other reasons like low sequence complementarity between the probes and
sample DNA. Since the probe filtering was performed to improve CNV calling, SNP
probes that are suitable for SNP genotyping but not for CNV calling, would have been
removed. Thus, the use of the recommend filtered probes provided in Locke et al1 is more
suited for CNV studies than SNP studies.
When testing the ability of the MDGA to provide genotype calls for the genus Mus
and for H. glaber samples, it was found that samples that are distantly related to mice can
artificially be made to appear more closely related if genotyped together with mouse
samples. Therefore, it is important that genotyping is performed using species-appropriate
reference files and genotyping groups. Likewise, the sample size of the species of interest
should be sufficiently large so that distinct genotype clusters can be generated. Lastly,
because the genotyping output for cross-species hybridization experiments was observed
to differ greatly depending on the approach used, biological confirmation is essential to
ensure that the correct approach is being applied to detect biological events and minimize
false calls.
For the broad mouse survey study and the mouse cohort study, the greatest limitation
is that the tissue that was used to generate the CEL files was not available for CNV
confirmation. Although mouse-specific CNVs cannot be confirmed without the sample
tissue, it may be possible to confirm strain-specific CNVs in a different member of the
same strain. For identification of strain-specific and subspecies-specific CNVs to be
possible, the sample size for each group should be increased so that recurrent CNVs can
be identified. Using the same mouse subspecies for classical laboratory, wild-derived, and
wild caught mouse cohort comparisons would help identify cohort differences that result
from life in a laboratory environment or in a natural environment without any confounding
effects from the inclusion of multiple subspecies.
When using the MDGA to study somatic mosaicism, it is important to keep in mind
that microarrays have limited sensitivity and resolution. This means that the CNVs that
are most likely to be detected in a tissue sample are those that have a clonal size that meets
the required detection threshold. For large clonal sizes to be present in normal tissue, the
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CNV event either arose early in development or in a tissue with a high cell turnover rate
where there is more opportunity for CNV formation to occur via replication errors2. The
MDGA’s resolution limit does not allow for exact CNV breakpoint identification, so
sequencing of the predicted breakpoint regions is required to locate the exact CNV start
and end. Sequencing of these regions may also uncover the potential mechanisms by which
CNVs arose. In the mouse family study, sequencing is required to determine if the Hoxa
cluster deletions involve the same mechanism and CNV breakpoints in all members of the
mouse family.
The inclusion of adjacent normal tissue is needed to establish which CNVs in the
cancerous tissues are associated with tumorigenesis and metastasis and which CNVs
constitute the normal background genotype. The high amount of genetic heterogeneity
present in cancerous tissues3 poses a challenge in CNV detection since CNVs will only be
detected if they are present in a sufficient clonal size. Therefore, experimental confirmation
of putative CNVs is necessary to identify biological events and determine false positive
rates. Due to genomic instability in cancer, the CNVs found in cancerous tissues may be
byproducts of an unstable genome without being contributors to cancer phenotypes.
Therefore, confirmed CNVs need to be characterized through further experimentation to
determine their role in cancer formation and development, metastasis, and treatment
resistance. Another caveat of the cancer study described here, is that the CNV landscape
that was observed is specific to the cancer model used here and could differ with the use
of different cancer models, mouse strains, and mouse habitat conditions4–6. Likewise, the
results observed in mouse models may not be reproducible in human studies due to
biological differences between the species7.

6.2 Future extensions
The experiments conducted in this thesis all used filtered probe lists for SNP and CNV
genotyping. To further improve on the probe lists used, a future study should be conducted
to provide biological confirmation of the impact of probe filtering on genotyping. The
impact of probe list filtering on CNV calling reliability can be assessed by using known
CNVs (i.e. samples with known genotypes) to compare if CNV calling is more accurate
before or after probe filtering. Similarly, the impact of probe list filtering on SNP genotype
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calling can be assessed with PCR-based genotyping of samples to determine if the filtered
probe list provides more reliable SNP genotype calls than the unfiltered list. Since
algorithm selection and the composition of the dataset can influence SNP and CNV
genotyping, experimental confirmation can be used to determine the best approach for
detecting SNPs and CNVs with accuracy. Further experiments can be performed to assess
the variant detection abilities of the MDGA in cross-species hybridization experiments.
These experiments would need large sample sizes with species-appropriate model files,
probe filtering based on a reference genome to identify and annotate useable probes in the
species of interest, and biological confirmation of the results. Overall, these experiments
would greatly improve the reliability of the MDGA in SNP and CNV detection in mice and
possibly provide a SNP and CNV detection tool for studies where there is not a microarray
available for the species of interest.

6.2.1

Evolution and adaptation studies

There are also multiple future extensions possible for the broad mouse survey study and
the mouse cohort study. Future studies can be designed to investigate the role of CNVs in
different mouse strains, and in mouse evolution and adaptation to different environments.
At a mouse strain level, study extensions could include characterizing mouse strainspecific CNV differences to assist with phenotype characterization and the determination
of appropriate background strains to use in mouse model studies. From the perspective of
evolution, evolutionary differences would be observable by studying different mouse
subspecies and populations to find and characterize CNVs that contribute to phenotypic
differences among these groups. A study that would be particularly relevant to the
evolution of M. musculus subspecies is the role of CNVs in reproductive isolation,
speciation, and hybrid sterility, since genetic incompatibilities leading to hybrid sterility
are known to occur between M. musculus subspecies8. These CNV studies would first
require characterization of the mating outcome of subspecies crosses and the fitness of
offspring. Then CNV studies can be performed to identify differences between samples
where mating was unsuccessful, or offspring fitness was reduced, in comparison to samples
where cross-subspecies mating was successful and offspring fitness was not affected. For
all future experiments, CNVs detected with microarray approaches would require
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experimental confirmation, and the impact of a CNV on phenotype can only be established
following additional functional genomics experiments that focus on the impact of the CNV
on transcription, translation, gene expression regulation, protein or RNA functions and
interactions, cell function, and organism development and fitness.
In the mouse cohort study, CNV differences between mouse cohorts were indirectly
studied but can be expanded upon using a more informative direct experimental approach.
Further extensions would include identifying recurrent CNVs and characterizing them for
phenotypic impact and to sequence the breakpoint junctions to identify the mechanisms of
CNV formation. The mouse cohort study can be improved by using the same mouse
subspecies for each cohort to reduce subspecies-related confounding factors. Ideally, CNV
changes related to environmental adaptation would be studied by characterizing CNV
profiles in wild caught founder populations and then observing how the CNV landscape is
altered following the generation of inbred strains from the founding population, under
laboratory housing conditions. The generated inbred strains would not contain genetic
modifications like gene knockouts or selection for disease-related phenotypes since
targeted genetic modifications may be confounding factors when studying CNV landscape
alterations over generations. The goal would be to ensure that a different environment is
the only or predominant factor influencing the CNV landscape in the mice. Conducting
additional broad CNV survey studies across various mouse groups would also be of great
value. Broad survey studies with single nucleotide resolution of CNV breakpoint junctions
would be informative about common mechanisms of CNV formation in the mouse genome
and where mutation hotspots are located. Furthermore, these studies could help identify
which genomic regions highly conserved regardless of environment, and which are copy
number variable allowing for different phenotypic traits.

6.2.2

Study extensions for genome mosaicism in healthy tissues
and cancer

In this thesis, the contribution of CNVs to mosaicism was studied from the perspective of
healthy tissues (mouse family study) and cancerous tissues. The mouse family study will
need to be repeated due to problems with the data quality, and there are several
modifications that can be included in the repeat experiments. First, the tissue samples that
210

are selected for study should include samples that represent only one germ layer rather than
a mix of germ layers. This will allow for the determination of when a CNV arose in somatic
tissue. Blood should also be included in the study to assess its usefulness as a sentinel
tissue. More C57BL/6J mouse families, as well as other strains, can be included in future
studies to generate CNV profiles are representative of most laboratory strains and to ensure
that the data are not biased due to small sample sizes. In addition, somatic mosaicism
experiments can be performed using wild mouse populations to determine if CNV
mosaicism levels are influenced by the level of genetic diversity in a population and by an
individual’s environment.
Although reliable CNV profiles could not be generated for the mouse family study,
the suggestive occurrence of a nonstochastic, postzygotic HOXA gene cluster deletion
opened an unexpected area for confirmation and hypothesis testing related to a
developmentally-programmed mutational event. Future studies can be performed to
determine if the occurrence of the deletion is a wild-spread phenomenon in Mus, and if the
deletions are programmed or occur due to being in an area susceptible to structural
mutations. Sequencing of the Hoxa gene region will provide information on the exact
genomic position and surrounding genomic context of the deletion in different tissues,
which can be used to determine the mutation’s origin and mechanism of formation. If the
Hoxa cluster is a mutation hotspot, then it is likely that germ cells are affected as well as
the soma. Therefore, germ cells could be included in future studies to determine the
frequency of Hoxa deletion occurrence and what are the impacts on reproduction success
and offspring health.
When studying mosaicism in cancer, the genetic heterogeneity of the cancerous
tissue created challenges in microarray-based CNV detection. To better characterize the
CNV landscape in tumours with respect to improved resolution and sensitivity, a
sequencing-based approach would be recommended in combination with isolation of cell
subpopulations. Comparisons between CNV profiles of primary tumour cell populations to
metastasis cells and normal adjacent cells could provide insight into mechanisms of
tumorigenesis and successful metastasis. The use of large sample sizes would be required
to be able to identify patterns and statistically significant differences between sample
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groups. To attribute functional roles to CNVs of interest, functional genomics and
phenotypic impact experiments would be required. Future aims for the MMTV-PyMT
Rhamm cancer study include conducting additional experiments to determine phenotypic
impacts of genic CNVs, determining if Rhamm genotype influences that mechanism of
CNV formation, and establishing if there is positive selection for cells with a specific
genotype due to microenvironment changes in the absence of Rhamm.
The MDGA may also prove useful in studying how the CNV landscape is altered
in a mouse or specific tissues of a mouse following mutagen exposure. Normal CNV
profiles from somatic mosaicism studies can serve as a baseline for comparison to
mutagen-exposed samples, while some cancer profiles may represent the extreme end of
genomic instability. There is also potential for using the MDGA as a biomonitoring tool
for laboratory and natural mouse populations with the goal of monitoring levels of genetic
diversity and checking for environmental mutagen exposure. In conclusion, the work
presented in this thesis provides researchers with a CNV detection pipeline compatible with
MDGA data, with potential use in studying the CNV landscapes of Mus musculus and
closely related species from the perspective of evolution and adaptation, and genome
mosaicism in healthy and disease-afflicted individuals.

212

6.3 References
1.

Locke, M. E. O. et al. Genomic copy number variation in Mus musculus. BMC
Genomics 16, 497 (2015).

2.

Chen, L. et al. CNV instability associated with DNA replication dynamics:
evidence for replicative mechanisms in CNV mutagenesis. Hum. Mol. Genet. 24,
1574–1583 (2015).

3.

Burrell, R. A., McGranahan, N., Bartek, J. & Swanton, C. The causes and
consequences of genetic heterogeneity in cancer evolution. Nature 501, 338–345
(2013).

4.

Zhang, N., Wang, M., Zhang, P. & Huang, T. Classification of cancers based on
copy number variation landscapes. Biochim. Biophys. Acta - Gen. Subj. 1860,
2750–2755 (2016).

5.

Hunter, K. W. Mouse models of cancer: does the strain matter? Nat. Rev. Cancer
12, 144–149 (2012).

6.

Justice, M. J. & Dhillon, P. Using the mouse to model human disease: increasing
validity and reproducibility. Dis. Model. Mech. 9, 101–103 (2016).

7.

Burkhardt, A. M. & Zlotnik, A. Translating translational research: mouse models
of human disease. Cell. Mol. Immunol. 10, 373–374 (2013).

8.

Turner, L. M. & Harr, B. Genome-wide mapping in a house mouse hybrid zone
reveals hybrid sterility loci and Dobzhansky-Muller interactions. Elife 3, e02504
(2014).

213

Appendices
Appendix 2A: Genome-Wide Human SNP Array 6.0 filtered probe list. (Online)
Appendix 2B: Genome-Wide Human SNP Array 6.0 filtered probe list including
flanking regions. (Online)
Appendix 2C: 874 HapMap3 CEL files. (Online)
Appendix 2D: Sample Affymetrix Power Tools commands for using Birdseed
version 1 and version 2 algorithms for SNP genotyping with the apt-probe-genotype
program.
#Birdseed v1 example
apt-probeset-genotype \
-o Output_Directory/ \
-c GenomeWideSNP_6.Full.cdf \
-s Probe_list.txt \
--special-snps GenomeWideSNP_6.Full.specialSNPs \
--read-models-birdseed GenomeWideSNP_6.birdseed.models \
-a birdseed \
--cel-files CEL_Files.txt \
--verbose 2
#Birdseed v2 example
apt-probeset-genotype \
-o Output_Directory/ \
-c GenomeWideSNP_6.Full.cdf \
-s Probe_list.txt \
--chrX-probes GenomeWideSNP_6.chrXprobes \
--chrY-probes GenomeWideSNP_6.chrYprobes \
--special-snps GenomeWideSNP_6.Full.specialSNPs \
--read-models-birdseed GenomeWideSNP_6.birdseed-v2.models \
-a birdseed-v2 \
--cel-files CEL_Files.txt \
--verbose 2
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Appendix 2E: 351 Mouse Diversity Genotyping Array CEL files from The Center for
Genome Dynamics at The Jackson Laboratory and sample ID. (Online)
Appendix 2F: List of Mouse Diversity Genotyping Array SNP probes from filtered
probe list that produced a No Call genotype in all 351 mouse samples. (Online)
Appendix 2G: List of genes unlikely to vary in copy number. (Online)
Appendix 3A: Mouse sample information for 351 Mouse Diversity Genotyping Array
CEL files. (Online)
Appendix 3B: Mouse sample cohort, subspecies and origin information for 215 Mouse
Diversity Genotyping Array CEL files. (Online)
Appendix 3C: Autosomal CNVs detected for 351 mouse samples. (Online)
Appendix 3D: Chromosome X CNVs detected for 351 mouse samples. (Online)
Appendix 3E: Summary of autosomal and Chromosome X CNVs detected for 351
mouse samples. (Online)
Appendix 3F: CNVs detected for 210 mouse samples. (Online)
Appendix 3G: Summary of autosomal and Chromosome X CNVs detected for 210
mouse samples. (Online)
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Appendix 3H: Summary of the predicted and experimental ddPCR copy number (CN) states for nine genic copy number
variant regions (CNVRs) in three classical laboratory mouse strains.
Predicted CN state summary
(number of mice)

ddPCR CN state summary

CNVR locationa

CNVR
size
(bp)

Number
probes in
CNVR
(SNP, IGP)

C57BL/6J
(n = 8)

CBA/CaJ
(n = 1)

DBA/2J
(n = 1)

C57BL/6J
(n = 5)

CBA/CaJ
(n = 5)

DBA/2J
(n = 4)

Mm00735212_cn

chr1:173206026173208119

2,093

2, 18

2 (5), 3 (3)c

2

2

2

2

2

Fgfbp3

Mm00630217_cn

chr19:3699033537045706

55,371

12, 38

2 (5), 3 (3)

2

2

2 and 3

2

2

Glo1

Mm00735212_cn

chr17:3059366331058945

465,282

61, 273

1(6), 2 (2)

3

3

2

4

4

Hdhd3

Mm00553493_cn

chr4:6215737862185081

27,703

3, 33

2 (8)

4

3

2

6

6

Ide

Mm00496897_cn

chr19:3731797437451133

133,159

31, 54

2 (2), 3
(5,1)

2

2

2

2

2

Itln1

Mm00534147_cn

chr1:173391344173508077

116,733

12, 43

1 (8)

2

2

2

2

2

Nlrp1bb

Mm00635379_cn

chr11:7101466471099017

84,353

3, 29

2 (1), 3 (2),
4 (5)

2

2

2

2

2

Skint3

Mm00735949_cn

chr4:111745396112064463

319,067

0, 61

4 (2,6)

2

2

2

0

0

Trim30eps1

Mm00657977_cn

chr7:111681502111683670

2,168

0, 7

2 (5), 4 (3)

2

2

2

0

0

CNVR
gene
target

TaqMan® Copy
Number
Assay ID

B4galt3b

a

The CNVR start and end positions are determined by the earliest start position and latest end position in a group of overlapping
CNVs for CNVs detected in C57BL/6J, CBA/CaJ and DBA/2J mice
b
These genes partially overlap the CNVR
c
The number of mice where the observed CNV only partially overlapped the gene of interest is underlined
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Appendix 3I: Western University ethics approval for animal use in research.

2009-033::6:
AUP Number: 2009-033
AUP Title: Mutational Mechanisms
Yearly Renewal Date: 10/01/2015
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2009-033 has been approved and will be
approved for one year following the above review date.

1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the
ACVS office.
Health certificates will be required.
REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are
familiar with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components
(biosafety, radiation safety, general laboratory safety) comply with institutional safety standards and have
received all necessary approvals. Please consult directly with your institutional safety officers.
Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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Appendix 3J: CNV and SNP genetic distance matrices. (Online)
Appendix 3K: Ingenuity Pathway Analysis core analysis of genes overlapping CNV
regions for different copy number states and two mouse cohorts. (Online)
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Appendix 3L: DdPCR confirmation of CN state in 14 mice of three different inbred strains for nine select genic CNVRs
detected using the Mouse Diversity Genotyping Array.
Gene assay
B4galt3
Fgfbp3a
Glo1a
Hdhd3a,c
Ide
Itln1a,b
Nlrp1b
Skint3
Trim30e-ps1

1
1.99
1.87
1.97
2.04
1.89
2.01
1.93
1.96
1.89
1.94
1.96
1.90
2.09
2.09
2.09
2.02
2.07
2.00

C57B/6J mouse
2
3
4
1.80
2.01
1.90
1.87
1.87
1.99
2.92
2.06
2.07
2.89
2.03
2.04
2.04
2.05
1.94
1.97
1.97
2.01
1.78
1.98
1.98
1.71
1.95
1.98
1.86
1.92
1.88
1.89
1.93
1.92
1.89
1.95
1.95
1.90
2.03
2.02
2.01
2.01
1.99
1.97
1.89
1.99
2.19
1.91
2.08
2.04
2.02
1.98
1.88
1.98
2.10
1.91
1.94
2.01

5
1.94
2.00
2.12
2.04
1.94
1.99
1.96
1.96
1.87
1.89
2.06
1.97
1.86
1.97
2.09
1.99
1.94
1.99

1
2.04
2.02
2.02
2.05
3.94
3.93
5.85
5.80
1.91
1.94
1.94
1.9
1.98
1.99
0
0
0
0

a

ddPCR CN state
CBA/CaJ mouse
2
3
4
2.09
2.02
1.97
2.17
2.00
1.85
2.11
2.00
1.99
2.03
2.15
2.00
3.88
3.84
3.97
3.94
3.99
4.00
5.87
5.93
6.02
5.80
6.01
5.78
1.90
1.94
1.89
1.91
2.01
1.94
1.92
1.98
1.93
1.93
1.96
1.88
1.96
1.95
1.92
2.01
2.04
1.99
0
0
0
0
0
0
0
0
0
0
0
0

5
1.89
1.96
2.11
2.05
3.99
3.99
5.86
5.81
1.94
1.90
1.92
2.06
1.99
2.02
0
0
0
0

1
2.01
1.87
2.11
1.99
3.86
3.96
5.66
5.69
1.97
1.99
1.95
2.01
2.09
1.96
0
0
0
0

DBA/2J mouse
2
3
1.94
1.94
1.90
2.02
2.09
2.00
2.02
1.97
4.12
3.87
4.10
3.94
5.90
5.90
5.71
5.89
1.94
1.86
1.94
1.96
1.89
2.01
1.94
1.99
2.11
2.04
2.04
1.98
0
0
0
0
0
0
0
0

4
1.97
2.03
2.05
2.00
3.90
3.74
5.70
5.90
1.99
1.97
1.94
1.92
2.06
1.99
0
0
0
0

The gene is entirely within the CNV observed in each mouse
All DBA/2J and CBA/CaJ samples had multiple droplet populations between the lowest amplitude negative droplet population and
the highest amplitude Itln1 postive droplet population. This may be caused by strain-specific genetic variation affecting amplification
efficiency
c
For C57BL/6J mouse 2, the CN is likely two but ddPCR values were lower than expected for a CN of two, possibly because the
duplicate regions are very close in proximity and further fragmentation of the sample is required to accurately detect the CN state
b
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Appendix 3M: List of CNVs found overlapping genes that are unlikely to vary in copy
number. (Online)
Appendix 4A: Log R ratio, B allele frequency, and waviness factor values for 26
mouse tissue samples and two PennCNV runs. (Online)
Appendix 4B: CNV calls for first PennCNV dataset. (Online)
Appendix 4C: CNV calls for second PennCNV dataset. (Online)
Appendix 5A: CNV calls for six mammary gland primary tumour samples and six
lung with metastasis samples from three MMTV-PyMT Rhamm-/- mice and three
MMTV-PyMT Rhamm+/+ mice. (Online)
Appendix 5B: CNV and SNP genetic distance matrices. (Online)
Appendix 5C: Copy number state, position and genic content of CNV regions that are
recurrent in all three samples with a shared Rhamm genotype and tumour type.
(Online)

220

Curriculum Vitae
Name:

Maja Milojevic

Post-secondary

2012-2019 Ph.D. Biology, 2008-2012 B.Sc.

Education and

The University of Western Ontario

Degrees:

London, Ontario, Canada

Honours and

2017 Dr. Irene Uchida Fellowships in Life Sciences

Awards:

2016 Queen Elizabeth II Graduate Scholarship in Science and
Technology
2016 EMGS Student and New Investigator Travel Award
2015 EMGS Student and New Investigator Travel Award
2015 Department of Biology Graduate Travel Award
2015 Department of Biology Graduate Student Teaching Award
2012 Dean's Honor List
2008 Western Scholarship of Excellence
2008 Queen Elizabeth II Aiming for the Top Tuition Scholarship

Related Work

2012-2018

Experience:

Teaching Assistant
The University of Western Ontario
London, Ontario, Canada

Publications:
Locke, M.E.O., Milojevic, M., Eitutis, S.T., Patel, N., Wishart, A.E., Daley, M., Hill,
K.A. Genomic copy number variation in Mus musculus. BMC Genomics 16, 497 (2015).
221

